<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Bioact Mater</journal-id><journal-id journal-id-type="iso-abbrev">Bioact Mater</journal-id><journal-id journal-id-type="pmc-domain-id">3413</journal-id><journal-id journal-id-type="pmc-domain">bioactmat</journal-id><journal-title-group><journal-title>Bioactive Materials</journal-title></journal-title-group><issn pub-type="epub">2452-199X</issn><publisher><publisher-name>KeAi Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10940734</article-id><article-id pub-id-type="pmcid-ver">PMC10940734.1</article-id><article-id pub-id-type="pmcaid">10940734</article-id><article-id pub-id-type="pmcaiid">10940734</article-id><article-id pub-id-type="pmid">38496036</article-id><article-id pub-id-type="doi">10.1016/j.bioactmat.2024.02.028</article-id><article-id pub-id-type="pii">S2452-199X(24)00073-2</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Engineering customized nanovaccines for enhanced cancer immunotherapy</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name name-style="western"><surname>Guo</surname><given-names initials="J">Jinyu</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au2"><name name-style="western"><surname>Liu</surname><given-names initials="C">Changhua</given-names></name><xref rid="aff2" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au3"><name name-style="western"><surname>Qi</surname><given-names initials="Z">Zhaoyang</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au4"><name name-style="western"><surname>Qiu</surname><given-names initials="T">Ting</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au5"><name name-style="western"><surname>Zhang</surname><given-names initials="J">Jin</given-names></name><email>J_Zhang929@fzu.edu.cn</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au6"><name name-style="western"><surname>Yang</surname><given-names initials="H">Huanghao</given-names></name><email>hhyang@fzu.edu.cn</email><xref rid="aff3" ref-type="aff">c</xref><xref rid="cor2" ref-type="corresp">&#8270;&#8270;</xref></contrib><aff id="aff1"><label>a</label>Qingyuan Innovation Laboratory, 1 Xueyuan Road, Quanzhou, 362801, PR China</aff><aff id="aff2"><label>b</label>College of Chemical Engineering, Fuzhou University, 2 Xueyuan Road, Fuzhou, 350108, PR China</aff><aff id="aff3"><label>c</label>MOE Key Laboratory for Analytical Science of Food Safety and Biology, State Key Laboratory of Photocatalysis on Energy and Environment, College of Chemistry, Fuzhou University, 2 Xueyuan Road, Fuzhou, 350108, PR China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. Qingyuan Innovation Laboratory, 1 Xueyuan Road, Quanzhou, 362801, PR China. <email>J_Zhang929@fzu.edu.cn</email></corresp><corresp id="cor2"><label>&#8270;&#8270;</label>Corresponding author. <email>hhyang@fzu.edu.cn</email></corresp><fn id="fn1"><label>1</label><p id="ntpara0015">J.Guo and H. Liu contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><month>6</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>10</day><month>3</month><year>2024</year></pub-date><volume>36</volume><issue-id pub-id-type="pmc-issue-id">456700</issue-id><fpage>330</fpage><lpage>357</lpage><history><date date-type="received"><day>28</day><month>10</month><year>2023</year></date><date date-type="rev-recd"><day>5</day><month>2</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>2</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>15</day><month>03</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-01 15:25:41.700"><day>01</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 The Authors</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>Nanovaccines have gathered significant attention for their potential to elicit tumor-specific immunological responses. Despite notable progress in tumor immunotherapy, nanovaccines still encounter considerable challenges such as low delivery efficiency, limited targeting ability, and suboptimal efficacy. With an aim of addressing these issues, engineering customized nanovaccines through modification or functionalization has emerged as a promising approach. These tailored nanovaccines not only enhance antigen presentation, but also effectively modulate immunosuppression within the tumor microenvironment. Specifically, they are distinguished by their diverse sizes, shapes, charges, structures, and unique physicochemical properties, along with targeting ligands. These features of nanovaccines facilitate lymph node accumulation and activation/regulation of immune cells. This overview of bespoke nanovaccines underscores their potential in both prophylactic and therapeutic applications, offering insights into their future development and role in cancer immunotherapy.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical abstract</title><p><fig id="undfig1" position="anchor" orientation="portrait"><alt-text id="alttext0010">Image 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ga1.jpg"/></fig></p></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#8226;</label><p id="p0010">Customized structured nanovaccines are classified and elucidated.</p></list-item><list-item id="u0015"><label>&#8226;</label><p id="p0015">Tailored-ligand-based of nanovaccines are engineered to augment efficacy of cancer immunotherapy.</p></list-item><list-item id="u0020"><label>&#8226;</label><p id="p0020">Custom nanovaccines unveil superior capabilities in targeting lymph nodes, enhancing antigen presentation, and modulating immunosuppression. Custom nanovaccines enable targeting lymph nodes, enhancing antigen presentation, and modulating immunosuppression.</p></list-item><list-item id="u0025"><label>&#8226;</label><p id="p0025">Progress in both prophylactic and therapeutic nanovaccines is detailed and explored in-depth.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Nanovaccines</kwd><kwd>Customized structure</kwd><kwd>Tailored-ligand</kwd><kwd>Enhanced cancer immunotherapy</kwd><kwd>Prophylactic and therapeutic applications</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0030">Since bacterial toxins were first proposed as an immunotherapy strategy to treat soft-tissue and bone sarcomas in 1891, cancer immunotherapy has become a burgeoning field revolutionizing oncology [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib2" ref-type="bibr">2</xref>]. Differing from conventional tumor treatments, cancer immunotherapy focuses on stimulating immune responses, modulating tumor microenvironment (TME), and providing unique therapeutic effects by integrating tumor-specific antibodies with cellular immune effectors [<xref rid="bib3" ref-type="bibr">3</xref>]. Primary cancer immunotherapy strategies include vaccines-based (active), antigens-based (passive), adaptive cells, cytokines, and immune checkpoint blockade (ICB) immunotherapy [<xref rid="bib4" ref-type="bibr">[4]</xref>, <xref rid="bib5" ref-type="bibr">[5]</xref>, <xref rid="bib6" ref-type="bibr">[6]</xref>]. For vaccines-based immunotherapy, cancer vaccines are primarily composed of tumor-associated antigens (TAA), immunotherapeutic agents (<italic toggle="yes">e.g.</italic>, adjuvants), and/or nanocarriers, which are elaborately-designed to activate of immune cells and provoke effective antitumor immunity [<xref rid="bib7" ref-type="bibr">7</xref>]. For example, Sipuleucel-T, as a well-known vaccine formulation, that has already been approved by the Food and Drug Administration (FDA) and is widely used in clinical settings, which owned an ability of initiating immune responses from prostatic acid phosphatase and then eliciting the patient's own immune system to proficiently identify and engage in combatting cancer [<xref rid="bib8" ref-type="bibr">8</xref>]. Nonetheless, a growing body of evidence underscores that efficacy of the cancer vaccines is compromised by intrinsic tumor cell resistance, potential off-target risks, and induction of local or systemic immunosuppressive mechanisms [<xref rid="bib9" ref-type="bibr">9</xref>]. These impediments present significant challenges in both advancement and broader clinical adoption of tumor-associated vaccines [<xref rid="bib10" ref-type="bibr">10</xref>].</p><p id="p0035">Nanovaccine is a subset of cancer vaccines with unique structures and physicochemical properties, which is accumulated in lymph nodes (LN) and taken up by antigen presenting cells (APC) in order to trigger immune responses [<xref rid="bib11" ref-type="bibr">11</xref>]. A prominent feature of the nanovaccines is tunable nanosizes, which determines entrance of active components into the LN and subsequent passive delivery of them in the TME [<xref rid="bib12" ref-type="bibr">12</xref>]. In particular, nanovaccines with diameters of 10&#8211;100&#160;nm easily access draining LN through peripheral lymphatic vessels (LV), whereas nanovaccines of larger sizes (&gt;100&#160;nm) are generally internalized by peripheral APC and migrated in LN after an accumulation at injection sites [<xref rid="bib13" ref-type="bibr">13</xref>]. Dimensions of nanovaccines have also been shown to influence effectiveness of cross-presentation, with fine nanoparticles showing greater efficiency [<xref rid="bib14" ref-type="bibr">14</xref>,<xref rid="bib15" ref-type="bibr">15</xref>]. Tunable physicochemical properties (<italic toggle="yes">e.g.</italic>, balanced surface charges, suitable shape, trade-off elasticity, targeting ligands, <italic toggle="yes">etc.</italic>) of the nanovaccines also play a crucial role in enhancing cancer immunotherapy [<xref rid="bib16" ref-type="bibr">16</xref>]. For instance, customized nanovaccines with positive charges were attracted to negatively-charged membranes <italic toggle="yes">via</italic> the electrostatic interaction, which effectively enhanced cellular internalization and antigen presentation [<xref rid="bib17" ref-type="bibr">[17]</xref>, <xref rid="bib18" ref-type="bibr">[18]</xref>, <xref rid="bib19" ref-type="bibr">[19]</xref>]. Shape of engineered nanoparticles also influences antibody and cytokine secretions. A study comparing spherical, rod, and cubic gold nanovaccines in stimulating antibody production against West Nile Virus showed that the nanorods induced secretions of inflammasome-dependent cytokines (interleukin(IL)-1&#946;, IL-18), while the sphere- and cube-vaccines induced secretions of pro-inflammatory cytokines (tumor necrosis factor (TNF)-&#945;, IL-6, IL-12, <italic toggle="yes">etc.</italic>) [<xref rid="bib20" ref-type="bibr">20</xref>]. Furthermore, nanovaccines with high permeability, biocompatibility, and stability also affect pharmacological properties of immune reagents and protect biological drugs from premature release or degradation [<xref rid="bib21" ref-type="bibr">21</xref>].</p><p id="p0040">Inorganic (hollow, core-shell, and nanosheet), polymeric (micelle and nanogel), and biomimetic (vesicle-like, nanodisc, and virus-like) nanovaccines with diverse morphologies have been systematically-explored, where proficiencies and efficiencies of these nanovaccines in delivering active components to tumor sites have been summarized [<xref rid="bib22" ref-type="bibr">22</xref>]. For example, polymer-based nanovaccines are identified with properties of exceptional stability, biocompatibility, adjuvanticity, and abilities of high endocytosis and trafficking within TME [<xref rid="bib23" ref-type="bibr">23</xref>]. Inorganic carriers like manganese ion-based nanovaccines enhance antigen presentation and amplify synergistic effects towards photothermal and photodynamic therapies [<xref rid="bib24" ref-type="bibr">24</xref>]. Moreover, inorganic carriers such as ferric ions mitigate risks associated with off-targeting effects, instability, and rapid clearance <italic toggle="yes">in vivo</italic> also facilitate timely unloading of active components after being quickly arrived at LN [<xref rid="bib25" ref-type="bibr">25</xref>]. Notably, incorporation of the targeting ligands involving artificial APC (aAPC), chemokines, agonists, inhibitors, cytokines, adjuvants, receptors, or tumor-specific peptides endows nanovaccines with the high specificity to combat tumors [<xref rid="bib26" ref-type="bibr">26</xref>]. This specificity allows for precise migration to LN and activation/regulation of immune cells [<xref rid="bib27" ref-type="bibr">27</xref>]. For instance, Wang et al. reported that &#945;-peptides-based nanovaccines M2-like tumor-associated macrophages (TAM) dual-targeting nanoparticle (M2NP) specifically depleted M2-like TAM and blocked M2-like TAM signaling pathways by loading anti-colony stimulating RNA [<xref rid="bib28" ref-type="bibr">28</xref>]. Hence, customized nanovaccines elaborately-designed from nanocarriers and active components on the basis of a specific clinical scenario, will effectively accumulate TME to induce activity of body's own immunological effectors, suppress intrinsic resistance of tumor cells, and reduce immunosuppressive effects [<xref rid="bib29" ref-type="bibr">29</xref>].</p><p id="p0045">After delivery of major active vaccine components towards the TME, personalized nanovaccines unearth capacities to amplify LN accumulation, bolster antigen presentation, and finely regulate immunosuppressive mechanisms at the single-cell level [<xref rid="bib30" ref-type="bibr">30</xref>]. Process of enhanced antigen presentation primarily involves inducing dendritic cell (DC) maturation, activating cytotoxic T lymphocytes (CTL), and targeting both B cells and natural killer (NK) cells [<xref rid="bib31" ref-type="bibr">31</xref>]. As principal APC, employing appropriate active or passive targeting strategies for DC (<italic toggle="yes">e.g.</italic>, modifications involving mannose, C-type Lectin, <italic toggle="yes">etc.</italic>) can promote effective nanovaccine phagocytosis [<xref rid="bib32" ref-type="bibr">32</xref>]. Moreover, stimulating activation and proliferation of CTL is of paramount importance for achieving efficacious immunotherapy [<xref rid="bib6" ref-type="bibr">6</xref>]. Concurrently, leveraging both B and NK cells as effective anchors can enhance nanovaccine accumulation and retention within tumors [<xref rid="bib33" ref-type="bibr">33</xref>]. Furthermore, meticulous modulation of the immunosuppressive microenvironment at the single-cell level primarily entails a targeted approach involving immune cells, including TAM, tumor-associated neutrophils (TAN), myeloid-derived suppressor cells (MDSC), natural killer T (NKT) cells, and regulatory T (Treg) Cells. Customized nanovaccines, furnished with functional ligands such as M2 macrophage-targeting peptides (M2pep), folate (FA), and stimulatory cytokines, have been employed with success in directing regulation of TAM [<xref rid="bib34" ref-type="bibr">34</xref>]. In a parallel manner, nanovaccines with a plethora of functional ligands, such as &#945;-galactosylceramide (GalCer), have feasibility in modulating NKT cell functions. Additionally, TAN regulation has been achieved by administration of the captopril-based vaccines, while MDSC can be anchored <italic toggle="yes">via</italic> tadalafil (TAD)-based vaccines.</p><p id="p0050">This review presents a comprehensive overview of the most recent progress in design and applicability of nanovaccines, especially for the bespoke nanovaccines with tweaked antigens and/or adjuvants. These nanovaccines exhibit versatilities by effectively targeting LN, activating and/or regulating diverse immune cells, as depicted in <xref rid="sch1" ref-type="fig">Scheme 1</xref>. Firstly, it is imperative to categorize diverse nanovaccines in a comprehensive manner, delineating their characteristics based on distinct typologies, including inorganic (hollow, core-shell, and nanosheet), polymeric (micelle and nanogel), and biomimetic (vesicle-like, nanodisc, and virus-like) vaccines. Secondly, it is worth noting that tailored nanovaccines function versatility at level of immune cells, which can be stratified into distinct stages. These functions encompass following as: 1) escalation of LN accumulation, 2) enhancement of antigen presentation at the single-cell level, and 3) modulation of immunosuppression at the single-cell level. Ultimate goal of such painstakingly-customized nanovaccines is a convergence of tumor eradication, tumor recurrence inhibition, and TME modulation. Finally, objective evaluations of advantages, disadvantages, and challenges of these customized nanovaccines applied in clinical trials are also presented. This review provides an exhaustive and in-depth exposition of the meticulously-tailored nanovaccines and their pivotal role in advancing cancer immunotherapy.<fig id="sch1" position="float" orientation="portrait"><label>Scheme 1</label><caption><p>Customized nanovaccines for enhanced cancer immunotherapy.</p></caption><alt-text id="alttext0055">Scheme 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="sc1.jpg"/></fig></p></sec><sec id="sec2"><label>2</label><title>Engineering customized nanovaccines</title><p id="p0055">Valid cancer vaccines including customized nanovaccines should meet a requirement of effectively <italic toggle="yes">co</italic>-delivering anti-tumor antigens as well as immunologic adjuvants to lymphoid tissues and APC (<italic toggle="yes">e.g.</italic>, macrophages and DC) for successful activation of immune system [<xref rid="bib35" ref-type="bibr">35</xref>]. Considering principal mechanism of the nanovaccines, various types of antigens and adjuvants have been developed and applied in nanoscale vaccines. The antigens, as crucial components, which constitute a pivotal component in cancer vaccines, often classified into pre-defined and unidentified antigens [<xref rid="bib36" ref-type="bibr">36</xref>]. Predefined antigens predominantly encompass TAA or tumor-specific antigens (TSA), such as neoantigens arising from aberrant gene expression or stochastic somatic mutations within cancer cells. Besides, biomimetic carriers, derived from biological entities like cell membranes (CM) or liposomes, skillfully integrate a diverse range of antigens. This integration yields personalized nanovaccines by embraced multi-targeting and multi-epitope capabilities. Up to now, nanovaccines harboring blends of unidentified antigens such as whole cancer cells or cellular lysates, have emerged as a promising avenue in cancer immunotherapy. As another essential component, the universal adjuvant mainly includes stimulator of interferon genes (STING) agonists (<italic toggle="yes">e.g. 2</italic>&#8242;,<italic toggle="yes">3</italic>&#8242;-cGAMP, <italic toggle="yes">3</italic>&#8242;,<italic toggle="yes">3</italic>&#8242;-cGAMP, <italic toggle="yes">c</italic>-<italic toggle="yes">di</italic>-GMP, <italic toggle="yes">etc.</italic>) [<xref rid="bib37" ref-type="bibr">37</xref>,<xref rid="bib38" ref-type="bibr">38</xref>], cytokines [<xref rid="bib39" ref-type="bibr">39</xref>], <italic toggle="yes">co</italic>stimulatory ligands (<italic toggle="yes">e.g.</italic>, <italic toggle="yes">4</italic>-1 BBL (CD137L)) [<xref rid="bib40" ref-type="bibr">40</xref>], toll-like receptor (TLR) agonists (<italic toggle="yes">e.g.</italic>, poly(I:C) [<xref rid="bib41" ref-type="bibr">41</xref>], cytosine-phosphate-guanosine oligodeoxynucleotide (CpG-ODN) 1826 [<xref rid="bib42" ref-type="bibr">42</xref>], R837 [<xref rid="bib43" ref-type="bibr">43</xref>], resiquimod (R848) [<xref rid="bib44" ref-type="bibr">44</xref>], <italic toggle="yes">etc.</italic>) and monophosphoryl lipid A (MPLA) [<xref rid="bib45" ref-type="bibr">45</xref>]. Specific inorganic ions, like manganese ions, and polymers, such as polyethylene glycol (PEG), are notable for their dual functionality in nanovaccine development, simultaneously acting as carriers and exhibiting adjuvant or adjuvant-like properties. This multifaceted role of nanoparticles enhances design flexibility of bespoke nanovaccines and amplifies benefits of their inherent characteristics (shape, size, charge, <italic toggle="yes">etc.</italic>). These dual capabilities are also instrumental in fine-tuning the balance between adjuvants and antigens, optimizing these nanovaccines for specific therapeutic targets. Their distinct structural composition serves dual purposes: functioning as efficient vehicles and promoting antigen presentation, thereby activating immune responses and eliminating cancers.</p><p id="p0060">Challenges faced by engineering nanoscale vaccines are how to effectively immobilize and precisely deliver various immune reagents (antigens and adjuvants) to ensure prompt and efficient immune responses [<xref rid="bib46" ref-type="bibr">46</xref>]. After bearing substantial active components, nanomaterials, functioning as vehicles and/or adjuvants, are precisely delivered to TME <italic toggle="yes">via</italic> various routes such as tissues (skin or mucosa), blood vessels, and nasal passages. Meanwhile, these components are released with or without endogenous or exogenous responses, activating specific immune responses against cancer through immune signal pathways [<xref rid="bib47" ref-type="bibr">47</xref>]. In this chapter, custom designs of nanovaccines comprising inorganic- (hollow structure, core-shell structure, and nanosheet), polymeric- (micelle and nanogel), and biomimetic-nanovaccines (vesicle-like, nanodisc, and virus-like) are elucidated, along with their intrinsic mechanisms and behavior profiles in cancer immunotherapy. Such precise engineering profoundly influences active components&#8217; loading, delivery, internalization, and release dynamics within TME [<xref rid="bib48" ref-type="bibr">48</xref>]. Compared with conventional vaccines, unique physical properties and physiological/biological advantages of customized nanovaccines boost immune responses, and detailed information about meticulous engineering of the nanovaccine is outlined in <xref rid="tbl1" ref-type="table">Table 1</xref> [<xref rid="bib49" ref-type="bibr">49</xref>].<table-wrap position="float" id="tbl1" orientation="portrait"><label>Table 1</label><caption><p>Engineering customized nanovaccines.</p></caption><alt-text id="alttext0060">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Customized morphologies</th><th colspan="1" rowspan="1">Antigens</th><th colspan="1" rowspan="1">Adjuvants</th><th colspan="1" rowspan="1">Nano-carriers</th><th colspan="1" rowspan="1">Nanovaccine types</th><th colspan="1" rowspan="1">Refs</th></tr></thead><tbody><tr><td rowspan="5" align="left" colspan="1">Hollow structure-based</td><td align="left" colspan="1" rowspan="1">miR-145</td><td align="left" colspan="1" rowspan="1">Amino-modified oligonucleotide<break/>CpG</td><td align="left" colspan="1" rowspan="1">Manganese dioxide (H&#8211;MnO<sub>2</sub>)</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib50" ref-type="bibr">50</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Tumor fragment (TF)</td><td align="left" colspan="1" rowspan="1">Hollow silica with spike-like aluminum hydroxide nanoparticle (SiAl NP)</td><td align="left" colspan="1" rowspan="1">SiAl NP</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib51" ref-type="bibr">51</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">OVA</td><td align="left" colspan="1" rowspan="1">Ammonium bicarbonate (ABC)</td><td align="left" colspan="1" rowspan="1">Mesoporous silica nanoparticle (MSN)</td><td align="left" colspan="1" rowspan="1">Prophylactic and therapeutic vaccines</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib52" ref-type="bibr">52</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">OVA</td><td align="left" colspan="1" rowspan="1">Metal-phenolic network (MPN)</td><td align="left" colspan="1" rowspan="1">Polyethylenimine (PEI)-based MSN</td><td align="left" colspan="1" rowspan="1">Prophylactic and therapeutic vaccines</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib27" ref-type="bibr">27</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Ovalbumin (OVA)</td><td align="left" colspan="1" rowspan="1">CpG</td><td align="left" colspan="1" rowspan="1">Europium-doped GdPO<sub>4</sub> hollow sphere</td><td align="left" colspan="1" rowspan="1">Prophylactic and therapeutic vaccines</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib53" ref-type="bibr">53</xref>]</td></tr><tr><td rowspan="4" align="left" colspan="1">Core-shell structure-based</td><td align="left" colspan="1" rowspan="1">OVA</td><td align="left" colspan="1" rowspan="1">PEI/CaCO<sub>3</sub> and CpG</td><td align="left" colspan="1" rowspan="1">PEI/CaCO<sub>3</sub></td><td align="left" colspan="1" rowspan="1">Prophylactic and therapeutic vaccines</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib54" ref-type="bibr">54</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">OVA</td><td align="left" colspan="1" rowspan="1">CaO<sub>2</sub></td><td align="left" colspan="1" rowspan="1">CaO<sub>2</sub></td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib55" ref-type="bibr">55</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">OVA</td><td align="left" colspan="1" rowspan="1">R848</td><td align="left" colspan="1" rowspan="1">MSN</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib56" ref-type="bibr">56</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Tumor cell lysate</td><td align="left" colspan="1" rowspan="1">CpG-ODN</td><td align="left" colspan="1" rowspan="1">Aluminum hydroxyphosphate (Alum) nanoparticle (NP)</td><td align="left" colspan="1" rowspan="1">Prophylactic and therapeutic vaccines</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib25" ref-type="bibr">25</xref>]</td></tr><tr><td rowspan="4" align="left" colspan="1">Nanosheets</td><td align="left" colspan="1" rowspan="1">Endogenous TAA</td><td align="left" colspan="1" rowspan="1">&#947;-MnO<sub>2</sub> nanodot</td><td align="left" colspan="1" rowspan="1">Ti<sub>3</sub>C<sub>2</sub>T<sub>x</sub></td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib57" ref-type="bibr">57</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Tumor autoantigen (TA)</td><td align="left" colspan="1" rowspan="1">R848</td><td align="left" colspan="1" rowspan="1">Boron bulk</td><td align="left" colspan="1" rowspan="1">Prophylactic and therapeutic vaccines</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib58" ref-type="bibr">58</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">OVA</td><td align="left" colspan="1" rowspan="1">CpG</td><td align="left" colspan="1" rowspan="1">Layered double hydroxide (LDH)</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib59" ref-type="bibr">59</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenylalanine-lysine-phenylalanine tripeptide-modified antigen epitope (FKF-OVAp)</td><td align="left" colspan="1" rowspan="1">Black phosphorus (BP) nanosheet</td><td align="left" colspan="1" rowspan="1">BP nanosheet</td><td align="left" colspan="1" rowspan="1">Prophylactic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib60" ref-type="bibr">60</xref>]</td></tr><tr><td rowspan="4" align="left" colspan="1">Micelles</td><td align="left" colspan="1" rowspan="1">OVA</td><td align="left" colspan="1" rowspan="1">CL264</td><td align="left" colspan="1" rowspan="1">Carboxylated-NP</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib61" ref-type="bibr">61</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Palmitoylated polypeptide</td><td align="left" colspan="1" rowspan="1">MPLA</td><td align="left" colspan="1" rowspan="1">PEG-phosphatidylethanolamine (PE)</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib62" ref-type="bibr">62</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">OVA</td><td align="left" colspan="1" rowspan="1">PEG-<italic toggle="yes">b</italic>-poly(<italic toggle="yes">l</italic>-lysine)-<italic toggle="yes">b</italic>-poly(<italic toggle="yes">l</italic>-leucine) (PEG-PLL-PLLeu)</td><td align="left" colspan="1" rowspan="1">PEG-PLL-PLLeu</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib63" ref-type="bibr">63</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Endogenous TAA</td><td align="left" colspan="1" rowspan="1">R848</td><td align="left" colspan="1" rowspan="1">PEG-<italic toggle="yes">ss</italic>-polycaprolactone (PCL) (PsP)</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib64" ref-type="bibr">64</xref>]</td></tr><tr><td rowspan="4" align="left" colspan="1">Nanogels</td><td align="left" colspan="1" rowspan="1">Tumor-associated antigen</td><td align="left" colspan="1" rowspan="1">R848</td><td align="left" colspan="1" rowspan="1">Hyaluronan (HA) dynamic hydrogel messenger RNA/R848/lipid nanoparticle (HA-mRLNP)</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib65" ref-type="bibr">65</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">OVA encoding mRNA</td><td align="left" colspan="1" rowspan="1">R848</td><td align="left" colspan="1" rowspan="1">Graphene oxide-low molecular weight PEI hydrogel</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib66" ref-type="bibr">66</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">OVA</td><td align="left" colspan="1" rowspan="1">Bioreducible alginate-PEI nanogel</td><td align="left" colspan="1" rowspan="1">Bioreducible alginate-poly(ethylenimine) nanogel (AP-SS)</td><td align="left" colspan="1" rowspan="1">Prophylactic and therapeutic vaccines</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib67" ref-type="bibr">67</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">OVA</td><td align="left" colspan="1" rowspan="1">Imidazo-quinolinetype TLR7/8 agonist</td><td align="left" colspan="1" rowspan="1">pH-responsive nanogel</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib68" ref-type="bibr">68</xref>]</td></tr><tr><td rowspan="6" align="left" colspan="1">Vesicle-like</td><td align="left" colspan="1" rowspan="1">OVA</td><td align="left" colspan="1" rowspan="1">HA-decorated cationic lipid-poly(lactide-<italic toggle="yes">co</italic>-glycolide) acid (PLGA) hybrid NP (HA-DOTAP-PLGA NP)</td><td align="left" colspan="1" rowspan="1">HA-DOTAP-PLGA NP</td><td align="left" colspan="1" rowspan="1">Prophylactic and therapeutic vaccines</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib69" ref-type="bibr">69</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Protein antigen</td><td align="left" colspan="1" rowspan="1">CpG</td><td align="left" colspan="1" rowspan="1">PH9-Aln-8020</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib70" ref-type="bibr">70</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Melanoma antigen peptide TRP2</td><td align="left" colspan="1" rowspan="1">MPLA</td><td align="left" colspan="1" rowspan="1">Liposomes-coated gold nanocage</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib71" ref-type="bibr">71</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Whole CM antigen</td><td align="left" colspan="1" rowspan="1">CpG and TLR9</td><td align="left" colspan="1" rowspan="1">Manganese porphyrin-based metal-organic framework (Mn-MOF)</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib72" ref-type="bibr">72</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Antigen from tumor cell death</td><td align="left" colspan="1" rowspan="1">MnO<sub>2</sub> NP</td><td align="left" colspan="1" rowspan="1">Hollow biomimetic nanoplatform (CMM-DiR)</td><td align="left" colspan="1" rowspan="1">Prophylactic and therapeutic vaccines</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib73" ref-type="bibr">73</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Antigenic motif from tumor cell membrane (TM)</td><td align="left" colspan="1" rowspan="1">Bacterial cytoplasmic membrane adjuvant</td><td align="left" colspan="1" rowspan="1">Hybrid membrane (HM) vesicle</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib74" ref-type="bibr">74</xref>]</td></tr><tr><td rowspan="3" align="left" colspan="1">Nanodisc</td><td align="left" colspan="1" rowspan="1">Antigen from tumor cell death</td><td align="left" colspan="1" rowspan="1">CpG and docetaxel (DTX)</td><td align="left" colspan="1" rowspan="1">Synthetic high-density lipoprotein mimicking nanodisc (sHDL)</td><td align="left" colspan="1" rowspan="1">Prophylactic and therapeutic vaccines</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib75" ref-type="bibr">75</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Antigen peptide</td><td align="left" colspan="1" rowspan="1">Cholesterol-modified CpG</td><td align="left" colspan="1" rowspan="1">sHDL</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib76" ref-type="bibr">76</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Aldehyde dehydrogenase (ALDH) antigen peptide</td><td align="left" colspan="1" rowspan="1">CpG</td><td align="left" colspan="1" rowspan="1">ALDH/CpG-based nanodisc</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib77" ref-type="bibr">77</xref>]</td></tr><tr><td rowspan="3" align="left" colspan="1">Virus-like</td><td align="left" colspan="1" rowspan="1">E75369-377 peptide</td><td align="left" colspan="1" rowspan="1">Bacteriophage &#955;F7</td><td align="left" colspan="1" rowspan="1">Bacterio-phage &#955;F7</td><td align="left" colspan="1" rowspan="1">Therapeutic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib78" ref-type="bibr">78</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Insulin-like growth factor-1 receptor</td><td align="left" colspan="1" rowspan="1">Human parvovirus B19</td><td align="left" colspan="1" rowspan="1">Human parvovirus B19</td><td align="left" colspan="1" rowspan="1">Prophylactic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib79" ref-type="bibr">79</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">M and M2 proteins</td><td align="left" colspan="1" rowspan="1">P22 virus-like particle (VLP)</td><td align="left" colspan="1" rowspan="1">P22 VLP</td><td align="left" colspan="1" rowspan="1">Prophylactic vaccine</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib80" ref-type="bibr">80</xref>]</td></tr></tbody></table></table-wrap></p><sec id="sec2.1"><label>2.1</label><title>Inorganic nanovaccines</title><p id="p0065">Inorganic nanomaterials possess significant value-addition potential for their numerous advantages essential to nanovaccine design, such as unique size-dependency, extremely high surface area-to-volume ratio, and strong affinity for antigen binding [<xref rid="bib81" ref-type="bibr">81</xref>]. For instance, these materials resist chemical degradation, directly influencing their lifespan <italic toggle="yes">in vivo</italic>. Gaussian size distribution of synthesized or extracted inorganic materials, with their variable number of surface atoms, facilitates formation of multilayer structures, like peripheral biocompatible polymer coatings. Additionally, tunable net charges of functional groups on inorganic materials determine endocytic efficiency of custom-designed nanovaccines. These features collectively play a strategic role formulation of bespoke nanovaccines, enhancing both cellular absorption and interactions with other biomolecules, thereby optimizing their efficacy and bioactivity.</p><sec id="sec2.1.1"><label>2.1.1</label><title>Hollow structures</title><p id="p0070">A vast hollow cavity is beneficial for encapsulation of components, where sufficient amounts of antigens are utilized to activate immune responses at tumor sites [<xref rid="bib82" ref-type="bibr">82</xref>]. These sizable cavities facilitate efficient component loading and reduce risks of clearance during transportations of adjuvants and/or antigens. Functional genes-covered biodegradable H&#8211;MnO<sub>2</sub> as an example, offers a sizable hole to be filled and/or conjugated with a significant quantity of immunological reagents (<xref rid="fig1" ref-type="fig">Fig. 1</xref>A&#8722;D) [<xref rid="bib50" ref-type="bibr">50</xref>]. Ce6 and DOX are encapsulated internally in this system, whereas amino-modified oligonucleotide CpG, S6-aptamers, and miR-145 are conjugated through amide reactions (<xref rid="fig1" ref-type="fig">Fig. 1</xref>E). Hollow MnO<sub>2</sub> reacts with hydrogen peroxide in a slightly acidic environment and decomposes to produce manganese ion (Mn<sup>2+</sup>) and oxygen, which releases loaded drugs and alleviates tumor's hypoxic environment. A hollow SiAl NP, featuring aluminum hydroxide spikes on its surface, exhibits high loading efficiencies, as demonstrated by its capacity to accommodate DOX (17%), TF (37.0%), and OVA (29.7%) (<xref rid="fig1" ref-type="fig">Fig. 1</xref>F&#8722;H) [<xref rid="bib51" ref-type="bibr">51</xref>]. This structural design significantly enhances potential for diverse payload integration, facilitating efficient drug and antigen delivery (<xref rid="fig1" ref-type="fig">Fig. 1</xref>I, J). Hollow porous structures like MSN also serve as a versatile framework adaptable for designs of personalized nanovaccines based on variations in their loaded active components. A MSNs-ABC@polydopamine-OVA (MSNs-ABC@PDA-OVA) nanovaccine as an example, employed polydopamine (PDA)-modified MSNs as a porous backbone, encapsulating ABC and conjugating thiolate ovalbumin <italic toggle="yes">via</italic> Michael addition reaction [<xref rid="bib52" ref-type="bibr">52</xref>]. Similarly, a pH-sensitive MSN-based nanovaccine is constructed by electrostatically adsorbing OVA and encapsulating MPN with numerous reducible disulfide bonds [<xref rid="bib27" ref-type="bibr">27</xref>]. The PMSN@OVA-MPN nanovaccine embraces a high loading efficiency for OVA, and the PEI shell with &#8220;proton sponge effect&#8221; promotes antigen lysosome escape. Meanwhile, disulfide bonds in external MPN induce OVA release in presence of the reduced glutathione. Furthermore, reports on large cavity structures include lanthanide-doped GdPO<sub>4</sub> hollow spheres (GdPO<sub>4</sub>:Eu), which efficiently <italic toggle="yes">co</italic>-deliver protein antigens like OVA and CpG-ODN to TME. These hollow sphere-based vaccines also serve as dual-modal imaging agents for tracking immune processes within the TME [<xref rid="bib53" ref-type="bibr">53</xref>].<fig id="fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p><bold>Fabrication processes of hollow structure-based nanovaccines for cancer immunotherapy.</bold> Transmission electron microscopy (TEM) images depicting (A) initial H&#8211;MnO<sub>2</sub>, (B) modification of H&#8211;MnO<sub>2</sub> with an external coating of acrylic acid and the polyelectrolyte poly(allylamine hydrochloride), accompanied by internal loading of doxorubicin (DOX) and Chlorin e6 (Ce6) (H-M-pp/C&amp;D), and (C) subsequent conjugation of modified structure with amino-modified oligonucleotides including CpG, S6-aptamers, and miR-145 (H-M-pp/C&amp;D&#160;+&#160;3). (D) Ultraviolet&#8211;visible (UV&#8211;<italic toggle="yes">vis</italic>)&#8722;near-infrared (NIR) spectra of free Ce6, DOX, H&#8211;MnO<sub>2</sub>, and H-M-pp/C&amp;D. (E) Schematic of synthesis process and various functions of finally prepared nanovaccine. Reproduced with permission [<xref rid="bib50" ref-type="bibr">50</xref>]. Copyright 2022, American Chemical Society. (F) Synthesis of SiAl NP by successive reverse microemulsion and hydrothermal processes. (G) TEM image and (H) Scanning TEM image of SiAl NP. (I) TF loading efficiencies in SiAl and its alongside incorporation of DOX. (J) OVA release profiles of SiAl@OVA in phosphate-buffered saline solution (PBS) with different pH values. Reproduced with permission [<xref rid="bib51" ref-type="bibr">51</xref>]. Copyright 2022, Wiley.</p></caption><alt-text id="alttext0015">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1.jpg"/></fig></p></sec><sec id="sec2.1.2"><label>2.1.2</label><title>Core-shell structures</title><p id="p0075">Oxide-based nanocarriers with adjuvants property have been employed for developing nanovaccines. Active components are strategically modified on exterior of core-shell structure of nanocarriers to make nanovaccines with cancer immunotherapy abilities [<xref rid="bib83" ref-type="bibr">83</xref>]. The core-shell nanovaccines are created by utilizing PEI-coated calcium carbonate (CaCO<sub>3</sub>) nanocarriers (PEI/CaCO<sub>3</sub>), which efficiently absorb both OVA and CpG [<xref rid="bib54" ref-type="bibr">54</xref>]. Additionally, PEI/CaCO<sub>3</sub> works as an underlying adjuvant to activate bone marrow-derived dendritic cell (BMDC) dose-dependently, leading to an increase in CD86 expression. Together with the assistant nanoparticles PEG/PEI/pSpam1 (pSpam1@NPs), the nanovaccines activate T cells and gene-mediated extracellular matrix scavengers for tumor elimination. Another biomineralized nanovaccine is also developed by assembling OVA onto an <italic toggle="yes">in-situ</italic> growth of calcium peroxide [<xref rid="bib55" ref-type="bibr">55</xref>]. The nanovaccine has a superhigh density of OVA antigen with a necessary calcium peroxide adjuvant (8.9%). Concerning acidic TME, the nanovaccine achieves lysosome escape and antigen cross-presentation within the cytoplasm. Furthermore, in the formulation of nanovaccines, a biopolymer-coated copper oxide core functioned as an adjuvant, eliciting an immunoglobulin (Ig) G response [<xref rid="bib84" ref-type="bibr">84</xref>]. This adjuvant effectively inhibits proliferation of breast cancer (MCF-7) and cervical cancer (HeLa) cells, following activations of type 1 helper T (Th1) cells and type 2 helper T (Th2) cells.</p><p id="p0080">Core-shell structure of nanoparticles excels in delivering and strategically releasing active components at multiple levels. This is demonstrated through two concise examples. The first involves synthesis of the core-shell mesoporous silica nanovaccines (MSN-R848-OVAp) utilizing a <italic toggle="yes">co</italic>-condensation method that incorporates cetyltrimethylammonium chloride and tetraethyl orthosilicate [<xref rid="bib56" ref-type="bibr">56</xref>]. These nanoparticles feature phenyl-functionalized cores to accommodate hydrophobic R848, coupling with a pH-responsive acetal linker and a biotin-avidin complex/OVA on the surface. This configuration facilitates antigen delivery and induces T cell responses. The second is the Alum-CpG@Fe-Shikonin nanovaccine, which is composed of an Alum NP core infused with CpG-ODN and enveloped in Fe-Shikonin networks [<xref rid="bib25" ref-type="bibr">25</xref>]. Upon disassembly, they release iron ion (II) and Shikonin, triggering immunogenic cell death (ICD) in tumor cells <italic toggle="yes">via</italic> ferroptosis and necroptosis. Subsequently, these components are absorbed by Alum NP and <italic toggle="yes">co</italic>-delivered with CpG-ODN to antigen-presenting cells, initiating a targeted, multistep antitumor immune response. Collectively, these examples underscore core-shell structure's adaptability and efficiency in targeted delivery and release of complex therapeutic agents within cancer immunotherapy.</p></sec><sec id="sec2.1.3"><label>2.1.3</label><title>Nanosheets</title><p id="p0085">Active components are also immobilized onto two-dimensional nanomaterials, capitalizing on their distinctive attributes, including exceptional electrochemical and mechanical properties. These advantages confer upon two-dimensional nanomaterials elevated thermal conductivity and outstanding photothermal conversion efficiency. Notably, intrinsic metallic-based nanosheets (Ti<sub>3</sub>C<sub>2</sub>T<sub>x</sub>, graphene oxide (GO), and two-dimensional MoSe<sub>2</sub> nanosheets) have become predictable reactive oxygen species (ROS) manufacturers, triggering ICD to release TAA and damage-associated molecular patterns [<xref rid="bib85" ref-type="bibr">[85]</xref>, <xref rid="bib86" ref-type="bibr">[86]</xref>, <xref rid="bib87" ref-type="bibr">[87]</xref>]. In this context, a Schottky heterojunction is engineered in the TC-MnO<sub>2</sub>@BSA nanovaccine by immobilizing ultrasmall &#947;-MnO<sub>2</sub> nanodots onto intrinsic metallic Ti<sub>3</sub>C<sub>2</sub>T<sub>x</sub> nanoflakes, followed by bull serum albumin (BSA) decoration (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A) [<xref rid="bib57" ref-type="bibr">57</xref>]. This Schottky heterojunction endows the nanovaccine with exceptional photoelectric performance and capabilities towards ROS generation and photothermal conversion. TEM and atomic force microscopy (AFM) images reveal a tightly integrated heterojunction, with Ti<sub>3</sub>C<sub>2</sub> maintaining its monolayer morphology and exhibiting distinctive wrinkles (<xref rid="fig2" ref-type="fig">Fig. 2</xref>B, C). Experimental findings also indicate that the nanovaccines induce ROS production after 24&#160;h. Simultaneously, they also lead to expression of CD44 on CD8<sup>+</sup> T cells and a reduced proportion of Treg cells within TME. In addition, ultrathin thickness and high surface area-to-mass ratio of two-dimensional nanomaterials enhance drug release profiles alongside optimization of delivery and efficacy of therapeutics. As an illustration, boron nanosheet-based nanovaccine (B@TA-R848) is constructed with nanosheet from exfoliated boron bulk, coated PDA, and then modified with TA from triple-negative breast cancer (TNBC) as well as adjuvant of R848 (<xref rid="fig2" ref-type="fig">Fig. 2</xref>D, F, <bold>2</bold>G) [<xref rid="bib58" ref-type="bibr">58</xref>]. Such B@TA-R848 increases DC internalization by intracellular endocytosis, thus promoting antigen release and presentation based on an ultrathin of <italic toggle="yes">&#946;</italic>-rhombohedral hexahedral boron structure. As expected, the B@TA-R848 also bespeaks high enrichment at tumor sites and desired photoacoustic imaging and synergetic photothermal therapy (PTT) in TNBC model (<xref rid="fig2" ref-type="fig">Fig. 2</xref>H). Similarly, a GO/polymer-famulated nanovaccine enhances antigen cross-presentation ability and amplifies cytokine productions of immune cells (<xref rid="fig2" ref-type="fig">Fig. 2</xref>E, I) [<xref rid="bib87" ref-type="bibr">87</xref>].<fig id="fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p><bold>Fabrication processes of layered structure-based nanovaccines for cancer immunotherapy.</bold> (A) Schematic diagram of NIR activated Schottky nanovaccine TC-MnO<sub>2</sub>@BSA and its mechanisms towards immune effects. (B) TEM images and (C) AFM image and height of TC-MnO<sub>2</sub>@BSA. Reproduced with permission [<xref rid="bib57" ref-type="bibr">57</xref>]. Copyright 2023, Wiley. (D) Preparations of personalized nanovaccine of B@TA-R848. Size, dispersity, and photo images of (F) boron nanosheet and (G) its loading TA. (H) Photoacoustic images of tumor site in B@TA-R848 groups at 12&#160;h post injection. Reproduced with permission [<xref rid="bib58" ref-type="bibr">58</xref>]. Copyright 2021, Walter de Gruyter. (E) Formation illustration of GO/polymer-famulated nanovaccine. (I) Confocal microscope image of BMDCs incubated with GO/polymer-famulated nanovaccine and fluorescein isothiocyanate (FITC). Reproduced with permission [<xref rid="bib87" ref-type="bibr">87</xref>]. Copyright 2022, Elsevier.</p></caption><alt-text id="alttext0020">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2.jpg"/></fig></p><p id="p0090">Moreover, well-defined layered structures of these nanovaccines augment blood flow, concurrently modifying interstitial pressure and increasing accumulation in tumor sites [<xref rid="bib88" ref-type="bibr">88</xref>]. For instance, LDH is utilized as nanoadjuvants with an average size from 77 to 285&#160;nm, and prompts accumulation in spleen as the most prominent secondary lymphoid organ owns highest density of APC and B/T cells. The LDH-based CO-LDH nanovaccine is also built with LDH, CpG, and OVA [<xref rid="bib59" ref-type="bibr">59</xref>]. Customized LDH structure endows this nanovaccine with a high spleen enrichment at 24&#160;h post <italic toggle="yes">i.v.</italic> injection. Taking <italic toggle="yes">in situ</italic> nanovaccine (LDHs-cGAMP) formed by LDH carrying cGAMP and adsorbed TAAs as another paradigm, it is demonstrated that this vaccine effectively accumulates in TME, inducing a robust response of type I interferon (IFN&#8211;I) [<xref rid="bib89" ref-type="bibr">89</xref>]. Furthermore, BP-based nanovaccine possesses biocompatibility, biodegradability, and multiple immunostimulatory properties. For instance, phenylalanine-lysine-phenylalanine (FKF) tripeptide-modified antigen was coated onto BP to generate a minimalized nanovaccine of FKF-OVAp@BP [<xref rid="bib60" ref-type="bibr">60</xref>]. The FKF-OVAp@BP nanovaccine harnessed immunomodulatory properties of BP and displayed significant compatibility with ICB, resulting in robust therapeutic efficacy in a melanoma mouse model. Besides, adjuvant effect mediated by BP is evidenced by efficient delivery of the mRNA nanovaccines. Yang et al. introduced the mRNA nanovaccines highlighting BP-mediated adjuvant effect being contributed efficient protein expression and enhanced immune activation [<xref rid="bib90" ref-type="bibr">90</xref>]. Compared to nanoerythrosomes (NER) without BP, the BP-NER combination efficiently delivered mRNA for coronavirus receptor-binding domain, significantly increasing antibody titers and pseudovirus neutralization effect.</p><p id="p0095">In short, inorganic materials, characterized by innate attributes such as photophysical properties, hold promise for developing customized nanovaccines. However, these &#8220;hard NP materials&#8221; (referred to as inorganic materials) often emanate limited inherent solubility, necessitating surface modifications to hasten their dissolution or maintain stability in aqueous environments [<xref rid="bib81" ref-type="bibr">81</xref>]. Such modifications in tandem with intrinsic characteristics of inorganic materials significantly determine versatility of inorganic-based vaccines, thereby influencing chemical properties recognized by biological organisms and dictating nature of their interactions with immune cells. Consequently, when employing these materials as carriers or adjuvants, there is a critical need to strike an optimal balance between surface functionalization with soluble polymers and efficient loading of antigens.</p></sec></sec><sec id="sec2.2"><label>2.2</label><title>Polymeric nanovaccines</title><p id="p0100">Polymers are particularly-important in the personalized design of nanovaccines due to their high biocompatibility, adjustable side chain length, stimuli-responsive surface as a point of anchored chain, and structural flexibility, enabling their practical use as carriers and/or adjuvants. In this field, polymer modifications are indispensable in nanovaccines based on inorganic or biomimetic materials. They enhance solubility of inorganic nanovaccines and facilitate <italic toggle="yes">co</italic>-delivery of antigens and adjuvants in biomimetic formulations. As a pivotal component of nanovaccines, their discussion primarily focuses on nanomicelles with a two-dimensional arrangement and nanogels forming three-dimensional polymeric networks. A detailed examination of the polymer structures reveals their distinct properties and functions, providing critical insights into their mechanisms and instrumental role in advancement of nanovaccine technologies. As for other secondary or bridging components, they are succinctly described in other sections dedicated to inorganic and biomimetic-based nanovaccines.</p><sec id="sec2.2.1"><label>2.2.1</label><title>Micelles</title><p id="p0105">Amphiphilic block copolymers typically engage in self-assembly to form micelles, and these micelle-centered nanovaccines possess several advantageous characteristics including targeting capabilities, enhanced cellular uptake, and specific stimulus responsiveness [<xref rid="bib91" ref-type="bibr">91</xref>,<xref rid="bib92" ref-type="bibr">92</xref>]. Owing to their functional embedded designs, micelles inherit endocytic receptor targeting properties, presenting an alternative avenue for enhancing vaccine internalization, as exemplified by Pluronics [<xref rid="bib93" ref-type="bibr">[93]</xref>, <xref rid="bib94" ref-type="bibr">[94]</xref>, <xref rid="bib95" ref-type="bibr">[95]</xref>]. Amphiphilic diblock copolymer of poly(<italic toggle="yes">2</italic>-ethyl-<italic toggle="yes">2</italic>-oxazoline)-poly(<italic toggle="yes">d</italic>, <sc><italic toggle="yes">l</italic></sc>-lactide) (PEOz-PLA) and carboxylterminated-pluronic F127 are utilized to yield micelles (denoted as carboxylated-NPs) as an example [<xref rid="bib61" ref-type="bibr">61</xref>]. These micelles demonstrate aptitudes to infiltrate LV and precisely reach LN due to strategic incorporation of carboxylic groups. This design confers targeting capability to the micelles, allowing them to utilize a scavenger receptor-mediated endocytosis pathway for precise delivery.</p><p id="p0110">Polymeric micelles, including polypeptides, exhibit efficient cytosolic delivery and enhanced adjuvanticity [<xref rid="bib96" ref-type="bibr">96</xref>,<xref rid="bib97" ref-type="bibr">97</xref>]. As depicted, the self-assembled micelles are consisted of PEG-PE, palmitoylated polypeptide, and MPLA, where palmitoylated polypeptide and MPLA are inserted into hydrophobic core of micelles (<xref rid="fig3" ref-type="fig">Fig. 3</xref>A) [<xref rid="bib62" ref-type="bibr">62</xref>]. Designed PEG-PE micelles not only serve as chaperons for TLR signaling and perform adjuvant effects towards DC, but also transform soluble peptides into &#945;-helix and enhance cytosolic delivery efficiency (<xref rid="fig3" ref-type="fig">Fig. 3</xref>C). These self-assembled cationic micelles, derived from PEG-PLL-PLLeu, exhibited particle stability during OVA transportation [<xref rid="bib63" ref-type="bibr">63</xref>]. <italic toggle="yes">In vivo</italic> results showed that PEG-PLL-PLLeu-based nanovaccine significantly enhanced adjuvanticity, vaccine-induced germinal center formation, and antibody production. Efficient delivery of contents is also evidenced by mannose-modified stearic acid-grafted chitosan (M&#8211;CS&#8211;SA) micelles; upon being taken up by DC <italic toggle="yes">via</italic> mannose receptors, these micelles escape lysosomes and disperse in the cytoplasm [<xref rid="bib98" ref-type="bibr">98</xref>]. The dispersed micelles trigger mitochondrial ROS generation, activating cytosolic DNA/cyclic GMP-AMP synthase (cGAS)-STING signaling pathway and stimulating IFN-I secretion. Moreover, Hubbell et al. reported two different PEG-conjugated-poly(propylene sulfide) (PEG-PPS)-based micelles [<xref rid="bib99" ref-type="bibr">99</xref>,<xref rid="bib100" ref-type="bibr">100</xref>]. These micelles were capable of conjugating antigens and adjuvants comprising CpG [<xref rid="bib99" ref-type="bibr">99</xref>] or MPLA [<xref rid="bib100" ref-type="bibr">100</xref>], thereby enhancing antigen presentations. Also, such micellar vaccine formulation markedly enhanced cellular and humoral responses while eliminating the need for dual adjuvants, simplifying platform preparation, and reducing costs.<fig id="fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p><bold>Fabrications and applications of micelles in cancer immunotherapy.</bold> (A) Schematic diagram of self-assembly micelle, comprising PEG-PE, palmitoylated polypeptide, and MPLA, where hydrophobic components, palmitic acid, and MPLA are integrated into micelle's hydrophobic core. (C) Accumulation of different FITC formulations (FITC; FITC-labeled micelle, F-M; FITC-labeled liposome, F-L) in draining LN (DLN) at indicated time points (axillary LNs are referred as &#8220;aLNs&#8221; and inguinal LNs are referred as &#8220;iLNs&#8221;). Reproduced with permission [<xref rid="bib62" ref-type="bibr">62</xref>]. Copyright 2017, Springer. (B) Schematic illustration of Man-VIPER delivery systems, consisting of disulfide-conjugated OVA antigens and membranolytic melittin (either releasable Man-VIPER-R or non-releasable Man-VIPER-NR). System self-assembles into micelles is endocytosed <italic toggle="yes">via</italic> mannosylated segments, leading to disassembly in endosomes and subsequent MHC I or MHC II epitope presentation to respective T-cell subsets. (D) Size distributions of non-membranolytic D-melittin-free analogues (Man-AP), Man-VIPER-R and Man-VIPER-NR characterized by dynamic light scattering (DLS; <italic toggle="yes">d</italic><sub>mean</sub>&#160;=&#160;27.6&#160;nm, 51.6&#160;nm, 40&#160;nm, respectively). (E) pH-dependent micellization of Man-AP, Man-VIPER-R and Man-VIPER-NR. Reproduced with permission [<xref rid="bib102" ref-type="bibr">102</xref>]. Copyright 2023, Elsevier.</p></caption><alt-text id="alttext0025">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3.jpg"/></fig></p><p id="p0115">The personalized micelles are meticulously engineered to incorporate sensitivity groups, such as pH-responsive functionalization and disulfide bonds, enabling them to effectively deliver and release their contents upon deconstruction. pH-sensitive micelles have been formulated when peptide antigens are conjugated to pH-sensitive hydrophobic blocks [<xref rid="bib101" ref-type="bibr">[101]</xref>, <xref rid="bib102" ref-type="bibr">[102]</xref>, <xref rid="bib103" ref-type="bibr">[103]</xref>]. A notable example is a mannosylated Virus-Inspired Polymers for Endosomal Release (Man-VIPER) nanosystem comprising formulations with disulfide-conjugated OVA antigens. These formulations include either releasable disulfide-conjugated membranolytic melittin (Man-VIPER-R) or non-releasable pentafluorobenzyl-conjugated melittin (Man-VIPER-NR) (<xref rid="fig3" ref-type="fig">Fig. 3</xref>B) [<xref rid="bib102" ref-type="bibr">102</xref>]. These formulations undergo self-assembly to form well-defined micelles, characterized by their preferential endocytosis mediated by mannosylated hydrophilic segments. The micelles disintegrate upon endosomal maturation, leading to either endosomal disruption and cross-presentation of major histocompatibility complex (MHC) I epitopes or lysosomal maturation and presentation of MHC II epitopes, targeting specific T cell subsets (<xref rid="fig3" ref-type="fig">Fig. 3</xref>D, E). In a similar vein, amphiphilic diblock of PCL-based arginine-glycine-aspartic acid (RGD)-PEG-<italic toggle="yes">ss</italic>-PCL (RPsP) is introduced where PCL is grafted with PEI <italic toggle="yes">via</italic> disulfide bonds and modifies with RGD [<xref rid="bib64" ref-type="bibr">64</xref>]. These nano-sized micelles are disintegrated by a high concentration of glutathione in tumor cells, leading to on-demand release of DOX and R848 and inducing activation of DC.</p></sec><sec id="sec2.2.2"><label>2.2.2</label><title>Nanogels</title><p id="p0120">Nanogels constitute nanoscale three-dimensional polymeric networks with the inherent capacity to encapsulate a diverse arrange of immune reagents. This encapsulation process is accomplished through widespread utilization of cross-linking agents, harnessing electrostatic interactions and oxidative self-polymerization mechanisms, culminating in sustained immune potency [<xref rid="bib104" ref-type="bibr">104</xref>,<xref rid="bib105" ref-type="bibr">105</xref>]. In cancer vaccine delivery, nanogels have demonstrated their overwhelming utility in facilitating controlled and prolonged release of encapsulated therapeutic agents [<xref rid="bib34" ref-type="bibr">34</xref>,<xref rid="bib106" ref-type="bibr">106</xref>]. For instance, HA-mRLNPs were developed to <italic toggle="yes">co</italic>-load mRNA-based lipid nanoparticles (LNP) and R838 into a hyaluronic acid (HA) dynamic hydrogel with a high molecular weight, resulting in long-lasting cancer immunotherapy [<xref rid="bib65" ref-type="bibr">65</xref>]. HA-based hydrogels controlled release of the mRLNPs after undergoing state transitions in a physiological environment. Further, the nanovaccines in the LNPs-hydrogel system retained their functions after 14 days of storage at room temperature. Similarly, an injectable hydrogel based on graphene oxide and low molecular weight PEI is electrostatically combined and employed to encapsulate mRNA (OVA and antigen) and adjuvants (R848) [<xref rid="bib66" ref-type="bibr">66</xref>]. After an injection into subcutaneous layers, these transformable nanogels release mRNA for at least thirty days.</p><p id="p0125">Apart from their outstanding biocompatibility, abundant raw material resources, and substantial antigen-loading capacities, nanogels also possess abilities to facilitate controlled release and degradation of antigens [<xref rid="bib107" ref-type="bibr">107</xref>]. Based on these, AP-SS nanogel is fabricated by disulfide cross-linking before electrostatic interaction of negatively-charged alginate sodium with branched PEI<sub>2k</sub> [<xref rid="bib67" ref-type="bibr">67</xref>]. These nanogels exhibit minimal cytotoxicity, great antigen-loading capacity, and enhanced vaccine-elicited humoral and cellular immune responses. In addition to promoting antigen uptake by BMDC, reducible AP-SS nanogels also promote antigen release and cytosolic degradation. Except for this, a pH-degradable nanogel containing block copolymer micelles covalently functionalized with TLR7/8 agonist <italic toggle="yes">1</italic>-(<italic toggle="yes">4</italic>-(aminomethyl)benzyl)-<italic toggle="yes">2</italic>-butyl-1<italic toggle="yes">H</italic>-imidazo[<italic toggle="yes">4</italic>,<italic toggle="yes">5</italic>-<italic toggle="yes">c</italic>]quinolin-<italic toggle="yes">4</italic>-amine (IMDQ) and Texas Red cadaverine is proposed [<xref rid="bib68" ref-type="bibr">68</xref>]. Precise calculation of hydrodynamic radii deduced from resultant autocorrelation functions, substantiates not only conjugation of dibenzyl cyclooctyne-modified OVA but also degradation of IMDQ-loaded nanogels upon acidification. Such a nanogel carrier system is pre-defined in morphology, and guarantees control over <italic toggle="yes">co</italic>-delivery of each vaccine component. This nanogel emphasizes importance of incorporations of immune adjuvant and antigen into the same carrier system. Also, the self-adjuvant nanovaccine that is assembled by amphiphilic pH-sensitive galactosyl dextran-retinal and OVA, facilitates cytosolic antigen release and improves cancer vaccine efficacy after triggering a lysosomal rupture [<xref rid="bib108" ref-type="bibr">108</xref>].</p><p id="p0130">In brief, utilizing polymeric micelles and nanogels provides outstanding functionality and adaptability in engineering bespoke nanovaccine. Micelles, synthesized from amphiphilic block copolymers, exhibit their distinctive structural and compositional attributes, which is crucial for significant cellular uptake and specific stimulus responsiveness. These engineered micelles enable structure transformation, precise targeting and potentiate effective immune activation. Meanwhile, meticulously-engineered polymeric network structures within the nanogels ensure stable encapsulation and prolonged release of the vaccine constituents. Such a configuration of nanogels is pivotal in preserving biocompatibility while facilitating effective encapsulation and incremental release of diverse immunogenic elements. This strategic approach significantly augments therapeutic efficacy and longevity of the personalized nanovaccines. However, the development of polymeric nanovaccines underscores the crucial balance between innovation and practicality. While the structural design of micelles and nanogels provides promising pathways for targeted delivery and sustained release, the associated complexities in clinical translation highlight the need for continued research to optimize their therapeutic efficacy and safety in varied treatment contexts. Challenges such as potential toxicity from degradation products, non-specific immune reactions including allergic responses, and barriers to stable antigen release are notable considerations.</p></sec></sec><sec id="sec2.3"><label>2.3</label><title>Biomimetic nanovaccines</title><p id="p0135">Biomimetic syntheses entail synthesis and presentation of protein cargos on cell surfaces, offering a promising approach for efficient development of the ligand-targeted nanovaccines. Such biosynthesis process has been upheld native conformations, structures, and activities of functional proteins/lipids of interest. Depending on different preparation sources or approaches, biomimetic nanovaccines can be broadly categorized into vesicle-like, nanodisc, virus-like-oriented nanovaccines.</p><sec id="sec2.3.1"><label>2.3.1</label><title>Vesicle-like</title><p id="p0140">Large amphiphilic molecules form vesicles as nanoscale containers extending liposome skeletons. Their self-assembly into vesicles protects biomolecules, facilitating endocytosis and subsequent release in early endosomes before lysosomal fusion. This design is leveraged in lipid-based antigen delivery systems, inducing membrane fusion or endosomal destabilization for effective cytoplasmic antigen delivery. Nanocarriers with natural lipid-embedded vesicular structures are amenable to functionalization to form personalization nanovaccines, which achieve antigen-specific immune responses <italic toggle="yes">via</italic> multiple signaling pathways [<xref rid="bib109" ref-type="bibr">109</xref>]. An example of HA-DOTAP-PLGA NPs has been investigated as vaccine delivery vehicles, exhibiting enhanced antigen presentation <italic toggle="yes">via</italic> both MHC I/II pathways after HA-CD44 receptor-mediated endocytosis [<xref rid="bib69" ref-type="bibr">69</xref>]. Self-assembled liposomes-based nanovaccines, that were composed of monophosphatidyl (A) and CpG-ODN, had desirable antitumor immunities, especially Th1 cell response through activations of nuclear factor-&#954;B (NF-&#954;B) and protein kinase (MAPK) signaling pathways [<xref rid="bib110" ref-type="bibr">110</xref>]. Liposomal vesicles based on pH-responsive systems represent one of the most common design strategies towards nanovaccines [<xref rid="bib111" ref-type="bibr">111</xref>]. Yuba and colleagues have documented a series of highly pH-sensitive liposomes that have been shown promise in augmenting cancer immunotherapy [<xref rid="bib112" ref-type="bibr">[112]</xref>, <xref rid="bib113" ref-type="bibr">[113]</xref>, <xref rid="bib114" ref-type="bibr">[114]</xref>, <xref rid="bib115" ref-type="bibr">[115]</xref>]. By incorporating pH-sensitive <italic toggle="yes">3</italic>-methylglutarylated residues (MGlu-Dex) as the antigen delivery system, the mGlu-Dex-modified liposome is internalized by DCs through endocytosis and subsequently entrapped within endosomal compartments [<xref rid="bib112" ref-type="bibr">112</xref>]. A mildly acidic microenvironment destabilizes liposomes, thereby prompting release of antigenic molecules confined within the endosome. Besides solid lipids [<xref rid="bib116" ref-type="bibr">116</xref>], phospholipids [<xref rid="bib117" ref-type="bibr">117</xref>], lipids [<xref rid="bib118" ref-type="bibr">118</xref>], and cationic/helper polymers [<xref rid="bib70" ref-type="bibr">70</xref>] -centered nanovesicles have also been explored for personalized treatment of cancer.</p><p id="p0145">Exosomes represent a category of diminutive extracellular vesicles, characterized by approximate diameters spanning from 30 to 100&#160;nm [<xref rid="bib119" ref-type="bibr">119</xref>]. They encompass considerable therapeutic potential by virtue of their multifaceted cargo, containing proteins, lipids, nucleic acids, microRNAs, and long non-coding RNAs [<xref rid="bib120" ref-type="bibr">120</xref>]. From diverse cellular sources, the exosome-based vaccines manifest a broad spectrum of immunomodulatory activities, endowing them with remarkable versatility as antigen-delivery vehicles [<xref rid="bib121" ref-type="bibr">121</xref>]. For instance, exosomes derived from DCs possess capacity to activate CD4<sup>+</sup> and CD8<sup>+</sup> T cells <italic toggle="yes">via</italic> antigenic complexes adorning their surface [<xref rid="bib122" ref-type="bibr">122</xref>]. Similarly, exosomes derived from B cell lymphoma cells can induce both clonal expansion of T cells and secretion of cytokines including IL-6 and TNF-&#945; [<xref rid="bib123" ref-type="bibr">123</xref>]. Given their interactions with immune cells and ability to instigate downstream signaling cascades, these exosome-based vaccines function as indispensable antigen carriers and immunomodulatory adjuvants within cancer immunotherapy [<xref rid="bib124" ref-type="bibr">124</xref>]. Furthermore, exosomes have been identified as effective biomarkers for gauging adaptive immune activation, playing a crucial role in the diagnosis and treatment of cancers [<xref rid="bib121" ref-type="bibr">121</xref>].</p><p id="p0150">Besides, artificial cytomembranes-based nanovesicles are also derived from various sources, including DC [<xref rid="bib125" ref-type="bibr">125</xref>], cancer cells [<xref rid="bib126" ref-type="bibr">126</xref>], bacteria [<xref rid="bib127" ref-type="bibr">127</xref>], red CM [<xref rid="bib128" ref-type="bibr">128</xref>], TM [<xref rid="bib85" ref-type="bibr">85</xref>], <italic toggle="yes">etc</italic>. The cytomembrane-base vesicle widened nanovaccine applications for multiple tumor types [<xref rid="bib71" ref-type="bibr">71</xref>]. For instance, a personalized cancer vaccine based on recombinant adenovirus-infected DC membranes was genetically engineered, inheriting complete surface functional proteins of mature DC and enabling direct antigen presentation to naive T cells [<xref rid="bib125" ref-type="bibr">125</xref>]. Immune reagents coated on CM [<xref rid="bib129" ref-type="bibr">129</xref>], such as TMs, allow acquisitions of a comprehensive array of CM protein antigens, thereby eliciting a specific immune response against corresponding tumors (<xref rid="fig4" ref-type="fig">Fig. 4</xref>A) [<xref rid="bib130" ref-type="bibr">130</xref>]. For instance, the cMnMOF@CM nanovaccine is established from TM derived from OVA-overexpressing melanoma B16&#160;cells after encapsulations of CpG and TLR9 within Mn-MOF (<xref rid="fig4" ref-type="fig">Fig. 4</xref>B) [<xref rid="bib72" ref-type="bibr">72</xref>]. cMn-MOF@CM nanovaccines obtain a comprehensive CM antigen array exposed to calreticulin and enhance DC endocytosis. Similarly, an advanced biomimetic nanovaccine, CMM-DiR, encapsulates STING agonists (MnO<sub>2</sub> nanoparticles) and photothermal agent DiR within TM (<xref rid="fig4" ref-type="fig">Fig. 4</xref>D) [<xref rid="bib73" ref-type="bibr">73</xref>]. This formulation promotes a rapid, explosive release of Mn<sup>2+</sup> and enhances tumor cell uptake <italic toggle="yes">via</italic> homotypic adhesion properties (<xref rid="fig4" ref-type="fig">Fig. 4</xref>C, E). Notably, Mn<sup>2+</sup> activates intracellular STING pathway and is a robust activator of cGAS within innate immune system's response against malignancies [<xref rid="bib131" ref-type="bibr">131</xref>,<xref rid="bib132" ref-type="bibr">132</xref>]. Mechanistically, Mn<sup>2+</sup> enhances binding affinity between cGAMP and STING while simultaneously increasing sensitivity of cGAS to double-stranded DNA, amplifying STING signaling and eliciting downstream immunostimulatory responses (<xref rid="fig4" ref-type="fig">Fig. 4</xref>F&#8722;H). Moreover, membrane fusion technology facilitates formations of HM vesicles, combining Escherichia coli cytoplasmic membrane with TM derived from resected autologous tumor tissue [<xref rid="bib74" ref-type="bibr">74</xref>]. These autologous HM vesicles extend antigen-specific tolerance, while pathogen-associated molecular patterns (PAMP) in bacterial membranes trigger innate immune responses by engaging pattern recognition receptors on epithelial and immune cells. Fusion of tumor neoantigens and bacterial PAMP is also an effective cancer vaccine strategy, potentially eliciting robust antitumor immunity.<fig id="fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p><bold>Fabrications and applications of vesicles or nanodisc in cancer immunotherapy.</bold> (A) Schematic illustration of personalized nanovaccine by coating adjuvant R837-loaded PLGA NP with calcinetin-expressed Luc-4T1 cell membrane antigens. Reproduced with permission [<xref rid="bib130" ref-type="bibr">130</xref>]. Copyright 2021, American Chemical Society. (B) Diagram of cMn-MOF@CM nanovaccine. Reproduced with permission [<xref rid="bib72" ref-type="bibr">72</xref>]. Copyright 2021, Elsevier. (C) Detail mechanism of <italic toggle="yes">in situ</italic> STING-activating vaccination strategy. (D) Composition of CMM-DiR and functions of each component. (E) Mn<sup>2+</sup> release profiles in pH 7.4 and pH 6.8 solutions (H<sub>2</sub>O<sub>2</sub>). (F) Expression of proteins on different groups. (G) Western blot for activation of cGAS-STING pathway in DC 2.4&#160;cells with different treatments: Complete reaction liquid (CMM-DiR<sup>1</sup>), supernatant (CMM-DiR<sup>sup</sup>), and precipitation (CMM-DiR<sup>pre</sup>) from <italic toggle="yes">co</italic>-incubated CMM-DiR and H<sub>2</sub>O<sub>2</sub> solution (pH 6.8). (H) Real-time quantitative polymerase chain reaction analysis for relative expression of cGAS-STING axis in tumor sites of mice with different treatment (<italic toggle="yes">n</italic>&#160;=&#160;5). Reproduced with permission [<xref rid="bib73" ref-type="bibr">73</xref>]. Copyright 2021, Elsevier. (I) Whole cancer cell derived of TM, followed by incubation with MPLA and styrene-maleic acid to form MPLA-loaded cancer cell membrane nanodisc (CCND/MPLA). (J) Size of cancer cell membrane-based nanodisc (CCND) and CCND/MPLA (<italic toggle="yes">n</italic>&#160;=&#160;3). (K) TEM images of CCND (left) and CCND/MPLA (right) negatively stained with uranyl acetate. (L) Protein profiles of MC38&#160;cell membrane (1), CCND (2), and CCND/MPLA (3) after gel electrophoresis. (M) Western blot probing for tumor antigens in MC38&#160;cell membrane, CCND, and CCND/MPLA. Reproduced with permission [<xref rid="bib135" ref-type="bibr">135</xref>]. Copyright 2023, American Chemical Society.</p></caption><alt-text id="alttext0030">Fig. 4</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr4.jpg"/></fig></p></sec><sec id="sec2.3.2"><label>2.3.2</label><title>Nanodiscs</title><p id="p0155">Among the systems above, high-density lipoprotein (HDL) represents a naturally occurring nanodisc characterized by its prolonged circulation in plasma (with a half-life of approximately 3&#8764;4 days), distinguishing it from many synthetically engineered nanovesicles [<xref rid="bib75" ref-type="bibr">75</xref>]. Integration of small molecule drugs into HDLs has been shown to augment therapeutic efficacy, principally by enhancing the small molecules&#8217; solubility, circulation half-life, and distribution profile. Pre-formed sHDL nanodiscs offer a streamlined approach, wherein they can be readily combined with cholesteryl-CpG and tumor antigen peptides, including neoantigens identified through tumor DNA sequencing [<xref rid="bib76" ref-type="bibr">76</xref>]. This process yields homogeneous, stable, and ultra-small nanodiscs at ambient temperature in less than 2&#160;h. Employing sHDL as a matrix for encapsulating various bioactive compounds has proven effective in promoting immunotherapeutic interventions targeting MC38 tumors, glioblastoma multiforme, and cancer immunotherapy directed against cancer stem cells [<xref rid="bib77" ref-type="bibr">77</xref>,<xref rid="bib133" ref-type="bibr">133</xref>]. Furthermore, alternative formulations, such as CM fortified with styrene-maleic acid as a scaffold, have been employed in construction of nanodiscs, in which designs function as potent modalities for anti-tumor vaccination strategies (<xref rid="fig4" ref-type="fig">Fig. 4</xref>I) [<xref rid="bib134" ref-type="bibr">134</xref>,<xref rid="bib135" ref-type="bibr">135</xref>]. Following characterization, the CCND/MPLA nanodiscs, measuring 16&#160;nm in diameter and displaying circular morphology, exhibit protein profiles akin to the MC38 plasma membrane (<xref rid="fig4" ref-type="fig">Fig. 4</xref>J&#8722;L). Notably, these nanodiscs have been confirmed to contain tumor-promoting markers such as CD44, programmed death ligand 1 (PD-L1), and the tumor-associated antigen EphA247 (<xref rid="fig4" ref-type="fig">Fig. 4</xref>M). This nanodisc-based formulation thus holds potential for applicability across a broad spectrum of cancer types.</p></sec><sec id="sec2.3.3"><label>2.3.3</label><title>Virus-like</title><p id="p0160">Biomimetic nanovaccines, originating from viral sources, employ self-assembled viral capsid proteins devoid of genetic material and have found widespread applications in vaccine design, especially in the context of cancer vaccines [<xref rid="bib78" ref-type="bibr">78</xref>,<xref rid="bib79" ref-type="bibr">79</xref>,<xref rid="bib136" ref-type="bibr">136</xref>]. These VLPs, functioning as biomaterial scaffolds characterized by pathogen-like polyvalent structures and versatile chimeric multiepitope, hold the potential to serve as nanocarriers for antigen delivery and the induction of immune responses [<xref rid="bib137" ref-type="bibr">137</xref>]. Cervarix, the FDA-approved human papillomavirus (HPV) vaccine, consisting of HPV16 and HPV18 L1-protein-based VLP has been produced using the virus-like nanoformulation. Another instance involved engineered <italic toggle="yes">Salmonella typhimurium</italic> bacteriophage P22-based VLP, which were <italic toggle="yes">co</italic>-encapsulated with two proteins of respiratory syncytial virus (M and M2) [<xref rid="bib80" ref-type="bibr">80</xref>]. <italic toggle="yes">In vivo</italic> results showed that the P22-M/M2-treated mice exhibited significantly decreased lung viral titers, indicating potential of the VLP-based strategies in designing nanovaccines generating immune responses towards multiple subunit antigens. Except for that, those of prokaryotic or eukaryotic origin, which are called protein cages and vaults, are generally for immune molecular transportation and induce robust immune responses. Cages like the 13&#160;nm cage of human heavy chain ferritin (an iron storage protein) [<xref rid="bib138" ref-type="bibr">138</xref>], 25&#160;nm E2 cage derived from the pyruvate dehydrogenase complex of <italic toggle="yes">Bacillus stearothermophilus</italic> [<xref rid="bib139" ref-type="bibr">139</xref>], and 24&#160;nm encapsulins of bacteria and archaea, have all been employed as nanocarriers for delivering antigens and eliciting immune responses post-immunization [<xref rid="bib140" ref-type="bibr">140</xref>]. In addition, eukaryotic ribonucleoproteins assembly of a cage-like barrel-shaped structure is also provided to design protein-based nanovaccines, increasing antigen-specific CD4<sup>+</sup> T cell responses with multiple cytokine secretion patterns [<xref rid="bib140" ref-type="bibr">140</xref>,<xref rid="bib141" ref-type="bibr">141</xref>].</p><p id="p0165">Biomimetic nanovaccines, comprising vesicles, nanodiscs, and VLP, advance cancer immunotherapy by optimizing antigen delivery and immune response specificity. These nanoscale entities emulate biological processes for targeted antigen presentation and activation of immune cells. However, their fabrication, being more complex than nanovaccines derived from inorganic materials and polymers, poses significant challenges in selecting and processing diverse nanomaterials for development of tailored vaccines, necessitating a sophisticated approach to their production methodology.</p></sec></sec></sec><sec id="sec3"><label>3</label><title>Nanovaccines-based strategies for enhanced cancer immunotherapy</title><p id="p0170">Based on the above description, engineering, and characterization of nanocarriers from a diverse array of sources, including inorganic, polymeric, and biomimetic materials, alongside their adjuvant attributes, are of paramount importance. Efficacy of these nanovaccines in the context of enhanced cancer immunotherapy depends on various factors: vaccination methodologies, antigen specificity, active constituents anchored to different immune cells, and dynamic profiles of TME specific to diseases.</p><p id="p0175">In strategies aimed at augmenting cancer immunotherapy, nanovaccines necessitate a focused approach on LN targeting for antigen delivery, efficacious antigen presentation, initiation of immune response signaling pathways, and synchronized modulation of TME under distinct disease profiles. Integration of different active components, encompassing adjuvants, receptors, agonists, cytokines, and chemokines, into formation of custom nanovaccines is advantageous for targeting immune cells and mitigating immunosuppressive milieu (<xref rid="tbl2" ref-type="table">Table 2</xref>). Specifically, efficacy of LN targeting and subsequent accumulation is intricately-linked to the vaccination strategy employed, including <italic toggle="yes">in situ</italic> and tumor-specific modalities. For activation of the immune system, stimulation and proliferation of T and B cells are fundamental. Addressing immunosuppressive TME, which encompasses TAM, and MDSC, among others, necessitates a strategic focus on personalized targeting ligands or antigens and modulation of associated signaling pathways. Subsequent sections will extensively examine these critical aspects in context of enhancing therapeutic potential of custom nanovaccines towards enhanced cancer immunotherapy.<table-wrap position="float" id="tbl2" orientation="portrait"><label>Table 2</label><caption><p>Customized nanovaccines targeting LN and immune cells.</p></caption><alt-text id="alttext0065">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Targeting sites</th><th colspan="1" rowspan="1">Nanovaccine names</th><th colspan="1" rowspan="1">Essential components</th><th colspan="1" rowspan="1">Features</th><th colspan="1" rowspan="1">Tumor types</th><th colspan="1" rowspan="1">Refs</th></tr></thead><tbody><tr><td rowspan="8" align="left" colspan="1">LN</td><td align="left" colspan="1" rowspan="1">AlO(OH)-polymer NP</td><td align="left" colspan="1" rowspan="1">OVA and CpG</td><td align="left" colspan="1" rowspan="1">Nanosized vaccine (90&#160;nm) for LN</td><td align="left" colspan="1" rowspan="1">B16-OVA and B16&#8211;F10 melanomas</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib142" ref-type="bibr">142</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Melittin-lipid based nanovaccine</td><td align="left" colspan="1" rowspan="1">Whole-cell tumor antigen</td><td align="left" colspan="1" rowspan="1">Nanosized vaccine (10&#8722;20&#160;nm) for LN</td><td align="left" colspan="1" rowspan="1">B16&#8211;F10 melanoma</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib143" ref-type="bibr">143</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Amphiphiles-based molecular vaccine</td><td align="left" colspan="1" rowspan="1">Peptide antigen</td><td align="left" colspan="1" rowspan="1">&#8220;Albumin hitchhiking&#8221; strategy</td><td align="left" colspan="1" rowspan="1">TC-1 tumor and B16&#8211;F10 melanoma</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib144" ref-type="bibr">144</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Tu-NP<sub>FN</sub>(+)/Ln-NP<sub>R848</sub></td><td align="left" colspan="1" rowspan="1">Ferrimagnetic nanocube (FN) and R848</td><td align="left" colspan="1" rowspan="1">Nanosized vaccine (&#8764;100&#160;nm) for LN</td><td align="left" colspan="1" rowspan="1">CT26 colon tumor</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib145" ref-type="bibr">145</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">OVA/CpG</td><td align="left" colspan="1" rowspan="1">OVA and CpG</td><td align="left" colspan="1" rowspan="1">Small size, narrow distribution, negative charge, and good stability for LN targeting</td><td align="left" colspan="1" rowspan="1">E.G7-OVA tumor</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib146" ref-type="bibr">146</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Gold nanoparticle (GNP)</td><td align="left" colspan="1" rowspan="1">OVA</td><td align="left" colspan="1" rowspan="1">Nanosized vaccine (10&#8722;20&#160;nm) for LN</td><td align="left" colspan="1" rowspan="1">E.G7-OVA tumor</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib147" ref-type="bibr">147</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Pluronic-stabilized poly(propylene) sulfide NP</td><td align="left" colspan="1" rowspan="1">CpG and paclitaxel</td><td align="left" colspan="1" rowspan="1">Nanosized vaccine (30&#160;nm) for LN</td><td align="left" colspan="1" rowspan="1">B16&#8211;F10 melanoma</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib148" ref-type="bibr">148</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">OVA@CpG (mNV)</td><td align="left" colspan="1" rowspan="1">OVA and CpG-SH</td><td align="left" colspan="1" rowspan="1">Extended &#8220;antigen depot&#8221; effect</td><td align="left" colspan="1" rowspan="1">B16-OVA melanoma</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib149" ref-type="bibr">149</xref>]</td></tr><tr><td rowspan="8" align="left" colspan="1">T Cell</td><td align="left" colspan="1" rowspan="1">Poly-lactide-<italic toggle="yes">co</italic>-glycolide (PLG) scaffold</td><td align="left" colspan="1" rowspan="1">Granulocyte-macrophage colony-stimulating factor (GM-CSF) and CpG-ODN</td><td align="left" colspan="1" rowspan="1">Release cytokine to recruit and house host DC</td><td align="left" colspan="1" rowspan="1">B16&#8211;F10 melanoma</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib150" ref-type="bibr">150</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Multifunctional bacterial membrane-coated nanoparticle (BNP)</td><td align="left" colspan="1" rowspan="1">PC7A/CpG and Neoantigen</td><td align="left" colspan="1" rowspan="1">Capturing cancer neoantigens resulting in enhancement of DC uptake and cross presentation</td><td align="left" colspan="1" rowspan="1">B78 melanoma and NXS2 neuroblastoma</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib151" ref-type="bibr">151</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">MSN-TY</td><td align="left" colspan="1" rowspan="1">Screened peptide (TY), OVA, and CpG</td><td align="left" colspan="1" rowspan="1">DC targeting peptide</td><td align="left" colspan="1" rowspan="1">B16-OVA melanoma</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib152" ref-type="bibr">152</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">NP-supported cytomembranes (NP@FM)</td><td align="left" colspan="1" rowspan="1">Whole tumor antigen complexes and immunological <italic toggle="yes">co</italic>-stimulatory molecules</td><td align="left" colspan="1" rowspan="1">Mimicking both APC and cancer cells</td><td align="left" colspan="1" rowspan="1">4T1 breast cancer</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib153" ref-type="bibr">153</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PLA-PEI NP</td><td align="left" colspan="1" rowspan="1">TLR9, CpG, and protein antigen</td><td align="left" colspan="1" rowspan="1">Antigen cross-presentation through &#8220;proton sponge effect&#8221;</td><td align="left" colspan="1" rowspan="1">B16-OVA, MC38, and E0771 tumors</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib154" ref-type="bibr">154</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">iDR-NCs/neoantigen complex</td><td align="left" colspan="1" rowspan="1">CpG, <italic toggle="yes">Stat3</italic> shRNA, and PPT-<italic toggle="yes">g</italic>-PEG</td><td align="left" colspan="1" rowspan="1">Neoantigen-specific T cell response</td><td align="left" colspan="1" rowspan="1">MC38 tumor</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib155" ref-type="bibr">155</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DNA nanodevice-based vaccine</td><td align="left" colspan="1" rowspan="1">Tumor antigen peptide, dsRNA, CpG loop, locking strands</td><td align="left" colspan="1" rowspan="1">Amenable size and pH-responsive manner in respond to acidic endosomal environment</td><td align="left" colspan="1" rowspan="1">B16-OVA melanoma</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib156" ref-type="bibr">156</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">mRNA/LNP</td><td align="left" colspan="1" rowspan="1">LNP, mRNA encoding CMV glycoproteins gB, and pentameric complex</td><td align="left" colspan="1" rowspan="1">Higher affinity between antigen and T cell</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib157" ref-type="bibr">157</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">B Cell</td><td align="left" colspan="1" rowspan="1"><sup>D</sup>CDX modified liposome (<sup>D</sup>CDX-sLip)</td><td align="left" colspan="1" rowspan="1">Brain-targeted <italic toggle="yes">D</italic>-peptide ligand (<sup>D</sup>CDX) and OVA</td><td align="left" colspan="1" rowspan="1">IgM-Fc receptor (Fc&#956;R) pathway to targeting B cell</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib158" ref-type="bibr">158</xref>]</td></tr><tr><td rowspan="3" align="left" colspan="1">NK Cell</td><td align="left" colspan="1" rowspan="1">Cyclic diguanylate monophosphate (cdGMP)/MPLA-encapsulated immuno-NP</td><td align="left" colspan="1" rowspan="1">cdGMP and MPLA</td><td align="left" colspan="1" rowspan="1">Cytokine gradient drive of NK cell upregulation</td><td align="left" colspan="1" rowspan="1">TNBC</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib159" ref-type="bibr">159</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Fe<sub>3</sub>O<sub>4</sub>/SiO<sub>2</sub> core/shell NP</td><td align="left" colspan="1" rowspan="1">Cyanine5.5 (Cy5.5) and NK-92MI cell</td><td align="left" colspan="1" rowspan="1">Modulation NK cell</td><td align="left" colspan="1" rowspan="1">Human B cell lymphoma</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib160" ref-type="bibr">160</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Fe<sub>3</sub>O<sub>4</sub>@PDA NP</td><td align="left" colspan="1" rowspan="1">Labeled NK cell</td><td align="left" colspan="1" rowspan="1">NK cell recruitment and its infiltration into tumor site</td><td align="left" colspan="1" rowspan="1">A549 cancer</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib161" ref-type="bibr">161</xref>]</td></tr><tr><td rowspan="6" align="left" colspan="1">TAM</td><td align="left" colspan="1" rowspan="1">Hybrid PEG micelle</td><td align="left" colspan="1" rowspan="1">BLZ-945, OVA, and NLG919</td><td align="left" colspan="1" rowspan="1">BLZ-945 and NLG919 caused effective M2-like TAM depletion</td><td align="left" colspan="1" rowspan="1">E.G7-OVA tumor</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib162" ref-type="bibr">162</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">PEG-FA-based liposome (PEG-FA-Lip)</td><td align="left" colspan="1" rowspan="1">CpG, FA, and DOX</td><td align="left" colspan="1" rowspan="1">FA-receptor mediate endocytosis</td><td align="left" colspan="1" rowspan="1">4T1 breast cancer</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib163" ref-type="bibr">163</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Dual-inhibitor loaded supramolecular NP</td><td align="left" colspan="1" rowspan="1">MCSF 1 receptor (CSF1R) and MAPK inhibitor</td><td align="left" colspan="1" rowspan="1">Inhibitions of CSF1R and MAPK signaling pathway to enhance repolarization of M2-TAM</td><td align="left" colspan="1" rowspan="1">4T1 breast cancer</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib164" ref-type="bibr">164</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">M2NP</td><td align="left" colspan="1" rowspan="1">&#945;-peptide</td><td align="left" colspan="1" rowspan="1">M2-TAM binding peptide</td><td align="left" colspan="1" rowspan="1">B16 melanoma</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib165" ref-type="bibr">165</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Peptide hydrogel</td><td align="left" colspan="1" rowspan="1">TLR7/8a</td><td align="left" colspan="1" rowspan="1">TLR7/8 for driving polarization of macrophage towards M1-TAM</td><td align="left" colspan="1" rowspan="1">4T1 and B16 tumors</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib166" ref-type="bibr">166</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Fe-MOF</td><td align="left" colspan="1" rowspan="1">Diclofenac and peptide</td><td align="left" colspan="1" rowspan="1">Decrease efflux by hepcidin/ferroportin signaling pathway</td><td align="left" colspan="1" rowspan="1">H22 tumor</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib167" ref-type="bibr">167</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">TAN</td><td align="left" colspan="1" rowspan="1">Mesoporous silica</td><td align="left" colspan="1" rowspan="1">Fe(III)-captopril</td><td align="left" colspan="1" rowspan="1">Repolarized N2 phenotype</td><td align="left" colspan="1" rowspan="1">H22 tumor</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib168" ref-type="bibr">168</xref>]</td></tr><tr><td rowspan="3" align="left" colspan="1">MDSC</td><td align="left" colspan="1" rowspan="1">TAD-based (FIT) NP</td><td align="left" colspan="1" rowspan="1">TAD and indocyanine green</td><td align="left" colspan="1" rowspan="1">Inhibit MDSC function by TAD</td><td align="left" colspan="1" rowspan="1">Colon tumor</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib169" ref-type="bibr">169</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Lipid nanocapsule</td><td align="left" colspan="1" rowspan="1">Gemcitabine-C12</td><td align="left" colspan="1" rowspan="1">Gemcitabine-C12 targeting monocytic MDSC subset</td><td align="left" colspan="1" rowspan="1">Lymphoma and melanoma tumors</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib170" ref-type="bibr">170</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Glyceryl-monooleate-based liquid-crystal core NP</td><td align="left" colspan="1" rowspan="1">CCL2, OVA, and RNAi sequence</td><td align="left" colspan="1" rowspan="1">Chemokine targeting MDSC</td><td align="left" colspan="1" rowspan="1">MCA-203 fibrosarcoma</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib171" ref-type="bibr">171</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">NKT Cell</td><td align="left" colspan="1" rowspan="1">PEGylated lipid-PLGA NP</td><td align="left" colspan="1" rowspan="1">CpG-ODN and MPLA</td><td align="left" colspan="1" rowspan="1">Presentation of GalCer <italic toggle="yes">via</italic> MHC I-like molecule (CD1) to NKT cell</td><td align="left" colspan="1" rowspan="1">B16&#8211;F10 melanoma</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib172" ref-type="bibr">172</xref>]</td></tr><tr><td rowspan="2" align="left" colspan="1">Treg Cell</td><td align="left" colspan="1" rowspan="1">Layer-by-layer hybrid NP</td><td align="left" colspan="1" rowspan="1">IR 780, Imatinib, and glucocorticoid-induced TNF receptor</td><td align="left" colspan="1" rowspan="1">Reductions of transcription factors of STAT3 and STAT5 in Treg cell</td><td align="left" colspan="1" rowspan="1">B16 and BL6 tumors</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib173" ref-type="bibr">173</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">CpG/cGAMP-hybrid liposome-Man (C/G-HL-Man)</td><td align="left" colspan="1" rowspan="1">Fenofibrate, cGAMP, CpG, and TM</td><td align="left" colspan="1" rowspan="1">Fenofibrate, activated peroxisome proliferator-activated receptor (PPAR)-&#945; pathway, and downstream genes related to FA metabolism</td><td align="left" colspan="1" rowspan="1">B16&#8211;F10 melanoma</td><td align="left" colspan="1" rowspan="1">[<xref rid="bib174" ref-type="bibr">174</xref>]</td></tr></tbody></table></table-wrap></p><sec id="sec3.1"><label>3.1</label><title>Escalation of lymph node accumulation</title><p id="p0180">In addition to their conventional surgical removal, increasing attention has been paid to modulation of the LN as a cancer treatment [<xref rid="bib175" ref-type="bibr">175</xref>]. LN are secondary-lymphoid tissues regarded as crucial hubs linking immune cells and regulating adaptive immune responses [<xref rid="bib176" ref-type="bibr">176</xref>]. They are distributed throughout the body and recruited leukocytes from the circulation screen antigen-laden lymph draining to different tissues [<xref rid="bib177" ref-type="bibr">177</xref>]. Efficient delivery of vaccines to LN is crucial in achieving cancer immunotherapy, with administration modes significantly influencing antigen accumulation and enrichment within LN. Nanovaccine delivery to LN commonly employs intratumoral and interstitial methods, resulting in a &#8220;depot effect&#8221; that prolongs antigen exposure within TME, thus inducing a potent immune response.</p><p id="p0185">Intratumoral injection is the direct and effective way for delivering <italic toggle="yes">in situ</italic> vaccines directly towards LN. This process involves engineered delivery of exogenous antigens directly into LN within tumors, eliciting immune responses [<xref rid="bib142" ref-type="bibr">142</xref>]. For instance, a high-density lipoprotein-mimicking peptide-phospholipid scaffold (termed &#945;-peptide-NP) was developed after lading melittin, forming an ultra-small (10&#8722;20&#160;nm) melittin-lipid nanoparticle (named &#945;-melittin-NP) [<xref rid="bib143" ref-type="bibr">143</xref>]. Compared with melittin, which had a molecular weight of 2840&#160;Da, as-fabricated &#945;-melittin-NP, within an ultra-small size range of 10&#8211;20&#160;nm, was favorable for LN uptake, and induced release of whole tumor antigen, retaining multiple immunogenic epitopes to trigger a robust immune response. Exogenous antigens are structurally encoded for LN delivery [<xref rid="bib178" ref-type="bibr">178</xref>]. Another innovative approach is the &#8220;albumin hitchhiking&#8221; strategy, designed for specific LN targeting by molecular vaccines [<xref rid="bib144" ref-type="bibr">144</xref>]. This strategy exploits albumin's role as a fatty acid transporter, whereby antigens or adjuvants, modified with a lipophilic albumin-binding domain, accumulate in lymphoid organs post-injection through <italic toggle="yes">in situ</italic> complexation and transportation with endogenous albumin. <italic toggle="yes">In situ</italic> vaccine programming within tumor sites provides another targeting-LN delivery method. For example, intratumoral injection of a composite containing adjuvant-loaded Ln-NP and antigen-inducing Tu-NP yields nanovaccines approximately 100&#160;nm in size with neutral/negative charge (<xref rid="fig5" ref-type="fig">Fig. 5</xref>A) [<xref rid="bib145" ref-type="bibr">145</xref>]. Under an alternating magnetic field, Tu-NP<sub>FN</sub> (100&#160;nm) generates prolifically antigens, while Ln-NP<sub>R848</sub> (35&#160;nm) captures a portion of the produced antigens, inducing <italic toggle="yes">in situ</italic> nanovaccines targeting LN after traversing interstitial space and LV (<xref rid="fig5" ref-type="fig">Fig. 5</xref>B, C). After intratumoral injection, the <italic toggle="yes">in situ</italic> programming nanovaccines convert primary tumors into whole-cell antigens for targeted LN delivery. Leveraging a hydrogel-based system, these <italic toggle="yes">in situ</italic> nanovaccines enable ROS-responsive DOX and nanoadjuvant (CpG-P-<italic toggle="yes">ss</italic>-M) releases, accumulating abundant tumor antigens within tumors [<xref rid="bib15" ref-type="bibr">15</xref>]. The CpG-P-<italic toggle="yes">ss</italic>-M's charge reversal facilitates adsorption and conversion into small, negatively charged tumor vaccines, optimizing LN priming.<fig id="fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p><bold>Nanovaccines for LN-targeted delivery and their enhanced cancer immunotherapy.</bold> (A) <italic toggle="yes">In situ</italic> programming of vaccines <italic toggle="yes">via</italic> two synergetic nanomedicines, Tu-NP<sub>FN</sub> and Ln-NP<sub>R848</sub>. (B) Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of total proteins generated by Tu-NP<sub>FN</sub> under an alternating magnetic field and proteins captured by Ln-NP<sub>R848</sub>. Proteins were stained with Coomassie Brilliant Blue. (C) Relative abundances of tumor antigens captured by Ln-NP<sub>R848</sub> as determined by liquid chromatography/tandem mass spectrometry. Reproduced with permission [<xref rid="bib145" ref-type="bibr">145</xref>]. Copyright 2022, American Chemical Society. (D) Schematic illustration of mNV-triggered antitumor immune responses. (G) Representative fluorescence images of DLN for groups of mNV that FAM-labeled CpG (mNV<sup>F</sup>) at the indicated time points. Reproduced with permission [<xref rid="bib149" ref-type="bibr">149</xref>]. Copyright 2018, American Chemical Society. (E) Personalized nanoDC that efficiently accumulates in LN after subcutaneous injection, directly stimulating TAA-specific T cells to kill tumor cells. (F) <italic toggle="yes">Ex vivo</italic> fluorescence image of FITC, FITC-labeled immature DCs membrane-based vaccines (nanoiDCs) or nanoDCs treated LN. Reproduced with permission [<xref rid="bib185" ref-type="bibr">185</xref>]. Copyright 2022, Wiley.</p></caption><alt-text id="alttext0035">Fig. 5</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr5.jpg"/></fig></p><p id="p0190">Intratumoral injection, while direct and efficient, often requires surgical, ultrasonic, or tracer dye guidance, adding complexity to the vaccination process [<xref rid="bib179" ref-type="bibr">179</xref>]. An alternative approach is to utilize interstitial administration methods such as subcutaneous, intramuscular, and intradermal injections to enable nanovaccines to enter capillary LV and reach LN. Efficiency of this transfer depends on the nanovaccines&#8217; characteristics like size, charge, and hydrophilic modifications, <italic toggle="yes">etc.</italic> These characteristics influence their movement through lymphatic pathways, interstitial structures (compositions of tangled collagen fibers and negatively charged HA), and blood flow rates [<xref rid="bib146" ref-type="bibr">146</xref>]. Size of antigen-bearing carriers reconciles diameter of LN vascular channels, approximately 100&#160;nm; larger nanoparticles fail to reach capillary LVs and are intercepted by tissue-resident DC, while particles smaller than 10&#160;nm are typically cleared through blood capillaries from intestine due to blood capillary flow rates being 100&#8211;500 times faster than LV [<xref rid="bib180" ref-type="bibr">180</xref>]. GNP-based nanovaccines of various sizes have been synthesized to evaluate their capacity for delivering payloads to the LN [<xref rid="bib147" ref-type="bibr">147</xref>]. Specifically, GNPs with 7, 14, and 28&#160;nm diameters are functionalized with OVA, resulting in corresponding hydrodynamic diameters of 10, 22, and 33&#160;nm, respectively. Significantly, OVA-GNPs with dimensions of 22 and 33&#160;nm exhibit superior delivery efficiency in targeting the draining LN compared to those with a diameter of 10&#160;nm. An adjuvant-targeted strategy also achieves passive accumulation within tumor-draining lymph nodes (TDLN), modulating effector responses and counteracting tumor-induced immunosuppression [<xref rid="bib181" ref-type="bibr">181</xref>]. Polymeric nanoparticles with a size of 30&#160;nm are prone to TDLN, mainly when administered in limbs on the same side as the tumor [<xref rid="bib148" ref-type="bibr">148</xref>].</p><p id="p0195">The &#8220;minimalist&#8221; nanovaccine design, which effectively captures nearly all cancer-related antigens [<xref rid="bib149" ref-type="bibr">149</xref>], exemplifies how extended antigen &#8220;depot&#8221; enhances LN-targeting potential of the nanovaccines. The nanovaccine (mNV), with a diameter of 50&#160;nm, is formulated using OVA and thiol-modified CpG (CpG-SH), resulting in a composition of 500 antigen molecules <italic toggle="yes">per</italic> nanoparticle [<xref rid="bib149" ref-type="bibr">149</xref>]. This substantial antigen-loading capacity of the nanovaccine facilitates efficient drainage into the LV and subsequent high retention in the LN, thereby initiating immune responses (<xref rid="fig5" ref-type="fig">Fig. 5</xref>D, G). Furthermore, an efficient accumulation of cargo within LN is achieved through application of the external forces, such as magnetic guiding mechanisms [<xref rid="bib182" ref-type="bibr">182</xref>]. Notably, functionalization of magnetic responsive components such as superparamagnetic oxides are harnessed as frameworks or scaffolds to guide homing of LN, with classical examples including ferric oxide as a magnetic nanocarrier. These intricately-crafted nanovaccines showcase a remarkable propensity for accumulation within profound regions of LN. Another example of superparamagnetic iron oxide coated with zinc oxide efficiently expedited LN homing through synergistic interactions between external forces and LN-homing leukocytes [<xref rid="bib183" ref-type="bibr">183</xref>]. Reports also indicate that DC-based vaccines exhibit enhanced LN targeting efficiency by incorporating key protein CC-chemokine receptor 7 from DC membrane vesicles, facilitating lymphatic homing [<xref rid="bib184" ref-type="bibr">184</xref>]. By maintaining <italic toggle="yes">co</italic>-stimulatory markers, MHC I antigen complexes, and lymphocyte homing receptors, a personalized DC-mimicking nanovaccine (nanoDC) also efficiently migrates to LN and elicits potent antigen-specific T-cell responses (<xref rid="fig5" ref-type="fig">Fig. 5</xref>E, F) [<xref rid="bib185" ref-type="bibr">185</xref>].</p><p id="p0200">In short, administration of the vaccination generally employs intratumoral and interstitial methods, efficiently facilitating antigen accumulation within LN and consequently triggering robust immune responses. Nanovaccine delivery strategies, encompassing intratumoral and interstitial routes, are meticulously designed to align with specific characteristics and structural complexities of LN. These passive targeting approaches, whether implemented <italic toggle="yes">via</italic> subcutaneous, intramuscular, or direct introduction into LV, are adept at ensuring targeted antigen accumulation within LNs in various tumor models. Furthermore, incorporation of active targeting mechanisms, driven by external forces, enhances precision of nanovaccine localization in LN. This holistic and versatile vaccine delivery approach significantly advances customized nanovaccines development in cancer immunotherapy. While these strategies hold promise, they also present challenges such as potential systemic toxicity, the necessity for precise targeting, and the complex interplay within TME that may impede effective vaccine delivery and action. The &#8220;albumin hitchhiking&#8221; strategy and <italic toggle="yes">in situ</italic> vaccine programming within tumor sites further illustrate the innovative approaches being explored to improve cancer immunotherapy. Addressing these challenges requires a nuanced understanding of the TME and a development of sophisticated nanovaccine systems capable of precise navigation and targeted delivery. As such, future research should not only aim to optimize these delivery methods but also to explore new targeting ligands and nanocarrier designs to enhance specificity, efficacy, and safety of the custom nanovaccines in cancer treatment.</p></sec><sec id="sec3.2"><label>3.2</label><title>Enhancing antigen presentation in single-cell level</title><sec id="sec3.2.1"><label>3.2.1</label><title>Enhancement of antigen presentation</title><p id="p0205">DC plays a central role in antigen presentation within context of cancer immunotherapy, which initiates and sustains effective immune responses through their efficient antigen presentation mechanisms [<xref rid="bib186" ref-type="bibr">186</xref>]. To ensure executing sufficient immune responses, customized nanovaccines are initially engulfed by DC. These tailored nanovaccines are internalized <italic toggle="yes">via</italic> receptor-mediated pathways in DCs, guaranteeing an effective immune response [<xref rid="bib187" ref-type="bibr">187</xref>,<xref rid="bib188" ref-type="bibr">188</xref>]. Specifically, the antigen presentation mediated by receptors from the C-type lectin family, such as DC-SIGN receptor, is one strategy for targeting DCs with custom nanovaccines [<xref rid="bib189" ref-type="bibr">189</xref>]. Additionally, nanovaccines engineered with mannose fragments, targeting overexpressed mannose receptors on APC surfaces, enhance cross-presentation of antigens [<xref rid="bib190" ref-type="bibr">190</xref>]. Moreover, appropriate delivery of regulatory cytokines, such as GM-CSF, creates a simulated infection microenvironment, enabling precise DC recruitments and proliferations [<xref rid="bib150" ref-type="bibr">150</xref>,<xref rid="bib191" ref-type="bibr">191</xref>,<xref rid="bib192" ref-type="bibr">192</xref>]. Omar et al. have underscored a critical role of GM-CSF released from PLG scaffolds in enhancing DC recruitment and proliferation in a dose-dependent manner [<xref rid="bib150" ref-type="bibr">150</xref>]. Experimental results demonstrated that implanting GM&#8211;CSF&#8211;based PLG matrices into mice significantly increased proportion of DC and regulated their maturation and dispersion. Furthermore, BNPs, abundant in PAMP such as TLR agonists, are recognized for their capacity to stimulate innate immunity and activate DC [<xref rid="bib151" ref-type="bibr">151</xref>]. Peptides are specifically binding to BMDCs and splenic DCs, identified through phage display technology, have also been incorporated into nanovaccine to targeting DCs effectively [<xref rid="bib152" ref-type="bibr">152</xref>,<xref rid="bib193" ref-type="bibr">193</xref>]. In brief, engineering inherent or specifically designed targets is a key strategy for activating and recruiting DCs with nanovaccines [<xref rid="bib32" ref-type="bibr">32</xref>].</p><p id="p0210">T cells, being integral to cell-mediated immunity and expressed by T-cell receptor (TCR), are pivotal in advanced cancer immunotherapy strategies [<xref rid="bib194" ref-type="bibr">194</xref>]. Central to these strategies is activation and proliferation of cytotoxic T-cells, notably CD8<sup>+</sup> T cells. Low immunogenicity and stability of antigens necessitate efficient antigen-specific delivery systems, with an emphasis on nanovaccines that stimulate CD8<sup>+</sup> T cell-mediated immunity [<xref rid="bib195" ref-type="bibr">195</xref>]. An ideal process should proficiently transport antigens to the cytoplasm of APC for MHC I-antigen complex formation through cross-presentation, thereby activating T cells for immune defense and pathogen clearance [<xref rid="bib196" ref-type="bibr">196</xref>]. Customized nano-based vaccination strategies, aimed at enhanced cross-presentation and T-cell responses can be categorized into several methods: aAPC based on membrane fusion, endosomal escape (<italic toggle="yes">e.g.</italic>, endosomal swelling rupture), photochemical internalization, and nucleic acid vaccines capable of sustained expression in APC [<xref rid="bib197" ref-type="bibr">197</xref>]. For example, a cytomembrane nanovaccine, engineered to mimic tumor cells and function as an APC, has demonstrated significant therapeutic effects (<xref rid="fig6" ref-type="fig">Fig. 6</xref>A) [<xref rid="bib153" ref-type="bibr">153</xref>]. Fusions of two types of cells result in high expressions of immunological <italic toggle="yes">co</italic>-stimulatory molecules and whole tumor antigen complexes on FM, allowing nanoparticle-supported FM (NP@FM) to behave as APC for T cell activation. Lipid bilayer, emulating natural APC membrane system, incites expansion of antigen-specific cytotoxic T-cell subpopulations <italic toggle="yes">via</italic> T-cell receptor stimulation [<xref rid="bib198" ref-type="bibr">198</xref>]. Similarly, nanosized artificial APC (naAPC)-based formulation induces antigen cross-presentation to T cells <italic toggle="yes">via</italic> size-transformation and peptide-MHC (pMHC) I complex/TCR signaling (<xref rid="fig6" ref-type="fig">Fig. 6</xref>C&#8722;G) [<xref rid="bib199" ref-type="bibr">199</xref>].<fig id="fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p><bold>Enhancement of antigen presentation with customized nanovaccines in cancer immunotherapy.</bold> (A) Preparation of MOF@cytomembrane. (B) Confocal laser scanning microscopy observation of fusion of DC (green fluorescence from anti-MHC II-FITC antibody) and 4T1 cell (red fluorescence from anti-CD44-APC antibody). Reproduced with permission [<xref rid="bib153" ref-type="bibr">153</xref>]. Copyright 2019, Springer. (C) Schematic illustration of mannan-decorated pathogen-like polymeric nanoparticle system (MPVax) and mechanism in eliciting antitumor immune responses. MPVax-CpG/Antigen is constructed with PLA-PEI core, loaded with CpG and antigens and shielded with oxidized mannan. MPVax-CpG/Antigen efficiently accumulates in LN by passive drainage or pDC and mannose-binding lectin mediated active transportation. After arriving at CD8<sup>+</sup> DC, antigens are presented to CD8<sup>+</sup> T cells and results in antigen-specific tumor eradication. Reproduced with permission [<xref rid="bib154" ref-type="bibr">154</xref>]. Copyright 2022, Elsevier. (D) Formation of size-transformable naAPC. Achieved through self-assembly of copolymer biotin-PEG-<italic toggle="yes">b</italic>-poly(<italic toggle="yes">N</italic>-<italic toggle="yes">2</italic>-hydroxypropyl methacrylamide-<italic toggle="yes">g</italic>-thiol)-<italic toggle="yes">b</italic>-poly[<italic toggle="yes">2</italic>-(dimethylamino) ethyl methacrylate], naAPC encapsulates IL-2 within their aqueous core and features a surface adorned with pMHC monomer and &#945;CD28. (E) Size and structure characterization of naAPC tested by DLS and TEM, respectively. <italic toggle="yes">In vitro</italic> CD3<sup>+</sup>CD8<sup>+</sup> T cell proliferation by (F) <italic toggle="yes">co</italic>-incubation of na&#239;ve T cells with mature DC 2.4&#160;cells, and <italic toggle="yes">co</italic>-incubation of mature DC 2.4&#160;cells and dying EG7-OVA cells with (G) T cells; and (H) preactivated T cells by photodynamic therapy (PDT) after treatment with different groups including (1) PBS, (2) naAPC, (3) OVA, (4) NP-OVA, (5) OVA-naAPC, and (6) NP-OVA/naAPC. Mixed cells had PBS or naAPC alone serve as control. (<italic toggle="yes">n</italic>&#160;=&#160;3; **<italic toggle="yes">P</italic>&#160;&lt;&#160;0.01, ***<italic toggle="yes">P</italic>&#160;&lt;&#160;0.001; <italic toggle="yes">ns</italic>, not significant; one-way ANOVA with multiple comparisons). Reproduced with permission [<xref rid="bib199" ref-type="bibr">199</xref>]. Copyright 2020, American Association for the Advancement of Science. (I) Schematic illustrations of responsive release and process for triggering anti-tumor immune response of cyclodextrin/PEI-based nanovaccine. Reproduced with permission [<xref rid="bib201" ref-type="bibr">201</xref>]. Copyright 2023, Wiley.</p></caption><alt-text id="alttext0040">Fig. 6</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr6.jpg"/></fig></p><p id="p0215">Polymers like PEI or PEG are increasingly used in nanovaccine development to enhance antigen cross-presentation through the &#8220;proton sponge effect&#8217;&#8217;. This effect involves rupturing endosomal membranes and releasing antigens into cytosol, thereby facilitating increased antigen cross-presentation and T-cell priming (<xref rid="fig6" ref-type="fig">Fig. 6</xref>B) [<xref rid="bib154" ref-type="bibr">154</xref>]. Nanovaccines, such as those with PEG-grafted polypeptide (PPT-<italic toggle="yes">g</italic>-PEG) copolymers, leverage acid-labile nature of the PEG for optimal solubility and to amplify the &#8220;proton sponge effect&#8221; [<xref rid="bib155" ref-type="bibr">155</xref>]. This effect enhances intracellular delivery following PEG detachment in an acidic endolysosomal environment, along with exposure to cationic polypeptide for improved cellular uptake and antigen presentation. PEG-based nanovaccines with pyridyl disulfide groups facilitate antigen conjugation through thiol-disulfide exchange, destabilizing acidic endosomes and releasing vaccine contents into cytosol for MHC I presentation and differentiation-associated protein 5 signaling pathway activation [<xref rid="bib200" ref-type="bibr">200</xref>]. Moreover, a streamlined and scalable platform, incorporating beta-cyclodextrin and PEI, provides a distinctive cavity structure, high charge density, and reactive disulfide bonds, facilitating endosomal escape of the neoantigens without inducing damage (<xref rid="fig6" ref-type="fig">Fig. 6</xref>H) [<xref rid="bib201" ref-type="bibr">201</xref>]. This unique composition not only enhances cross-presentation significantly but also mediates activation and expansion of na&#239;ve T lymphocytes, thus effectively strengthening antitumor immunity.</p><p id="p0220">Nucleic acid-based vaccines like DNA and mRNA are emerging as effective alternatives to traditional protein or peptide-based subunit vaccines, capable of inducing robust T-cell responses through host cellular mechanisms [<xref rid="bib202" ref-type="bibr">202</xref>]. Specifically, DNA illustrates this by transferring gene sequences to APC, which releases payloads in acidic endosomal environments, thereby eliciting strong antigen-specific T-cell responses [<xref rid="bib203" ref-type="bibr">203</xref>]. This mechanism is further exemplified by DNA nanodevices that also release payloads in response to acidic endosomal environments [<xref rid="bib156" ref-type="bibr">156</xref>]. These nanovaccines are particularly adept at stimulating CD8<sup>+</sup> T cell-mediated cellular immunity owing to their mode of intracellular expression [<xref rid="bib204" ref-type="bibr">204</xref>]. In comparison, mRNA vaccines present lower genetic risks and operate without need for nuclear entry, degrading after activation. This characteristic renders them promising for clinical applications, particularly in LNP-based systems [<xref rid="bib205" ref-type="bibr">205</xref>,<xref rid="bib206" ref-type="bibr">206</xref>]. These LNPs, including liposome-entrapped mRNA vaccines, have been successful in stimulating virus-specific CTLs [<xref rid="bib207" ref-type="bibr">207</xref>]. Furthermore, a versatile platform of the mRNA/LNP nanovaccine is demonstrated in its application for heterologous prime/boost T-cell responses [<xref rid="bib157" ref-type="bibr">157</xref>]. The recent remarkable success and demonstrated safety of mRNA lipid nanoparticle technology have been pivotal in production of the vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [<xref rid="bib208" ref-type="bibr">208</xref>].</p><p id="p0225">Photochemical internalization offers a powerful approach for endosomal escape <italic toggle="yes">via</italic> light-induced rupture [<xref rid="bib209" ref-type="bibr">209</xref>]. This technique involves integrating photosensitizers into nanovaccines which triggers ROS generation and endosome rupture upon exposure to specific light. This strategy enhances antigen internalization and cross-presentation, effectively stimulating antigen-specific CD8<sup>+</sup> T cell activation [<xref rid="bib210" ref-type="bibr">210</xref>]. The HA-OVA-AuNPs nanovaccine, based on gold NP adorned with HA and OVA, demonstrates this by generating a prompt antigen-specific CD8<sup>+</sup> T cell response when exposed to NIR irradiation [<xref rid="bib211" ref-type="bibr">211</xref>]. This response is attributed to increased proteasome activity and MHC I antigen presentation, driven by heat-mediated disruption of endo/lysosomes. Besides, a protein-based nanovaccine has also shown potential in photochemical internalization, causing CD8<sup>+</sup> T cell infiltration and caspase-3-dependent death, both of which inhibit tumor progression [<xref rid="bib212" ref-type="bibr">212</xref>].</p><p id="p0230">Simply put, activation and expansion of the cytotoxic T cells, facilitated by advanced nanovaccine strategies, represent a cornerstone in evolution of the cancer immunotherapy. The utilization of aAPC based on membrane fusion, endosomal escape mechanisms, photochemical internalization, and nucleic acid vaccines delineate a multifaceted approach towards optimizing antigen presentation and T-cell activation. These strategies, while promising, underscore the complexities of immune modulation at the cellular level, highlighting the delicate balance required to elicit a potent controlled immune response. The challenge lies not only in achieving efficient antigen delivery to APCs but also in navigating the myriad of immune regulatory mechanisms to ensure a sustained and targeted antitumor response. Furthermore, the integration of nucleic acid-based vaccines introduces a novel dimension to traditional immunotherapy paradigms, offering a dynamic and adaptable platform for inducing robust T-cell responses. However, success of these innovative approaches necessitates a comprehensive understanding of underlying biological interactions and development of sophisticated delivery systems capable of precise targeting and controlled release. As such, future research should endeavor to refine these strategies, exploring the potential of novel nanocarrier designs and targeting ligands to enhance specificity and efficacy of the bespoke nanovaccines in mediating cancer immunotherapy.</p></sec><sec id="sec3.2.2"><label>3.2.2</label><title>Activating B cells</title><p id="p0235">B cells play a pivotal role in orchestrating adaptive immune responses through communication mediated by B-cell receptor (BCR) [<xref rid="bib213" ref-type="bibr">[213]</xref>, <xref rid="bib214" ref-type="bibr">[214]</xref>, <xref rid="bib215" ref-type="bibr">[215]</xref>]. Signaling pathway of BCR entails participation of a membrane-anchored surface Ig, the distal portion of which is characterized by variable regions with antigen-binding sites [<xref rid="bib216" ref-type="bibr">[216]</xref>, <xref rid="bib217" ref-type="bibr">[217]</xref>, <xref rid="bib218" ref-type="bibr">[218]</xref>]. IgM is recombined Ig variable region genes and expressed on immature or mature B cells [<xref rid="bib219" ref-type="bibr">219</xref>]. Based on this finding, IgM-based nanovaccines (<sup>D</sup>CDX-sLip/OVA) are formulated using <sup>D</sup>CDX-modified liposomes, OVA, and IgM <italic toggle="yes">via</italic> electrostatic interactions, demonstrating a significantly-targeting ability to splenic B cells [<xref rid="bib158" ref-type="bibr">158</xref>]. IgM, alongside decorations of Fc&#956;R and CD21/35, plays a crucial role in enhancing antigen presentation and uptake by B cells residing in the splenic marginal zone. This phenomenon is evidenced by a robust biosafety profile observed in response to <sup>D</sup>CDX-sLip/OVA, characterized by sustained higher antibody titers (IgG1), which is facilitated through both IgM-complement and IgM-Fc&#956;R pathways. Complement-mediated B-cell targeting approach is also demonstrated by lectin-coated surfaces of dextran coated ferrous-based nanovaccines where surface-deposited active complement factor 3 (C3) results in predominant targeting to CR1/2-expressing B cells [<xref rid="bib220" ref-type="bibr">220</xref>]. BCR signaling is additionally believed to contribute to how malignant B cells proliferate and survive in individuals with lymphomas or leukemias [<xref rid="bib219" ref-type="bibr">219</xref>]. Development of the therapeutic medications that emphasize BCR signaling is gaining momentum. Examples of these medications are bruton tyrosine kinase inhibitors [<xref rid="bib221" ref-type="bibr">221</xref>] and phosphoinositide 3-kinase isoform-specific inhibitors [<xref rid="bib222" ref-type="bibr">222</xref>], which sparks further enthusiasm for development of the customized nanovaccines targeting B cells-related therapeutic pathways.</p></sec><sec id="sec3.2.3"><label>3.2.3</label><title>Activating natural killer cells</title><p id="p0240">Given their capacity for cytokine production and participation in immunosurveillance, NK cells have emerged as compelling targets for cancer immunotherapeutic approaches [<xref rid="bib223" ref-type="bibr">223</xref>]. An effective approach to enhance infiltration of NK cells into tumors involves inductions of stimulatory cytokines associated with NK cell activation [<xref rid="bib224" ref-type="bibr">224</xref>]. Utilizing functionalized ligands as an active targeting strategy, precisely-tailored nanovaccines can be designed to stimulate cytokine production and facilitate the trafficking of NK cells to tumor sites. Immune-NPs, which are engineered by cdGMP (a STING agonist), MPLA, and a TLR4 agonist, have shown promise in catalyzing production of type I IFN-<italic toggle="yes">&#946;</italic> and increasing accumulation of NK cells in TME [<xref rid="bib159" ref-type="bibr">159</xref>]. These nanovaccines are demonstrated to have significant therapeutic effects in a murine model of metastatic TNBC. In addition, the passive strategy to mediate NK cell activation is to sense chemokine attraction by an external stimulator. Magnetic-mediation nanovaccines enhance infiltration of NK cells. For example, Fe<sub>3</sub>O<sub>4</sub>/SiO<sub>2</sub> core/shell NPs conjugated with Cy5.5 exhibited a satisfactory cancer immunotherapy effect and significantly-increased infiltration of NK-92MI cells (17-fold greater than that detected without NP treatment) under an external magnetic field [<xref rid="bib160" ref-type="bibr">160</xref>]. Magnetic nanoparticles alongside PDA layer are also confirmed to improve accumulation and retention of NK in TME [<xref rid="bib161" ref-type="bibr">161</xref>]. By focusing on the intricacies of cytokine modulation, it underscores potential of customized nanovaccines to activate NK cells, enhancing efficacy of cancer immunotherapies.</p></sec></sec><sec id="sec3.3"><label>3.3</label><title>Modulating immunosuppression in single-cell level</title><sec id="sec3.3.1"><label>3.3.1</label><title>Modulating tumor-associated macrophage strategies</title><p id="p0245">Macrophages are integral components of the mononuclear phagocytic system and play pivotal roles in tumor progression [<xref rid="bib225" ref-type="bibr">225</xref>]. These versatile cells exhibit two distinct phenotypes: M1 macrophages with pro-inflammatory and anti-tumorigenic properties, and M2 macrophages with anti-inflammatory and pro-tumorigenic properties [<xref rid="bib226" ref-type="bibr">226</xref>]. Their inherent plasticity allows macrophages to adapt their functions and phenotypes based on the specific tissue microenvironment, making them amenable to reprogramming for targeted immunotherapies [<xref rid="bib227" ref-type="bibr">227</xref>]. TAM is the predominant cell type in TME, and clinical research has revealed a strong correlation between increased TAM infiltration in tumors, poor prognosis, and heightened metastasis risk. Therefore, targeting TAM involves activating M1 phenotype while inhibiting M2 phenotype [<xref rid="bib228" ref-type="bibr">228</xref>]. In this context, strategies for nanovaccines targeting TAM emphasize two aspects: inhibiting recruitment and viability of M2-type TAM and reprogramming TAM phenotypes [<xref rid="bib227" ref-type="bibr">227</xref>].</p><p id="p0250">Nanovaccines incorporated functionalized ligands, including small molecule CSF1R kinase inhibitors (pexidartinib, PLX7486, RG7155, and BLZ-945) and FA receptor-targeting agents, effectively redound conversion of M2-type to M1-type TAM [<xref rid="bib162" ref-type="bibr">162</xref>,<xref rid="bib163" ref-type="bibr">163</xref>,<xref rid="bib229" ref-type="bibr">229</xref>]. For example, a newly-developed bioactive nanovaccine generated a &#8220;depot effect&#8221; for NLG-919 and BLZ-945 into tumors, inducing M1-like TAM and depleting M2-like TAM. This approach also led to inhibition of indoleamine <italic toggle="yes">2</italic>,<italic toggle="yes">3</italic>-dioxygenase activity and effective depletion of M2-like TAM [<xref rid="bib28" ref-type="bibr">28</xref>,<xref rid="bib230" ref-type="bibr">230</xref>]. In addition, targeting overexpressed FA receptors in various solid malignancies, FA-mediated endocytosis-driven strategies have been applied. The matrix metalloprotease 2 responsive liposome (PEG-FA-Lip), focuses on M2-TAM and tumor cells, inhibiting Treg cell activation, reversing M2-TAM-mediated immunosuppression, and suppressing tumor growth and metastasis [<xref rid="bib231" ref-type="bibr">231</xref>]. Additionally, supramolecular nanoparticles loaded with CSF1R and MAPK inhibitors advance macrophage-targeting immunotherapy by blocking relevant signaling pathways [<xref rid="bib164" ref-type="bibr">164</xref>].</p><p id="p0255">Engineered nanovaccines are also effectively reprogramming TAM by incorporating anchored ligands like M2pep and TLR agonists [<xref rid="bib232" ref-type="bibr">232</xref>,<xref rid="bib233" ref-type="bibr">233</xref>]. These nanovaccines, such as M2NPs, integrate &#945;-peptides with targeting abilities to specifically deplete M2-like TAM and block their signaling pathways [<xref rid="bib165" ref-type="bibr">165</xref>]. Moreover, TLR agonist-based nanovaccines are repolarized M2-type macrophages towards an anti-tumor M1 phenotype, as demonstrated by a TLR7/8a conjugated hydrogel that aids in reprogramming TAM and enhances efficacy of PD1-blockade (<xref rid="fig7" ref-type="fig">Fig. 7</xref>A&#8722;C) [<xref rid="bib166" ref-type="bibr">166</xref>]. The DNA-polymer hybrid nanocomplex containing <italic toggle="yes">co</italic>-assembly of TLR9 agonist (CpG) and TLR7 agonist (loxoribine) also converts of suppressive M2 macrophage to active M1 macrophage (<xref rid="fig7" ref-type="fig">Fig. 7</xref>D&#8722;F) [<xref rid="bib234" ref-type="bibr">234</xref>]. Furthermore, iron ions are being explored for their role in repolarizing M2-like TAM, with innovations like an iron-based nanovaccine (Dic@M2pep-Fe-MOF) amplifying this repolarization and bolstering efficacy of cancer immunotherapy. These advancements underscore potential of customized nanovaccines in modulating immunosuppressive TME and improving efficacy of cancer immunotherapy [<xref rid="bib167" ref-type="bibr">167</xref>].<fig id="fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p><bold>Designs of targeting TAM-specific nanovaccines in cancer immunotherapy.</bold> (A) Schematic illustration of macrophage repolarization regulated by peptide hydrogel (Smac-TLR7/8 hydrogel) for overcoming radioresistance. Smac-TLR7/8 peptide self-assembles into nanofibrous hydrogel. Then, (i) after peritumoral injection, Smac-TLR7/8 hydrogel effectively reprograms TAM from M2 type toward M1 type, secreting inflammatory factors and activating anti-tumor functions. (ii) Immunosuppressive TME is rebuilt through tumor infiltrating lymphocytes recruitment, and downregulating Treg cells. (iii) Radioresistance is overcame which further improves anti-tumor efficacy combined with immunotherapy. (B) Percentage of M2-related (F4/80<sup>+</sup>CD206<sup>+</sup>) macrophages (<italic toggle="yes">n</italic>&#160;=&#160;5). (C) Protein expression level of NF-&#954;B, TNF-&#945;, inducible isoform of nitric oxide synthase (iNOS), IL-10, arginase 1 in macrophages determined by western blotting. RT: Radiotherapy. Reproduced with permission [<xref rid="bib166" ref-type="bibr">166</xref>]. Copyright 2022, KeAi Communications Co. Expression level of CD40 (D) and CD206 (E) on bone-marrow-derived macrophage cells that treated with different groups. All the data represented as mean&#160;&#177;&#160;SD, <italic toggle="yes">n</italic>&#160;=&#160;3. (F) Application of CpG-Lox-DPNFs vaccines composed of CpG, loxoribine, and <italic toggle="yes">co</italic>-loaded DNA-polymer hybrid nanocomplex in synergistic reprogramming tumor immune microenvironment for efficient cancer immunotherapy. Reproduced with permission [<xref rid="bib234" ref-type="bibr">234</xref>]. Copyright 2024, Elsevier.</p></caption><alt-text id="alttext0045">Fig. 7</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr7.jpg"/></fig></p><p id="p0260">Furthermore, surface markers on macrophages, particularly on TAM, are being targeted for phenotype reprogramming in cancer immunotherapy. For instance, overexpression of placental growth factor (PIGF) and vascular endothelial growth factor (VEGF) on M2-TAM and breast cancer cells led to their synergistic down-regulation, repolarization of M2-TAM as well as inhibiting breast cancer cell proliferation [<xref rid="bib235" ref-type="bibr">235</xref>,<xref rid="bib236" ref-type="bibr">236</xref>]. Similarly, a specialized nanoplatform referred to as PEG&#160;=&#160;MT/PC NPs (PEI, and mannose doubly modified trimethyl chitosan (PEG&#160;=&#160;MT) along with citraconic anhydride grafted poly (allylamine hydrochloride) (PC)) is engineered to facilitate deliveries of VEGF siRNA (siVEGF) and PIGF siRNA (siPIGF) to M2-TAM, thereby reprogramming of TAM [<xref rid="bib237" ref-type="bibr">237</xref>]. Vaccination with miR155-loaded of detachable PEG-PLL/galactose-PLL-poly(<sc><italic toggle="yes">l</italic></sc>-cysteine) (sPEG/GLC/155) nanovaccines, as an example, not only enhanced expression of miR155 and M1-TAM markers like IL-2 and MHC II but also suppressed expressions of M2-TAM markers such as arginase 1 and macrophage scavenger receptor 2 [<xref rid="bib238" ref-type="bibr">238</xref>]. Furthermore, an innovative &#8220;two-in-one&#8221; nanovaccine formulation, incorporating a legumain-derived antigenic sequence (a TAM biomarker) and trichosanthin, effectively stimulates cytokine secretion and initiates antitumor immunity by specifically targeting TAM and orchestrating a transformation in TME [<xref rid="bib239" ref-type="bibr">239</xref>,<xref rid="bib240" ref-type="bibr">240</xref>].</p><p id="p0265">Essentially, the focused modulation of TAM within TME is crucial for enhancing efficacy of the nanovaccine-based cancer immunotherapies. This section has highlighted the significance of selectively inhibiting M2 type TAMs while promoting activation of M1 type TAMs, a strategy that directly addresses immunosuppressive nature of TME. The successful application of this approach relies on the precise engineering of nanovaccines to target specific TAM receptors and signaling pathways, thereby reprogramming TAM phenotypes to support anti-tumor immunity. However, challenges remain in achieving selective targeting without affecting systemic immune response and in understanding dynamic interactions within TME. Future research must focus on overcoming these hurdles to fully realize the potential of TAM-modulating nanovaccines in cancer immunotherapy.</p></sec><sec id="sec3.3.2"><label>3.3.2</label><title>Modulating tumor-associated neutrophil strategies</title><p id="p0270">Neutrophils, the most abundant circulating leukocytes in humans, are a type of myeloid cells derived from the bone marrow, characterized by their short half-life and multilobed nuclear morphology [<xref rid="bib241" ref-type="bibr">[241]</xref>, <xref rid="bib242" ref-type="bibr">[242]</xref>, <xref rid="bib243" ref-type="bibr">[243]</xref>]. They are crucial players in tumor progression, especially within TME, and like TAM, TAN shows significant plasticity [<xref rid="bib244" ref-type="bibr">244</xref>,<xref rid="bib245" ref-type="bibr">245</xref>]. This variability is influenced by tissue types and specific molecular cues of their environment [<xref rid="bib246" ref-type="bibr">246</xref>,<xref rid="bib247" ref-type="bibr">247</xref>]. In the context of cancer immunotherapy, manipulating TAN polarization, which means transitioning the pro-tumor N2 phenotype to the anti-tumor N1 phenotype, is a key therapeutic target [<xref rid="bib248" ref-type="bibr">248</xref>]. Custom-designed nanovaccines have been developed to induce this polarization [<xref rid="bib249" ref-type="bibr">249</xref>]. For instance, Fe(III)-captopril-based nanovaccines had successfully repolarized TAN in a hepatocellular carcinoma model [<xref rid="bib168" ref-type="bibr">168</xref>]. Experimental results revealed that captopril was activated within the acidic TME, facilitating conversion of protumoral TAN into an antitumor phenotype. This transformation led to significant immune effects, resulting in complete tumor regression (83%) in H22 tumor-bearing mice. Additionally, Bacillus Calmette-Gu&#233;rin has also shown potential benefits in modulating TAN function [<xref rid="bib250" ref-type="bibr">250</xref>]. Although TAN are promising targets in cancer immunotherapy, further research is needed to understand molecular mechanisms for effectively targeting TAN with the customized nanovaccines.</p></sec><sec id="sec3.3.3"><label>3.3.3</label><title>Modulating myeloid-derived suppressor cell strategies</title><p id="p0275">MDSC constitute another pivotal class of immunosuppressive immune cells. Numerous high-quality studies, encompassing both preclinical and clinical research, have elucidated the strong correlation between abundant infiltration of MDSC within TME and unfavorable patient prognosis [<xref rid="bib181" ref-type="bibr">181</xref>]. Recent years have witnessed significant advancements in development of the inhibitory agent-based nanovaccine targeting MDSC at tumor sites. These advancements are grounded in various mechanisms, such as deactivation or depletion of MDSC, inhibition of MDSC development, and induction of MDSC differentiation into mature cells, among others [<xref rid="bib251" ref-type="bibr">251</xref>]. Notably, FDA's recent approval of the phosphodiesterase 5 inhibitor TAD has shown promise in enhancing antitumor immunity by inhibiting MDSC function and revitalizing T-cell responses [<xref rid="bib252" ref-type="bibr">252</xref>]. In this context, a supramolecular TAD nanovaccine has been developed to mitigate MDSC-induced suppression and enhance immunogenicity (<xref rid="fig8" ref-type="fig">Fig. 8</xref>) [<xref rid="bib169" ref-type="bibr">169</xref>]. These TAD-based vaccines are formulated by assembling indocyanine green and TAD in presence of Fe<sup>3+</sup> to form FIT NPs (<xref rid="fig8" ref-type="fig">Fig. 8</xref>A). The FIT NPs trigger ICD and relieve immunosuppressive activity of MDSC by releasing TAD at tumor sites, a process validated by observed apoptosis of MDSC (<xref rid="fig8" ref-type="fig">Fig. 8</xref>B&#8722;D). Besides, other strategies like manipulating chemokine like CCL2 <italic toggle="yes">via</italic> CCAAT/enhancer-binding protein beta pathways or employing low-dose gemcitabine-loaded lipid nanocapsules, have been effective in targeting MDSC, thus enhancing cancer immunotherapy by modulating TME [<xref rid="bib170" ref-type="bibr">170</xref>,<xref rid="bib171" ref-type="bibr">171</xref>]. Despite these advancements, further exploration in MDSC-targeting vaccines is needed to develop more effective nanovaccines to reshape TME and enhance antitumor efficacy [<xref rid="bib181" ref-type="bibr">181</xref>].<fig id="fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p><bold>Deductive procedure of FIT nanovaccine for cancer immunotherapy.</bold> (A) Preparation process of FIT nanoparticle, mechanism of MDSC regulation, ICD induction process, and dual-imaging medicated enhanced cancer immunotherapy. <italic toggle="yes">In vitro</italic> cellular experiment with FIT NP, (B) confocal laser scanning microscopy images of CT26 multicellular spheroids treated with different samples for 6&#160;h and stained with FDA (green) and propidium iodide (red). (C) Flow cytometry and (D) qualitative analysis of MDSC in tumors (<italic toggle="yes">n</italic>&#160;=&#160;3; *<italic toggle="yes">P</italic>&#160;&lt;&#160;0.05, **<italic toggle="yes">P</italic>&#160;&lt;&#160;0.01). Reproduced with permission [<xref rid="bib169" ref-type="bibr">169</xref>]. Copyright 2021, Wiley.</p></caption><alt-text id="alttext0050">Fig. 8</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr8.jpg"/></fig></p></sec><sec id="sec3.3.4"><label>3.3.4</label><title>Modulating invariant natural killer T cell strategies</title><p id="p0280">NKT cells divide into different types (I and II) as follows: Type II includes variant NKT cells identified by sulfatide/CD1d-tetramers [<xref rid="bib253" ref-type="bibr">[253]</xref>, <xref rid="bib254" ref-type="bibr">[254]</xref>, <xref rid="bib255" ref-type="bibr">[255]</xref>], whereas type I includes as invariant NKT cells that communicate with a semi-invariant TCR (V&#945;14J&#945;18 gene segment paired with V&#946;2, V&#946;7, and V&#946;8.2 in mice and V&#945;24J&#945;18 paired with V&#946;11 in humans) [<xref rid="bib256" ref-type="bibr">256</xref>,<xref rid="bib257" ref-type="bibr">257</xref>]. These NKT cells function as a bridge between adaptive and innate immune responses, influencing DC maturation, and activating downstream immune effectors such as B cells, NK cells, CD4<sup>+</sup> T cells, and CD8<sup>+</sup> T cells [<xref rid="bib258" ref-type="bibr">258</xref>]. Since they are recognized as both self and foreign by DC <italic toggle="yes">via</italic> the MHC I-like molecule CD1 (CD1-9 TCR ligand), type I NKT cells have attracted significant attention, and are activated by glycosphingolipid such as GalCer [<xref rid="bib172" ref-type="bibr">172</xref>,<xref rid="bib258" ref-type="bibr">258</xref>,<xref rid="bib259" ref-type="bibr">259</xref>]. GalCer-based nanovaccines modified with melanoma peptides and TLR ligands suppress melanoma [<xref rid="bib172" ref-type="bibr">172</xref>]. These nanovaccines enhance infiltrations of NKT and NK cells, and promote high-level secretions of INF-&#947; and IL-4. It is anticipated that development of more tailored nanovaccines targeting NK cells will be a focus of future research endeavors in this field.</p></sec><sec id="sec3.3.5"><label>3.3.5</label><title>Depletion of regulatory T cells</title><p id="p0285">Treg cells, known for their immunosuppressive role, are prevalent in TME, where they impede antitumor immunity, contributing to tumor progression [<xref rid="bib260" ref-type="bibr">260</xref>]. These cells are chemotactically attracted to the TME <italic toggle="yes">via</italic> specific chemokine gradients like CCR4-CCL17/22 and CCR8-CCL1, among others [<xref rid="bib261" ref-type="bibr">261</xref>]. Their high infiltration correlates with poor prognosis in various cancers. Treg cells suppress immune responses through mechanisms such as inhibition of <italic toggle="yes">co</italic>-stimulatory signals, interleukin-2 consumption, and metabolic modulation [<xref rid="bib262" ref-type="bibr">262</xref>]. Consequently, cancer immunotherapy focuses on depleting Treg cells or modulating their functions to enhance antitumor responses. Targeted therapies include antibodies or small molecules against Treg-specific markers like immune checkpoint molecules, chemokine receptors, metabolites, <italic toggle="yes">etc.</italic>, with aim of strengthening antitumor effects while avoiding systemic autoimmunity. Combinational cancer immunotherapy involving imatinib (IMT)-loaded glucocorticoid-induced TNF receptor family-related protein/PLGA (GITR-PLGA) with IR780 dye has shown promise [<xref rid="bib173" ref-type="bibr">173</xref>]. IMT triggers signal transducer and activator of transcription- (STAT)3 and STAT5 activation, thereby inhibiting Foxp3 expression and rendering Treg dysfunctionality. Additionally, genetically modified megakaryocytes stably expressing murine PD-1 have been developed to produce PD-1-presenting platelets, capable of carrying cyclophosphamide [<xref rid="bib263" ref-type="bibr">263</xref>]. This approach not only targets PD-L1 but also depletes Tregs in TME, enhancing antitumor effects of CD8<sup>+</sup> T lymphocytes. Furthermore, a combination of PPAR-&#945; agonist fenofibrate, PD-1 antibody, and custom nanovaccines has shown potential in modulating T-cell metabolism and enhancing CTL activity through PD-1 blockade [<xref rid="bib174" ref-type="bibr">174</xref>]. However, studies indicate that PD-1-blocked Treg cells exhibit reduced immunosuppressive activity, necessitating further research to fully understand the role of PD-1 in effector T cells and Treg cells in cancer contexts [<xref rid="bib264" ref-type="bibr">264</xref>].</p></sec></sec></sec><sec id="sec4"><label>4</label><title>Nanovaccines applied in cancer immunotherapies</title><p id="p0290">As discussed previously, nanovaccines have demonstrated capabilities to elicit a robust immune response and activate immunogenicity, owing to their adaptable nano-size ranges and customizable structures [<xref rid="bib265" ref-type="bibr">265</xref>]. These inherent advantages equip nanovaccines with diverse functionalities, allowing them to effectively-target immune cells and find applications in immunotherapies. These vaccines under consideration can be categorized as prophylactic, intended to avert future infections, or therapeutic, to treat existing diseases, including cancer and/or bacterial diseases. Prophylactic nanovaccines are designed to bolster immunogenic memory and trigger both antibody-mediated and cell-mediated immune responses. For instance, nanovaccines had been demonstrated a significant potential for preventing infectious diseases like acquired immunodeficiency syndrome, malaria, tuberculosis, influenza, and cancer [<xref rid="bib202" ref-type="bibr">202</xref>]. On the therapeutic front, custom-designed nanovaccines induce accumulation and expression of exogenous or neoantigens at tumor sites, curtailing tumor growth. Studies suggest that nanovaccines adeptly modulate the immune system, offering targeted preventive or therapeutic interventions for various pathological conditions. While prophylactic nanovaccines primarily focus on infection prevention, therapeutic nanovaccines are increasingly utilized in cancer immunotherapy.</p><sec id="sec4.1"><label>4.1</label><title>Prophylactic functionalities</title><p id="p0295">Despite progress in vaccine development, creation of effective vaccines for viruses like HIV and influenza is still a work in progress [<xref rid="bib266" ref-type="bibr">266</xref>]. Coronavirus disease 2019 (COVID-19) pandemic has accelerated development of viral vaccines, although there's a risk of these vaccines reverting to a pathogenic form [<xref rid="bib267" ref-type="bibr">267</xref>]. Prophylactic vaccines are given prior to onset of a disease to establish long-lasting immunogenic memory against infections [<xref rid="bib126" ref-type="bibr">126</xref>]. In response to these challenges, bespoke nanovaccines, have shown promise, enhancing both antibody-mediated and cell-mediated immune responses. There's growing recognition of efficacy of CD8<sup>+</sup> T cell-mediated cellular immunity in combating viruses and providing extended protection beyond traditional focused on neutralizing antibodies [<xref rid="bib268" ref-type="bibr">268</xref>]. This form of immunity targets eradicating viral infections within the body, while humoral immunity works by neutralizing the viruses in bodily fluids by producing soluble antibodies.</p><p id="p0300">The COVID-19 pandemic, caused by SARS-CoV-2, has rapidly spread globally, leading to significant mortality [<xref rid="bib269" ref-type="bibr">269</xref>]. Vaccination remains the most effective defense against COVID-19, with multiple innovative approaches being developed. One example was the SARS-CoV-2 DLNP vaccine, which was shown robust immunities in various animal models and offered single-shot protection against lethal challenges [<xref rid="bib270" ref-type="bibr">270</xref>]. Another prophylactic nanovaccines involved formulations of the virus's S1 subunit and dual adjuvants, successfully eliciting robust humoral immune responses and potent IgA antibodies in mice [<xref rid="bib271" ref-type="bibr">271</xref>]. Dual-adjuvant systems have been shown to enhance systemic and lung immunities by combining MnO<sub>x</sub> and CpG with a dimeric antigen version of the virus's receptor-binding domain [<xref rid="bib272" ref-type="bibr">272</xref>]. Additionally, several nanoadjuvants like selenium [<xref rid="bib273" ref-type="bibr">273</xref>], manganese [<xref rid="bib274" ref-type="bibr">274</xref>], and antigen-caged-adjuvants [<xref rid="bib275" ref-type="bibr">275</xref>], have also been employed in developing subunit vaccines for SARS-CoV-2. Innovative inhalable nanovaccines, such as biomimetic coronavirus structure-based [<xref rid="bib276" ref-type="bibr">276</xref>] and chitosan-based, have also been reported [<xref rid="bib277" ref-type="bibr">277</xref>]. Interestingly, the Bacillus Calmette-Guerin (BCG) vaccine has shown effectiveness against COVID-19, being attributed to its nonspecific protective effects against respiratory infections [<xref rid="bib278" ref-type="bibr">278</xref>]. Research indicated that BCG induced a robust biphasic innate immune response and antigen-specific Th1 cell response in lungs [<xref rid="bib279" ref-type="bibr">279</xref>]. In mouse models, BCG also protected against weight loss following infection with SARS-CoV-2 BA.5, SARS-CoV, and SHC014 coronaviruses. Overall, nanovaccines demonstrate significant potential in eliciting durable immune responses against pathogen infections or re-infections, with biosafety being a crucial consideration, especially for clinical preventive applications.</p></sec><sec id="sec4.2"><label>4.2</label><title>Therapeutic functionalities</title><p id="p0305">Therapeutic nanovaccines have shown promising potential in cancer treatment, particularly in development of highly potent foreign non-self-antigens (TSA), which are overexpressed at specific tumor sites but minimally presented in normal tissues [<xref rid="bib265" ref-type="bibr">265</xref>]. For instance, an intertwining DNA-RNA nanocapsule (referred to as iDR-NCs) has been demonstrated favorable prospects in cancer immunotherapy [<xref rid="bib155" ref-type="bibr">155</xref>]. The iDR-NCs nanovaccines efficiently delivered APC in draining LN, inducing durable neoantigen-specific T cell responses and significantly inhibiting progression of neoantigens-specific colorectal tumors. These neoantigen-based nanovaccines exhibited robust cancer immunotherapy, as evidenced by the syngeneic C57BL/6 mice bearing MC38 syngeneic colon adenocarcinoma tumor models. Similarly, a dual adjuvant-based nanoformulation (R848 and CpG) for colorectal cancer, combining neoantigens and adjuvants, has enhanced immunogenicity of neoantigens and reduced acute systemic toxicity [<xref rid="bib280" ref-type="bibr">280</xref>]. Personalized neoantigens nanovaccines have also shown promise in treatment of advanced pancreatic cancer [<xref rid="bib281" ref-type="bibr">281</xref>].</p><p id="p0310">Although cancer therapy faces numerous limitations, therapeutic nanovaccines offer effective alternatives or complements to conventional treatments, especially in combination with other modalities such as ICB therapy, PTT, PDT, chemotherapy, <italic toggle="yes">etc</italic>. [<xref rid="bib282" ref-type="bibr">[282]</xref>, <xref rid="bib283" ref-type="bibr">[283]</xref>, <xref rid="bib284" ref-type="bibr">[284]</xref>, <xref rid="bib285" ref-type="bibr">[285]</xref>, <xref rid="bib286" ref-type="bibr">[286]</xref>] PD-1 checkpoint blockade immunotherapy is the primary method and synergistic with nanovaccines for cancer immunotherapy [<xref rid="bib287" ref-type="bibr">287</xref>]. Su et al. reported on nanovaccines engineered to enhance efficacies of ICB, aiming to broaden repertoire of antitumor cells and increasing immune checkpoint expression levels to sensitize ICB [<xref rid="bib35" ref-type="bibr">35</xref>]. These vaccines, by <italic toggle="yes">co</italic>-delivering <italic toggle="yes">bi</italic>-adjuvants (R848 and CpG) along with TSA to LN, successfully induced enduring antigen-specific T cell responses and immune memory. When combined with ICB, these nanovaccines demonstrate significant therapeutic effects in different mouse tumor models [<xref rid="bib288" ref-type="bibr">288</xref>,<xref rid="bib289" ref-type="bibr">289</xref>]. Besides, tandem nanovaccines with PD-1 checkpoint blockade immunotherapy have also shown remarkable therapeutic effects in diverse cancer models, particularly when integrations of RT [<xref rid="bib89" ref-type="bibr">89</xref>], chemo-immunotherapy [<xref rid="bib290" ref-type="bibr">290</xref>], ultrasound [<xref rid="bib291" ref-type="bibr">291</xref>], PTT [<xref rid="bib292" ref-type="bibr">292</xref>], and PDT [<xref rid="bib293" ref-type="bibr">293</xref>]. Although therapeutic nanovaccines have demonstrated immense potential through formulation of effective antigens and their synergistic interactions with existing therapies, therapeutic efficacies of nanovaccines across various models and practical considerations of treatment strategies in clinical applications necessitate further assessment.</p></sec></sec><sec id="sec5"><label>5</label><title>Conclusions and perspectives</title><p id="p0315">The last decade has witnessed a shift from a focus on cytotoxic anti-cancer therapies towards approaches that increase anti-tumor immunity, as emerging immunotherapy shows promise in extending survival of patients [<xref rid="bib294" ref-type="bibr">294</xref>]. As a subtype of cancer immunotherapy, nano-based cancer vaccines have gained significant momentum owing to their advantage of size and proximity to pathogens as well as their controllable physicochemical and biophysical properties. A remarkable characteristic of nanovaccines lies in their exceptional diversity and tunability, which is engineered with various morphologies such as hollow, core-shell, nanosheet, micelle, nanogel, vesicle-like, nanodisc, and virus-like [<xref rid="bib295" ref-type="bibr">295</xref>]. These inherent characteristics bestow nanovaccines with notable targeting capabilities, prolonged bio-persistence, highly efficient transport capabilities, safeguarding of antigens against degradation, and potential for long-term therapeutic efficacy. Individualized nanovaccines, when laden with antigens and/or adjuvants, tend to accumulate within LN <italic toggle="yes">via</italic> LV. This distinctive accumulation pattern serves as a mitigation strategy against risks linked to leaky tumor vasculature, impaired lymphatic drainage, and potential off-target effects [<xref rid="bib296" ref-type="bibr">296</xref>]. Furthermore, tailored targeting nanovaccines are encapsulated or conjugated with antigens and/or adjuvants that exhibit targeting recognition capabilities for immune cells. As a result, a diverse range of nanovaccines has been meticulously-designed and deployed to passively or actively target different immune cell populations [<xref rid="bib297" ref-type="bibr">297</xref>]. This strategic targeting aims to enhance antigen presentation and modulate immunosuppression upon accumulation within LN. Consequently, these nanovaccines contribute to eradication of tumor cells, augmentation of the immune response, mitigation of TME resistance development, and inhibition of cancer recurrence [<xref rid="bib298" ref-type="bibr">298</xref>]. Considering complexity of the TME during tumor development, prophylactic and/or therapeutic nanovaccines are always combined with radiotherapy, ICB, PDT, PTT, and other therapeutic modalities to further magnify immune responses and generate sufficient long-lasting immune memory [<xref rid="bib266" ref-type="bibr">266</xref>,<xref rid="bib292" ref-type="bibr">292</xref>,<xref rid="bib299" ref-type="bibr">299</xref>,<xref rid="bib300" ref-type="bibr">300</xref>]. Overall, nanovaccines with design flexibility have numerous inherent advantages as they are tailored to target various immune cells. These attributes not only position nanovaccines as a viable substitute for conventional cancer treatments but also establish them as valuable clinical tools for screening vaccines tailored to different types of cancer.</p><p id="p0320">While nanovaccines represent a promising frontier in the field of personalized vaccines, there remain several formidable challenges that need to be addressed before their successful translation into clinical practice [<xref rid="bib288" ref-type="bibr">288</xref>]. In nanovaccine formulation, it requires a precise architecture for effective immune cell engagement and stability, ensuring antigen to release and targeting circulating immune cells [<xref rid="bib16" ref-type="bibr">16</xref>]. An integrated nanovaccine system, incorporating all vital components, is key to achieving varied therapeutic and diagnostic objectives in cancer treatment. In terms of nanovaccine fabrication, meticulous consideration and assessment of streamlined synthesis processes for purification of nanovaccines, coupled with minimizing use of organic solvents, are imperative. Synergy effects between immunotherapeutic agents and targeting carriers, in aspects of dosage and classification, are critical in securing efficacious therapeutic results. Second, toxicity assessment of the nanovaccines is currently in an incipient stage, and the long-term safety profile of these engineered nanovaccines demands further evaluation. Special attention should be directed towards potential emergence of the autoimmune responses. It is imperative to recognize that physicochemical properties of the nanoparticles may undergo alterations as they interact with various biological entities within human bodies; hence, an exhaustive examination of the final metabolites is warranted. Furthermore, there is a major hurdle to immunogenicity of the nanomaterial-based vaccines [<xref rid="bib301" ref-type="bibr">301</xref>]. Nanovaccines exhibit antigenic characteristics but often face swift clearance prior to manifestation of their anti-tumor therapeutic efficacy. Not only that, a vigorous immune response may inadvertently precipitate severe complications, such as hemolysis and thrombogenesis [<xref rid="bib302" ref-type="bibr">302</xref>]. Finally, limited knowledge of immune networks during tumorigenesis hinders widespread applications of the nanovaccines in cancer immunotherapy. Innate and adaptive immune systems are complex networks, and the influence of depletion or inhibition of one component on the entire network remains controversial [<xref rid="bib303" ref-type="bibr">303</xref>].</p><p id="p0325">Taken together, research progress in customized targeting nanovaccines lays a theoretical foundation for further development of novel cancer therapy options, and many excellent studies are exploring their potential in targeting and regulating/training immune cells. In the future, refinement of the nanovaccine design is likely to necessitate a closer alignment with clinical translation and the establishment of collaborative immune responses. This endeavor aims to enhance patient compliance by integrating diverse components (such as biepitope antigens) within the same nanosystem [<xref rid="bib304" ref-type="bibr">304</xref>]. This multifaceted approach seeks to achieve precise targeting of distinct elements, controlled release mechanisms, and tailored treatments at various stages of the disease. Nanovaccine development is also set to be shaped by key advancements in precise immunomodulation, focusing on targeted interventions within TME to mitigate systemic toxicity. Exploration of the therapeutic synergies, combining nanovaccines with existing treatments like radiation therapy and checkpoint inhibitors, promises to amplify immune responses and enhance efficacy. Technological innovations, such as mRNA-based and STING-activating nanovaccines, are pivotal for improving vaccine performance and patient compliance. Critical to this progress is the clinical translation of nanovaccines, necessitating rigorous safety evaluations and the development of scalable, stable formulations. Moreover, addressing economic and accessibility barriers will broaden patient access to these advanced therapies. Collectively, vaccine nanotechnology has been demonstrated with significant promise in experimental investigations. Synergistic integration of expertise from nanomaterial science, immunology, virology, oncology, and pharmaceutical sector is pivotal for advancing clinical translation and implementation of nanovaccines. This collaborative approach is essential for effectively addressing and managing a spectrum of formidable infectious diseases and malignancies.</p></sec><sec id="sec6"><title>Ethical statement</title><p id="p0330">Hereby, I Prof. Jin Zhang, consciously assure that for the manuscript entitled &#8220;<bold>Engineering customized nanovaccines for enhanced cancer immunotherapy</bold>&#8221; the following is fulfilled:<list list-type="simple" id="olist0010"><list-item id="o0010"><label>1)</label><p id="p0335">This material is the authors' own original work, which has not been previously published elsewhere.</p></list-item><list-item id="o0015"><label>2)</label><p id="p0340">The paper is not currently being considered for publication elsewhere.</p></list-item><list-item id="o0020"><label>3)</label><p id="p0345">The paper reflects the authors' own research and analysis in a truthful and complete manner.</p></list-item><list-item id="o0025"><label>4)</label><p id="p0350">The paper properly credits the meaningful contributions of coauthors and co-researchers.</p></list-item><list-item id="o0030"><label>5)</label><p id="p0355">The results are appropriately placed in the context of prior and existing research.</p></list-item><list-item id="o0035"><label>6)</label><p id="p0360">All sources used are properly disclosed (correct citation). Literally copying of text must be indicated as such by using quotation marks and giving proper reference.</p></list-item><list-item id="o0040"><label>7)</label><p id="p0365">All authors have been personally and actively involved in substantial work leading to the paper, and will take public responsibility for its content.</p></list-item></list></p></sec><sec id="sec7"><title>CRediT authorship contribution statement</title><p id="p0370"><bold>Jinyu Guo:</bold> Writing &#8211; review &amp; editing, Writing &#8211; original draft, Supervision, Investigation, Formal analysis, Conceptualization. <bold>Changhua Liu:</bold> Writing &#8211; review &amp; editing, Methodology. <bold>Zhaoyang Qi:</bold> Validation. <bold>Ting Qiu:</bold> Supervision. <bold>Jin Zhang:</bold> Supervision, Funding acquisition, Conceptualization. <bold>Huanghao Yang:</bold> Supervision.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0375">The authors declare no conflict of interest.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name name-style="western"><surname>McCarthy</surname><given-names>E.F.</given-names></name></person-group><article-title>The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas</article-title><source>Lowa Orthop. J.</source><volume>26</volume><year>2006</year><fpage>154</fpage><pub-id pub-id-type="pmcid">PMC1888599</pub-id><pub-id pub-id-type="pmid">16789469</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name name-style="western"><surname>Nam</surname><given-names>J.</given-names></name><name name-style="western"><surname>Son</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.S.</given-names></name><etal/></person-group><article-title>Cancer nanomedicine for combination cancer immunotherapy</article-title><source>Nat. Rev. Mater.</source><issue>4</issue><year>2019</year><fpage>398</fpage><lpage>414</lpage></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name name-style="western"><surname>Ribas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haining</surname><given-names>W.N.</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>T.N.M.</given-names></name></person-group><article-title>When cancer cells become the enablers of an antitumor immune response</article-title><source>Cancer Discov.</source><issue>12</issue><year>2022</year><fpage>2244</fpage><lpage>2248</lpage><pub-id pub-id-type="pmid">36196573</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-22-0706</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name name-style="western"><surname>Schuster</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nechansky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kircheis</surname><given-names>R.</given-names></name></person-group><article-title>Cancer immunotherapy</article-title><source>Biotechnol. J.: Healthcare, Nutrition, Technology</source><issue>1</issue><year>2006</year><fpage>138</fpage><lpage>147</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/biot.200500044</pub-id><pub-id pub-id-type="pmid">16892244</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name name-style="western"><surname>Saxena</surname><given-names>M.</given-names></name><name name-style="western"><surname>van der Burg</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Melief</surname><given-names>C.J.M.</given-names></name><etal/></person-group><article-title>Therapeutic cancer vaccines</article-title><source>Nat. Rev. Cancer</source><issue>21</issue><year>2021</year><fpage>360</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">33907315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-021-00346-0</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name name-style="western"><surname>Want</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Bashir</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Najar</surname><given-names>R.A.</given-names></name></person-group><article-title>T cell based immunotherapy for cancer: approaches and strategies</article-title><source>Vaccines</source><issue>11</issue><year>2023</year><fpage>835</fpage><pub-id pub-id-type="pmid">37112747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines11040835</pub-id><pub-id pub-id-type="pmcid">PMC10142387</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name></person-group><article-title>Nanotechnology for next-generation cancer immunotherapy: state of the art and future perspectives</article-title><source>J. Contr. Release</source><volume>356</volume><year>2023</year><fpage>14</fpage><lpage>25</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2023.02.016</pub-id><pub-id pub-id-type="pmid">36805873</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name name-style="western"><surname>Cheever</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Higano</surname><given-names>C.S.</given-names></name></person-group><article-title>PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine therapeutic prostate cancer vaccine</article-title><source>Clin. Cancer Res.</source><volume>17</volume><year>2011</year><fpage>3520</fpage><lpage>3526</lpage><pub-id pub-id-type="pmid">21471425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-10-3126</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name name-style="western"><surname>Immunoengineering</surname><given-names>M.S. Goldberg</given-names></name></person-group><article-title>How nanotechnology can enhance cancer immunotherapy</article-title><source>Cell</source><volume>161</volume><year>2015</year><fpage>201</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">25860604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2015.03.037</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name></person-group><article-title>Advances in immunogenic cell death for cancer immunotherapy</article-title><source>Small Methods</source><issue>7</issue><year>2023</year><object-id pub-id-type="publisher-id">2300354</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smtd.202300354</pub-id><pub-id pub-id-type="pmid">37191336</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Advances in cancer nanovaccines: harnessing nanotechnology for broadening cancer immune response</article-title><source>ChemMedChem</source><volume>18</volume><year>2023</year><object-id pub-id-type="publisher-id">e202200673</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cmdc.202200673</pub-id><pub-id pub-id-type="pmid">37088719</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Harashima</surname><given-names>H.</given-names></name></person-group><article-title>Dawn of lipid nanoparticles in lymph node targeting: potential in cancer immunotherapy</article-title><source>Adv. Drug Deliv. Rev.</source><volume>167</volume><year>2020</year><fpage>78</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">32512027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2020.06.003</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions</article-title><source>J. Nanobiotechnol.</source><volume>21</volume><year>2023</year><fpage>212</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-023-01977-1</pub-id><pub-id pub-id-type="pmcid">PMC10327386</pub-id><pub-id pub-id-type="pmid">37415161</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.X.</given-names></name><etal/></person-group><article-title>Lymph node-targeting nanovaccines for cancer immunotherapy</article-title><source>J. Contr. Release</source><volume>351</volume><year>2022</year><fpage>102</fpage><lpage>122</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.09.015</pub-id><pub-id pub-id-type="pmid">36115556</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>H.</given-names></name><etal/></person-group><article-title><italic toggle="yes">In situ</italic> tumor vaccine for lymph nodes delivery and cancer therapy based on small size nanoadjuvant</article-title><source>Small</source><volume>19</volume><year>2023</year><object-id pub-id-type="publisher-id">2301041</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202301041</pub-id><pub-id pub-id-type="pmid">37078903</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.P.</given-names></name></person-group><article-title>Nanoparticle-based nanomedicines to promote cancer immunotherapy: recent advances and future directions</article-title><source>Small</source><volume>15</volume><year>2019</year><object-id pub-id-type="publisher-id">e1900262</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.201900262</pub-id><pub-id pub-id-type="pmid">30908864</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name name-style="western"><surname>Mant</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chinnery</surname><given-names>F.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>T.</given-names></name><etal/></person-group><article-title>The pathway of cross-presentation is influenced by the particle size of phagocytosed antigen</article-title><source>Immunology</source><volume>136</volume><year>2012</year><fpage>163</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">22260486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2567.2012.03558.x</pub-id><pub-id pub-id-type="pmcid">PMC3403259</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name name-style="western"><surname>Carmona-Ribeiro</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>P&#233;rez-Betancourt</surname><given-names>Y.</given-names></name></person-group><article-title>Cationic nanostructures for vaccines design</article-title><source>Biomimetics</source><issue>5</issue><year>2020</year><fpage>32</fpage><pub-id pub-id-type="pmid">32645946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomimetics5030032</pub-id><pub-id pub-id-type="pmcid">PMC7560170</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Kroll</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Holay</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Biomimetic nanotechnology toward personalized vaccines</article-title><source>Adv. Mater.</source><volume>32</volume><year>2019</year><object-id pub-id-type="publisher-id">1901255</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.201901255</pub-id><pub-id pub-id-type="pmcid">PMC6918015</pub-id><pub-id pub-id-type="pmid">31206841</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name name-style="western"><surname>Niikura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matsunaga</surname><given-names>T.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic></article-title><source>ACS Nano</source><volume>7</volume><year>2013</year><fpage>3926</fpage><lpage>3938</lpage><pub-id pub-id-type="pmid">23631767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/nn3057005</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name name-style="western"><surname>Ochyl</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Bazzill</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Park</surname><given-names>C.</given-names></name><etal/></person-group><article-title>PEGylated tumor cell membrane vesicles as a new vaccine platform for cancer immunotherapy</article-title><source>Biomaterials</source><issue>182</issue><year>2018</year><fpage>157</fpage><lpage>166</lpage><pub-id pub-id-type="pmid">30121425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2018.08.016</pub-id><pub-id pub-id-type="pmcid">PMC6156795</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Duschl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Himly</surname><given-names>M.</given-names></name></person-group><article-title>Nanotechnology-based vaccines for allergen-specific immunotherapy: potentials and challenges of conventional and novel adjuvants under research</article-title><source>Vaccines</source><issue>8</issue><year>2020</year><fpage>237</fpage><pub-id pub-id-type="pmid">32443671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines8020237</pub-id><pub-id pub-id-type="pmcid">PMC7349961</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name name-style="western"><surname>Xekouki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lagopati</surname><given-names>N.</given-names></name><name name-style="western"><surname>Demetzos</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A mini review for lipid-based nanovaccines: from their design to their applications</article-title><source>J. Liposome Res.</source><volume>33</volume><year>2023</year><fpage>214</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">36856671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08982104.2023.2170408</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name></person-group><article-title>Tumor microenvironment-responsive manganese-based nanomaterials for cancer treatment</article-title><source>Coord. Chem. Rev.</source><volume>480</volume><year>2023</year><object-id pub-id-type="publisher-id">215027</object-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Ferroptosis and necroptosis produced autologous tumor cell lysates <italic toggle="yes">co</italic>-delivering with combined immnoadjuvants as personalized <italic toggle="yes">in situ</italic> nanovaccines for antitumor immunity</article-title><source>ACS Nano</source><volume>17</volume><year>2023</year><fpage>14475</fpage><lpage>14493</lpage><pub-id pub-id-type="pmid">37466500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c00901</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Chiral polypeptide nanoparticles as nanoadjuvants of nanovaccines for efficient cancer prevention and therapy</article-title><source>Sci. Bull.</source><volume>68</volume><year>2023</year><fpage>284</fpage><lpage>294</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.scib.2023.01.024</pub-id><pub-id pub-id-type="pmid">36732117</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Q.H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.W.</given-names></name><etal/></person-group><article-title>Metal-phenolic network-encapsulated nanovaccine with pH and reduction dual responsiveness for enhanced cancer immunotherapy</article-title><source>Mol. Pharm.</source><volume>17</volume><year>2020</year><fpage>4603</fpage><lpage>4615</lpage><pub-id pub-id-type="pmid">33175556</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.0c00802</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Precise depletion of tumor seed and growing soil with shrinkable nanocarrier for potentiated cancer chemoimmunotherapy</article-title><source>ACS Nano</source><volume>15</volume><year>2021</year><fpage>4636</fpage><lpage>4646</lpage><pub-id pub-id-type="pmid">33651592</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.0c08996</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>C.</given-names></name><name name-style="western"><surname>You</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>A nanovaccine based on adjuvant peptide FK-13 and <italic toggle="yes">L</italic>-phenylalanine poly(ester amide) enhances CD8<sup>+</sup> T cell-mediated antitumor immunity</article-title><source>Adv. Sci.</source><volume>10</volume><year>2023</year><object-id pub-id-type="publisher-id">2300418</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202300418</pub-id><pub-id pub-id-type="pmcid">PMC10369282</pub-id><pub-id pub-id-type="pmid">37162249</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A &#8220;trained immunity&#8221; inducer-adjuvanted nanovaccine reverses the growth of established tumors in mice</article-title><source>J. Nanobiotechnol.</source><volume>21</volume><year>2023</year><fpage>74</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-023-01832-3</pub-id><pub-id pub-id-type="pmcid">PMC9980871</pub-id><pub-id pub-id-type="pmid">36864424</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><etal/></person-group><article-title>CaCO<sub>3</sub> powder-mediated biomineralization of antigen nanosponges synergize with PD-1 blockade to potentiate anti-tumor immunity</article-title><source>J. Nanobiotechnol.</source><volume>21</volume><year>2023</year><fpage>120</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-023-01870-x</pub-id><pub-id pub-id-type="pmcid">PMC10080855</pub-id><pub-id pub-id-type="pmid">37024939</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name name-style="western"><surname>El-Sayed</surname><given-names>N.</given-names></name><name name-style="western"><surname>Korotchenko</surname><given-names>E.</given-names></name><name name-style="western"><surname>Scheiblhofer</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Functionalized multifunctional nanovaccine for targeting dendritic cells and modulation of immune response</article-title><source>Int. J. Pharm.</source><volume>593</volume><year>2021</year><object-id pub-id-type="publisher-id">120123</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijpharm.2020.120123</pub-id><pub-id pub-id-type="pmid">33278496</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name name-style="western"><surname>Qiao</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A MnAl double adjuvant nanovaccine to induce strong humoral and cellular immune responses</article-title><source>J. Contr. Release</source><volume>358</volume><year>2023</year><fpage>190</fpage><lpage>203</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2023.04.036</pub-id><pub-id pub-id-type="pmid">37116543</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name><name name-style="western"><surname>Su</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect</article-title><source>Sci. Adv.</source><volume>9</volume><year>2023</year><object-id pub-id-type="publisher-id">eade6257</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.ade6257</pub-id><pub-id pub-id-type="pmcid">PMC10348685</pub-id><pub-id pub-id-type="pmid">37450588</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy</article-title><source>Bioact. Mater.</source><issue>26</issue><year>2023</year><fpage>169</fpage><lpage>180</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2023.02.016</pub-id><pub-id pub-id-type="pmcid">PMC9982230</pub-id><pub-id pub-id-type="pmid">36883121</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name name-style="western"><surname>Diao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name></person-group><article-title>Rethinking antigen source: cancer vaccines based on whole tumor cell/tissue lysate or whole tumor cell</article-title><source>Adv. Sci.</source><volume>10</volume><year>2023</year><object-id pub-id-type="publisher-id">2300121</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202300121</pub-id><pub-id pub-id-type="pmcid">PMC10401146</pub-id><pub-id pub-id-type="pmid">37254712</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name name-style="western"><surname>Van Herck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name></person-group><article-title>Delivery of STING agonists for adjuvanting subunit vaccines</article-title><source>Adv. Drug Deliv. Rev.</source><volume>179</volume><year>2021</year><object-id pub-id-type="publisher-id">114020</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2021.114020</pub-id><pub-id pub-id-type="pmid">34756942</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name name-style="western"><surname>Hopfner</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Hornung</surname><given-names>V.</given-names></name></person-group><article-title>Molecular mechanisms and cellular functions of cGAS-STING signalling</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>21</volume><year>2020</year><fpage>501</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">32424334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41580-020-0244-x</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name name-style="western"><surname>Boyaka</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>McGhee</surname><given-names>J.R.</given-names></name></person-group><article-title>Cytokines as adjuvants for the induction of mucosal immunity</article-title><source>Adv. Drug Deliv. Rev.</source><volume>51</volume><year>2001</year><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">11516780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0169-409x(01)00170-3</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name name-style="western"><surname>Bukczynski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ellefsen</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>101</volume><year>2004</year><fpage>1291</fpage><lpage>1296</lpage><pub-id pub-id-type="pmid">14745033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0306567101</pub-id><pub-id pub-id-type="pmcid">PMC337046</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name name-style="western"><surname>Uppu</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Turvey</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Sharif</surname><given-names>A.R.M.</given-names></name><etal/></person-group><article-title>Temporal release of a three-component protein subunit vaccine from polymer multilayers</article-title><source>J. Contr. Release</source><volume>317</volume><year>2020</year><fpage>130</fpage><lpage>141</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2019.11.022</pub-id><pub-id pub-id-type="pmid">31756392</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Construction of pH-sensitive nanovaccines encapsulating tumor cell lysates and immune adjuvants for breast cancer therapy</article-title><source>Small</source><volume>19</volume><year>2023</year><object-id pub-id-type="publisher-id">2301420</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202301420</pub-id><pub-id pub-id-type="pmid">37154213</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Oxygen-carrying nanoplatform to reprogram tumor immunosuppressive microenvironment and enhance photothermal-immunotherapy</article-title><source>Mater. Today Bio</source><volume>19</volume><year>2023</year><object-id pub-id-type="publisher-id">100555</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mtbio.2023.100555</pub-id><pub-id pub-id-type="pmcid">PMC9922928</pub-id><pub-id pub-id-type="pmid">36793322</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name name-style="western"><surname>Banete</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Basta</surname><given-names>S.</given-names></name></person-group><article-title>Sustained IL-4 priming of macrophages enhances the inflammatory response to TLR7/8 ligand R848</article-title><source>J. Leukoc. Biol.</source><volume>111</volume><year>2022</year><fpage>401</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">34013552</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/JLB.3A0520-293RR</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name name-style="western"><surname>Pires</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>K.</given-names></name><name name-style="western"><surname>Melo</surname><given-names>M.B.</given-names></name><etal/></person-group><article-title>Controlled lipid self-assembly for scalable manufacturing of next-generation immune stimulating complexes</article-title><source>Chem. Eng. J.</source><volume>464</volume><year>2023</year><object-id pub-id-type="publisher-id">142664</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cej.2023.142664</pub-id><pub-id pub-id-type="pmcid">PMC11081102</pub-id><pub-id pub-id-type="pmid">38737525</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A therapeutic nanovaccine that generates anti-amyloid antibodies and amyloid-specific regulatory T cells for alzheimer's disease</article-title><source>Adv. Mater.</source><volume>35</volume><year>2023</year><object-id pub-id-type="publisher-id">e2207719</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202207719</pub-id><pub-id pub-id-type="pmid">36329674</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name name-style="western"><surname>Carreno</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>M.</given-names></name></person-group><article-title>The B7 family of ligands and its receptors: new pathways of costimulation and inhibition of immune responses</article-title><source>Annu. Rev. Immunol.</source><volume>20</volume><year>2002</year><fpage>29</fpage><pub-id pub-id-type="pmid">11861596</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.immunol.20.091101.091806</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Singha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Casares</surname><given-names>X.C.</given-names></name><etal/></person-group><article-title>Nanoparticle-based immunotherapy for cancer</article-title><source>ACS Nano</source><volume>9</volume><year>2015</year><fpage>16</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">25469470</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/nn5062029</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The application of nanoparticles in cancer immunotherapy: targeting tumor microenvironment</article-title><source>Bioact. Mater.</source><issue>6</issue><year>2021</year><fpage>1973</fpage><lpage>1987</lpage><pub-id pub-id-type="pmid">33426371</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2020.12.010</pub-id><pub-id pub-id-type="pmcid">PMC7773537</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Hollow MnO<sub>2</sub> nanoparticles loaded with functional genes as nanovaccines for synergistic cancer therapy</article-title><source>ACS Appl. Nano Mater.</source><issue>5</issue><year>2022</year><fpage>10537</fpage><lpage>10547</lpage></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Hollow aluminum hydroxide modified silica nanoadjuvants with amplified immunotherapy effects through immunogenic cell death induction and antigen release</article-title><source>Small</source><volume>18</volume><year>2022</year><object-id pub-id-type="publisher-id">2202462</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.202202462</pub-id><pub-id pub-id-type="pmid">35896867</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Robust nanovaccine based on polydopamine-coated mesoporous silica nanoparticles for effective photothermal-immunotherapy against melanoma</article-title><source>Adv. Funct. Mater.</source><volume>31</volume><year>2021</year><object-id pub-id-type="publisher-id">2010637</object-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Combination delivery of antigens and CpG by lanthanides-based core-shell nanoparticles for enhanced immune response and dual-mode imaging</article-title><source>Adv. Healthcare Mater.</source><issue>2</issue><year>2013</year><fpage>1309</fpage><lpage>1313</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.201200364</pub-id><pub-id pub-id-type="pmid">23526798</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger</article-title><source>Biomaterials</source><issue>252</issue><year>2020</year><object-id pub-id-type="publisher-id">120114</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2020.120114</pub-id><pub-id pub-id-type="pmid">32422491</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Nanovaccine biomineralization for cancer immunotherapy: a NADPH oxidase-inspired strategy for improving antigen cross-presentation <italic toggle="yes">via</italic> lipid peroxidation</article-title><source>Biomaterials</source><issue>277</issue><year>2021</year><object-id pub-id-type="publisher-id">121089</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2021.121089</pub-id><pub-id pub-id-type="pmid">34481292</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gossl</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ustyanovska</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Mesoporous silica nanoparticles as pH-responsive carrier for the immune-activating drug resiquimod enhance the local immune response in mice</article-title><source>ACS Nano</source><volume>15</volume><year>2021</year><fpage>4450</fpage><lpage>4466</lpage><pub-id pub-id-type="pmid">33648336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.0c08384</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>X.R.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.F.</given-names></name><etal/></person-group><article-title>Schottky heterojunction realizes <italic toggle="yes">in situ</italic> vaccine-like antitumor efficacy and microenvironment remodeling upon near-infrared laser response in cold tumors</article-title><source>Adv. Funct. Mater.</source><volume>33</volume><year>2023</year><object-id pub-id-type="publisher-id">2306734</object-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Autologous tumor antigens and boron nanosheet-based nanovaccines for enhanced photo-immunotherapy against immune desert tumors</article-title><source>Nanophotonics</source><volume>10</volume><year>2021</year><fpage>2519</fpage><lpage>2535</lpage></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.X.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.R.</given-names></name><etal/></person-group><article-title>Efficient delivery of clay-based nanovaccines to the mouse spleen promotes potent anti-tumor immunity for both prevention and treatment of lymphoma</article-title><source>Nano Res.</source><volume>14</volume><year>2021</year><fpage>1326</fpage><lpage>1334</lpage></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Black phosphorous nanosheet: a novel immune-potentiating nanoadjuvant for near-infrared-improved immunotherapy</article-title><source>Biomaterials</source><volume>273</volume><year>2021</year><object-id pub-id-type="publisher-id">120788</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2021.120788</pub-id><pub-id pub-id-type="pmid">33933912</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C.X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Synthetic polymeric mixed micelles targeting lymph nodes trigger enhanced cellular and humoral immune responses</article-title><source>ACS Appl. Mater. Interfaces</source><issue>10</issue><year>2018</year><fpage>2874</fpage><lpage>2889</lpage><pub-id pub-id-type="pmid">29285934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsami.7b14004</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z.D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Coordinating antigen cytosolic delivery and danger signaling to program potent cross-priming by micelle-based nanovaccine</article-title><source>Cell Discov</source><issue>3</issue><year>2017</year><object-id pub-id-type="publisher-id">17007</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/celldisc.2017.7</pub-id><pub-id pub-id-type="pmcid">PMC5379745</pub-id><pub-id pub-id-type="pmid">28417012</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Cationic polypeptide micelle-based antigen delivery system: a simple and robust adjuvant to improve vaccine efficacy</article-title><source>J. Contr. Release</source><volume>170</volume><year>2013</year><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2013.05.027</pub-id><pub-id pub-id-type="pmid">23742880</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.Y.</given-names></name><etal/></person-group><article-title>A redox-responsive nanovaccine combined with A2A receptor antagonist for cancer immunotherapy</article-title><source>Adv. Healthcare Mater.</source><volume>10</volume><year>2021</year><object-id pub-id-type="publisher-id">2101222</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202101222</pub-id><pub-id pub-id-type="pmid">34494380</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>F.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Stabilizing RNA nanovaccines with transformable hyaluronan dynamic hydrogel for durable cancer immunotherapy</article-title><source>Adv. Funct. Mater.</source><volume>33</volume><year>2023</year><object-id pub-id-type="publisher-id">2204636</object-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>H.</given-names></name><etal/></person-group><article-title><italic toggle="yes">In situ</italic> transforming RNA nanovaccines from polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy</article-title><source>Nano Lett.</source><volume>21</volume><year>2021</year><fpage>2224</fpage><lpage>2231</lpage><pub-id pub-id-type="pmid">33594887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.0c05039</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Bioreducible alginate-poly(ethylenimine) nanogels as an antigen-delivery system robustly enhance vaccine-elicited humoral and cellular immune responses</article-title><source>J. Contr. Release</source><volume>168</volume><year>2013</year><fpage>271</fpage><lpage>279</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2013.03.025</pub-id><pub-id pub-id-type="pmid">23562637</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name name-style="western"><surname>Stickdorn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>L.</given-names></name><name name-style="western"><surname>Arnold Schild</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Systemically administered TLR7/8 agonist and antigen-conjugated nanogels govern immune responses against tumors</article-title><source>ACS Nano</source><volume>16</volume><year>2022</year><fpage>4426</fpage><lpage>4443</lpage><pub-id pub-id-type="pmid">35103463</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.1c10709</pub-id><pub-id pub-id-type="pmcid">PMC8945363</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticles as a nanovaccine induce robust humoral and cellular immune responses</article-title><source>ACS Appl. Mater. Interfaces</source><issue>8</issue><year>2016</year><fpage>11969</fpage><lpage>11979</lpage><pub-id pub-id-type="pmid">27088457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsami.6b01135</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>W.</given-names></name><name name-style="western"><surname>An</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Tuning the organ tropism of polymersome for spleen-selective nanovaccine delivery to boost cancer immunotherapy</article-title><source>Adv. Mater.</source><year>2023</year><object-id pub-id-type="publisher-id">2301686</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202301686</pub-id><pub-id pub-id-type="pmid">37165781</pub-id></element-citation></ref><ref id="bib71"><label>71</label><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response</article-title><source>Biomaterials</source><volume>149</volume><year>2017</year><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">28992509</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2017.09.029</pub-id></element-citation></ref><ref id="bib72"><label>72</label><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name name-style="western"><surname>Zhan</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.L.</given-names></name><etal/></person-group><article-title>Biomimetic sonodynamic therapy-nanovaccine integration platform potentiates anti-PD-1 therapy in hypoxic tumors</article-title><source>Nano Today</source><volume>38</volume><year>2021</year><object-id pub-id-type="publisher-id">101195</object-id></element-citation></ref><ref id="bib73"><label>73</label><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bian</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Converting primary tumor towards an in situ STING-activating vaccine <italic toggle="yes">via</italic> a biomimetic nanoplatform against recurrent and metastatic tumors</article-title><source>Nano Today</source><volume>38</volume><year>2021</year><object-id pub-id-type="publisher-id">101109</object-id></element-citation></ref><ref id="bib74"><label>74</label><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>R.F.</given-names></name><etal/></person-group><article-title>Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines</article-title><source>Sci. Transl. Med.</source><volume>13</volume><year>2021</year><object-id pub-id-type="publisher-id">eabc2816</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/scitranslmed.abc2816</pub-id><pub-id pub-id-type="pmid">34233949</pub-id></element-citation></ref><ref id="bib75"><label>75</label><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name name-style="western"><surname>Kadiyala</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nunez</surname><given-names>F.M.</given-names></name><etal/></person-group><article-title>High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme</article-title><source>ACS Nano</source><volume>13</volume><year>2019</year><fpage>1365</fpage><lpage>1384</lpage><pub-id pub-id-type="pmid">30721028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.8b06842</pub-id><pub-id pub-id-type="pmcid">PMC6484828</pub-id></element-citation></ref><ref id="bib76"><label>76</label><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name name-style="western"><surname>Kuai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ochyl</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Bahjat</surname><given-names>K.S.</given-names></name><etal/></person-group><article-title>Designer vaccine nanodiscs for personalized cancer immunotherapy</article-title><source>Nat. Mater.</source><volume>16</volume><year>2017</year><fpage>489</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">28024156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmat4822</pub-id><pub-id pub-id-type="pmcid">PMC5374005</pub-id></element-citation></ref><ref id="bib77"><label>77</label><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name name-style="western"><surname>Hassani Najafabadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aikins</surname><given-names>M.E.</given-names></name><etal/></person-group><article-title>Cancer immunotherapy <italic toggle="yes">via</italic> targeting cancer stem cells using vaccine nanodiscs</article-title><source>Nano Lett.</source><volume>20</volume><year>2020</year><fpage>7783</fpage><lpage>7792</lpage><pub-id pub-id-type="pmid">32926633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.0c03414</pub-id><pub-id pub-id-type="pmcid">PMC7572838</pub-id></element-citation></ref><ref id="bib78"><label>78</label><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name name-style="western"><surname>Arab</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nicastro</surname><given-names>J.</given-names></name><name name-style="western"><surname>Slavcev</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8<sup>+</sup> T response</article-title><source>Immunol. Res.</source><volume>66</volume><year>2018</year><fpage>200</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">29143917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12026-017-8969-0</pub-id></element-citation></ref><ref id="bib79"><label>79</label><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name name-style="western"><surname>Salazar Gonzalez</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Ruiz-Cruz</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Bustos-Jaimes</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Expression of breast cancer-related epitopes targeting the IGF-1 receptor in chimeric human parvovirus B19 virus-like particles</article-title><source>Mol. Biotechnol.</source><volume>61</volume><year>2019</year><fpage>742</fpage><lpage>753</lpage><pub-id pub-id-type="pmid">31317318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12033-019-00198-y</pub-id></element-citation></ref><ref id="bib80"><label>80</label><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name name-style="western"><surname>Schwarz</surname><given-names>B.</given-names></name><name name-style="western"><surname>Morabito</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Ruckwardt</surname><given-names>T.J.</given-names></name><etal/></person-group><article-title>Virus-like particles encapsidating respiratory syncytial virus M and M2 proteins induce robust T cell responses</article-title><source>ACS Biomater. Sci. Eng.</source><issue>2</issue><year>2016</year><fpage>2324</fpage><lpage>2332</lpage><pub-id pub-id-type="pmid">29367948</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsbiomaterials.6b00532</pub-id><pub-id pub-id-type="pmcid">PMC5777520</pub-id></element-citation></ref><ref id="bib81"><label>81</label><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name name-style="western"><surname>Hess</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Medintz</surname><given-names>I.L.</given-names></name><name name-style="western"><surname>Jewell</surname><given-names>C.M.</given-names></name></person-group><article-title>Designing inorganic nanomaterials for vaccines and immunotherapies</article-title><source>Nano Today</source><volume>27</volume><year>2019</year><fpage>73</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">32292488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nantod.2019.04.005</pub-id><pub-id pub-id-type="pmcid">PMC7156029</pub-id></element-citation></ref><ref id="bib82"><label>82</label><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name name-style="western"><surname>Praetorius</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Mandal</surname><given-names>T.K.</given-names></name></person-group><article-title>Engineered nanoparticles in cancer therapy. Recent Pat</article-title><source>Drug Delivery Formulation</source><volume>1</volume><year>2007</year><fpage>37</fpage><lpage>51</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/187221107779814104</pub-id><pub-id pub-id-type="pmid">19075873</pub-id></element-citation></ref><ref id="bib83"><label>83</label><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name name-style="western"><surname>Vinardell</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Mitjans</surname><given-names>M.</given-names></name></person-group><article-title>Antitumor activities of metal oxide nanoparticles</article-title><source>Nanomaterials</source><issue>5</issue><year>2015</year><fpage>1004</fpage><lpage>1021</lpage><pub-id pub-id-type="pmid">28347048</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nano5021004</pub-id><pub-id pub-id-type="pmcid">PMC5312892</pub-id></element-citation></ref><ref id="bib84"><label>84</label><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name name-style="western"><surname>Dey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Manna</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Immunostimulatory effect of chitosan conjugated green copper oxide nanoparticles in tumor immunotherapy</article-title><source>Cytokine</source><volume>127</volume><year>2020</year><object-id pub-id-type="publisher-id">154958</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cyto.2019.154958</pub-id><pub-id pub-id-type="pmid">31923815</pub-id></element-citation></ref><ref id="bib85"><label>85</label><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>L.Z.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>T.Q.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.J.</given-names></name><etal/></person-group><article-title>Designing bioinspired 2D MoSe<sub>2</sub> nanosheet for efficient photothermal-triggered cancer immunotherapy with reprogramming tumor-associated macrophages</article-title><source>Adv. Funct. Mater.</source><volume>29</volume><year>2019</year><object-id pub-id-type="publisher-id">1901240</object-id></element-citation></ref><ref id="bib86"><label>86</label><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Nanomedicine-boosting tumor immunogenicity for enhanced immunotherapy</article-title><source>Adv. Funct. Mater.</source><volume>31</volume><year>2021</year><object-id pub-id-type="publisher-id">2011171</object-id></element-citation></ref><ref id="bib87"><label>87</label><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A novel therapeutic vaccine based on graphene oxide nanocomposite for tumor immunotherapy</article-title><source>Chin. Chem. Lett.</source><volume>33</volume><year>2022</year><fpage>4089</fpage><lpage>4095</lpage></element-citation></ref><ref id="bib88"><label>88</label><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Immunogenic exosome-encapsulated black phosphorus nanoparticles as an effective anticancer photo-nanovaccine</article-title><source>Nanoscale</source><volume>12</volume><year>2020</year><fpage>19939</fpage><lpage>19952</lpage><pub-id pub-id-type="pmid">32991664</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/d0nr05953f</pub-id></element-citation></ref><ref id="bib89"><label>89</label><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>A booster for radiofrequency ablation: advanced adjuvant therapy <italic toggle="yes">via in situ</italic> nanovaccine synergized with anti-programmed death ligand 1 immunotherapy for systemically constraining hepatocellular carcinoma</article-title><source>ACS Nano</source><volume>17</volume><year>2023</year><fpage>19441</fpage><lpage>19458</lpage><pub-id pub-id-type="pmid">37733578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c08064</pub-id></element-citation></ref><ref id="bib90"><label>90</label><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Black phosphorus nanosheets assist nanoerythrosomes for efficient mrna vaccine delivery and immune activation</article-title><source>Adv. Healthcare Mater.</source><issue>12</issue><year>2023</year><object-id pub-id-type="publisher-id">2300935</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202300935</pub-id><pub-id pub-id-type="pmid">37363954</pub-id></element-citation></ref><ref id="bib91"><label>91</label><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name name-style="western"><surname>Blanco</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kessinger</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Sumer</surname><given-names>B.D.</given-names></name><etal/></person-group><article-title>Multifunctional micellar nanomedicine for cancer therapy</article-title><source>Exp. Biol. Med.</source><volume>234</volume><year>2009</year><fpage>123</fpage><lpage>131</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3181/0808-MR-250</pub-id><pub-id pub-id-type="pmcid">PMC2864888</pub-id><pub-id pub-id-type="pmid">19064945</pub-id></element-citation></ref><ref id="bib92"><label>92</label><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Biswas</surname><given-names>S.</given-names></name></person-group><article-title>Polymeric micelles in cancer therapy: state of the art</article-title><source>J. Contr. Release</source><volume>332</volume><year>2021</year><fpage>127</fpage><lpage>147</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2021.02.016</pub-id><pub-id pub-id-type="pmid">33609621</pub-id></element-citation></ref><ref id="bib93"><label>93</label><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name name-style="western"><surname>Van Der Vlies</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>O'Neil</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>U.</given-names></name><etal/></person-group><article-title>Synthesis of pyridyl disulfide-functionalized nanoparticles for conjugating thiol-containing small molecules, peptides, and proteins</article-title><source>Bioconjugate Chem.</source><volume>21</volume><year>2010</year><fpage>653</fpage><lpage>662</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/bc9004443</pub-id><pub-id pub-id-type="pmid">20369815</pub-id></element-citation></ref><ref id="bib94"><label>94</label><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name name-style="western"><surname>Hubbell</surname><given-names>J.A.</given-names></name></person-group><article-title>Enhancing drug function</article-title><source>Science</source><volume>300</volume><year>2003</year><fpage>595</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">12714733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1083625</pub-id></element-citation></ref><ref id="bib95"><label>95</label><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name name-style="western"><surname>O'Neil</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>van der Vlies</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Velluto</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Extracellular matrix binding mixed micelles for drug delivery applications</article-title><source>J. Contr. Release</source><volume>137</volume><year>2009</year><fpage>146</fpage><lpage>151</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2009.03.013</pub-id><pub-id pub-id-type="pmid">19332089</pub-id></element-citation></ref><ref id="bib96"><label>96</label><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Biofilm microenvironment-responsive polymeric CO releasing micelles for enhanced amikacin efficacy</article-title><source>J. Contr. Release</source><volume>357</volume><year>2023</year><fpage>561</fpage><lpage>571</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2023.04.025</pub-id><pub-id pub-id-type="pmid">37076015</pub-id></element-citation></ref><ref id="bib97"><label>97</label><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Chiral polymer micelles alleviate adriamycin cardiotoxicity <italic toggle="yes">via</italic> iron chelation and ferroptosis inhibition</article-title><source>Adv. Funct. Mater.</source><volume>33</volume><year>2023</year><object-id pub-id-type="publisher-id">2300689</object-id></element-citation></ref><ref id="bib98"><label>98</label><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Chitosan-based nano-micelles for potential anti-tumor immunotherapy: synergistic effect of cGAS-STING signaling pathway activation and tumor antigen absorption</article-title><source>Carbohydr. Polym.</source><volume>321</volume><year>2023</year><object-id pub-id-type="publisher-id">121346</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.carbpol.2023.121346</pub-id><pub-id pub-id-type="pmid">37739513</pub-id></element-citation></ref><ref id="bib99"><label>99</label><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name name-style="western"><surname>Eby</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Dane</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>O'Neil</surname><given-names>C.P.</given-names></name><etal/></person-group><article-title>Polymer micelles with pyridyl disulfide-coupled antigen travel through lymphatics and show enhanced cellular responses following immunization</article-title><source>Acta Biomater.</source><issue>8</issue><year>2012</year><fpage>3210</fpage><lpage>3217</lpage><pub-id pub-id-type="pmid">22698945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2012.06.007</pub-id></element-citation></ref><ref id="bib100"><label>100</label><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name name-style="western"><surname>Brubaker</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Panagiotou</surname><given-names>V.</given-names></name><name name-style="western"><surname>Demurtas</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A cationic micelle complex improves CD8<sup>+</sup> T cell responses in vaccination against unmodified protein antigen</article-title><source>ACS Biomater. Sci. Eng.</source><issue>2</issue><year>2016</year><fpage>231</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">33418636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsbiomaterials.5b00456</pub-id></element-citation></ref><ref id="bib101"><label>101</label><element-citation publication-type="journal" id="sref101"><person-group person-group-type="author"><name name-style="western"><surname>Peeler</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Luera</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Lytic polyplex vaccines enhance antigen&#8208;specific cytotoxic T cell response through induction of local cell death</article-title><source>Adv. Ther.</source><volume>4</volume><year>2021</year><object-id pub-id-type="publisher-id">2100005</object-id></element-citation></ref><ref id="bib102"><label>102</label><element-citation publication-type="journal" id="sref102"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Luu</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A mannosylated polymer with endosomal release properties for peptide antigen delivery</article-title><source>J. Contr. Release</source><volume>356</volume><year>2023</year><fpage>232</fpage><lpage>241</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2023.03.004</pub-id><pub-id pub-id-type="pmcid">PMC10693254</pub-id><pub-id pub-id-type="pmid">36878319</pub-id></element-citation></ref><ref id="bib103"><label>103</label><element-citation publication-type="journal" id="sref103"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Well-defined mannosylated polymer for peptide vaccine delivery with enhanced antitumor immunity</article-title><source>Adv. Healthcare Mater.</source><volume>11</volume><year>2022</year><object-id pub-id-type="publisher-id">2101651</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202101651</pub-id><pub-id pub-id-type="pmcid">PMC9043035</pub-id><pub-id pub-id-type="pmid">34706166</pub-id></element-citation></ref><ref id="bib104"><label>104</label><element-citation publication-type="journal" id="sref104"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Gama</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Vilanova</surname><given-names>M.</given-names></name></person-group><article-title>Polymeric nanogels as vaccine delivery systems</article-title><source>Nanomed-Nanotechnol.</source><issue>9</issue><year>2013</year><fpage>159</fpage><lpage>173</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.nano.2012.06.001</pub-id><pub-id pub-id-type="pmid">22772049</pub-id></element-citation></ref><ref id="bib105"><label>105</label><element-citation publication-type="journal" id="sref105"><person-group person-group-type="author"><name name-style="western"><surname>Muraoka</surname><given-names>D.</given-names></name><name name-style="western"><surname>Harada</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shiku</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance</article-title><source>J. Contr. Release</source><volume>347</volume><year>2022</year><fpage>175</fpage><lpage>182</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.05.004</pub-id><pub-id pub-id-type="pmid">35526613</pub-id></element-citation></ref><ref id="bib106"><label>106</label><element-citation publication-type="journal" id="sref106"><person-group person-group-type="author"><name name-style="western"><surname>Yuki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Harada</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sawada</surname><given-names>S.I.</given-names></name><etal/></person-group><article-title>Biodistribution assessment of cationic pullulan nanogel, a nasal vaccine delivery system, in mice and non-human primates</article-title><source>Vaccine</source><issue>41</issue><year>2023</year><fpage>4941</fpage><lpage>4949</lpage><pub-id pub-id-type="pmid">37385890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2023.06.065</pub-id></element-citation></ref><ref id="bib107"><label>107</label><element-citation publication-type="journal" id="sref107"><person-group person-group-type="author"><name name-style="western"><surname>Molofsky</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Locksley</surname><given-names>R.M.</given-names></name></person-group><article-title>The ins and outs of innate and adaptive type 2 immunity</article-title><source>Immunity</source><issue>56</issue><year>2023</year><fpage>704</fpage><lpage>722</lpage><pub-id pub-id-type="pmid">37044061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2023.03.014</pub-id><pub-id pub-id-type="pmcid">PMC10120575</pub-id></element-citation></ref><ref id="bib108"><label>108</label><element-citation publication-type="journal" id="sref108"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.L.</given-names></name><etal/></person-group><article-title>Self-adjuvanted nanovaccine for cancer immunotherapy: role of lysosomal rupture-induced ROS in MHC class I antigen presentation</article-title><source>Biomaterials</source><volume>79</volume><year>2016</year><fpage>88</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">26702587</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2015.11.040</pub-id></element-citation></ref><ref id="bib109"><label>109</label><element-citation publication-type="journal" id="sref109"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name></person-group><article-title>Liposomes used as a vaccine adjuvant-delivery system: from basics to clinical immunization</article-title><source>J. Contr. Release</source><volume>303</volume><year>2019</year><fpage>130</fpage><lpage>150</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2019.04.025</pub-id><pub-id pub-id-type="pmcid">PMC7111479</pub-id><pub-id pub-id-type="pmid">31022431</pub-id></element-citation></ref><ref id="bib110"><label>110</label><element-citation publication-type="journal" id="sref110"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Enhanced antitumor immune responses <italic toggle="yes">via</italic> a self-assembled carrier-free nanovaccine</article-title><source>Nano Lett.</source><volume>21</volume><year>2021</year><fpage>3965</fpage><lpage>3973</lpage><pub-id pub-id-type="pmid">33886338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.1c00648</pub-id></element-citation></ref><ref id="bib111"><label>111</label><element-citation publication-type="journal" id="sref111"><person-group person-group-type="author"><name name-style="western"><surname>Tretiakova</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Vodovozova</surname><given-names>E.L.</given-names></name></person-group><article-title>Liposomes as adjuvants and vaccine delivery systems</article-title><source>Biochem. (Mosc) Suppl. Ser. A Membr. Cell Biol.</source><issue>16</issue><year>2022</year><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1134/S1990747822020076</pub-id><pub-id pub-id-type="pmcid">PMC8853224</pub-id><pub-id pub-id-type="pmid">35194485</pub-id></element-citation></ref><ref id="bib112"><label>112</label><element-citation publication-type="journal" id="sref112"><person-group person-group-type="author"><name name-style="western"><surname>Yuba</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tajima</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yoshizaki</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Dextran derivative-based pH-sensitive liposomes for cancer immunotherapy</article-title><source>Biomaterials</source><volume>35</volume><year>2014</year><fpage>3091</fpage><lpage>3101</lpage><pub-id pub-id-type="pmid">24406217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2013.12.024</pub-id></element-citation></ref><ref id="bib113"><label>113</label><element-citation publication-type="journal" id="sref113"><person-group person-group-type="author"><name name-style="western"><surname>Yoshizaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuba</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Potentiation of pH-sensitive polymer-modified liposomes with cationic lipid inclusion as antigen delivery carriers for cancer immunotherapy</article-title><source>Biomaterials</source><volume>35</volume><year>2014</year><fpage>8186</fpage><lpage>8196</lpage><pub-id pub-id-type="pmid">24969637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2014.05.077</pub-id></element-citation></ref><ref id="bib114"><label>114</label><element-citation publication-type="journal" id="sref114"><person-group person-group-type="author"><name name-style="western"><surname>Yoshizaki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuba</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>N.</given-names></name><etal/></person-group><article-title>pH-sensitive polymer-modified liposome-based immunity-inducing system: effects of inclusion of cationic lipid and CpG-DNA</article-title><source>Biomaterials</source><volume>141</volume><year>2017</year><fpage>272</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">28704679</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2017.07.001</pub-id></element-citation></ref><ref id="bib115"><label>115</label><element-citation publication-type="journal" id="sref115"><person-group person-group-type="author"><name name-style="western"><surname>Yuba</surname><given-names>E.</given-names></name><name name-style="western"><surname>Harada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sakanishi</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy</article-title><source>Biomaterials</source><volume>34</volume><year>2013</year><fpage>3042</fpage><lpage>3052</lpage><pub-id pub-id-type="pmid">23374704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2012.12.031</pub-id></element-citation></ref><ref id="bib116"><label>116</label><element-citation publication-type="journal" id="sref116"><person-group person-group-type="author"><name name-style="western"><surname>Prasanna</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Current status of nanoscale drug delivery and the future of nano-vaccine development for leishmaniasis-A review</article-title><source>Biomed. Pharmacother.</source><volume>141</volume><year>2021</year><object-id pub-id-type="publisher-id">111920</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2021.111920</pub-id><pub-id pub-id-type="pmid">34328115</pub-id></element-citation></ref><ref id="bib117"><label>117</label><element-citation publication-type="journal" id="sref117"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q.Q.</given-names></name><etal/></person-group><article-title>Necroptotic cancer cells-mimicry nanovaccine boosts anti-tumor immunity with tailored immune-stimulatory modality</article-title><source>Biomaterials</source><volume>164</volume><year>2018</year><fpage>80</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">29499438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2018.02.033</pub-id></element-citation></ref><ref id="bib118"><label>118</label><element-citation publication-type="journal" id="sref118"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>X.M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>X.Y.</given-names></name><etal/></person-group><article-title>Tumor lysate-loaded lipid hybrid nanovaccine collaborated with an immune checkpoint antagonist for combination immunotherapy</article-title><source>Adv. Healthcare Mater.</source><issue>8</issue><year>2019</year><object-id pub-id-type="publisher-id">1800837</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.201800837</pub-id><pub-id pub-id-type="pmid">30506847</pub-id></element-citation></ref><ref id="bib119"><label>119</label><element-citation publication-type="journal" id="sref119"><person-group person-group-type="author"><name name-style="western"><surname>Thakur</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parra</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Motallebnejad</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Exosomes: small vesicles with big roles in cancer, vaccine development, and therapeutics</article-title><source>Bioact. Mater.</source><volume>10</volume><year>2022</year><fpage>281</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">34901546</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2021.08.029</pub-id><pub-id pub-id-type="pmcid">PMC8636666</pub-id></element-citation></ref><ref id="bib120"><label>120</label><element-citation publication-type="journal" id="sref120"><person-group person-group-type="author"><name name-style="western"><surname>Huda</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Nurunnabi</surname><given-names>M.</given-names></name></person-group><article-title>Potential application of exosomes in vaccine development and delivery</article-title><source>Pharm. Res. (N. Y.)</source><volume>39</volume><year>2022</year><fpage>2635</fpage><lpage>2671</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-021-03143-4</pub-id><pub-id pub-id-type="pmcid">PMC8757927</pub-id><pub-id pub-id-type="pmid">35028802</pub-id></element-citation></ref><ref id="bib121"><label>121</label><element-citation publication-type="journal" id="sref121"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Exosome-based immunotherapy: a promising approach for cancer treatment</article-title><source>Mol. Cancer</source><volume>19</volume><year>2020</year><fpage>160</fpage><pub-id pub-id-type="pmid">33183286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-020-01278-3</pub-id><pub-id pub-id-type="pmcid">PMC7661275</pub-id></element-citation></ref><ref id="bib122"><label>122</label><element-citation publication-type="journal" id="sref122"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Novel exosome-targeted CD4<sup>+</sup> T cell vaccine counteracting CD4<sup>+</sup>25<sup>+</sup> regulatory T cell-mediated immune suppression and stimulating efficient central memory CD8<sup>+</sup> CTL responses</article-title><source>J. Immunol.</source><volume>179</volume><year>2007</year><fpage>2731</fpage><lpage>2740</lpage><pub-id pub-id-type="pmid">17709486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.179.5.2731</pub-id><pub-id pub-id-type="pmcid">PMC2567870</pub-id></element-citation></ref><ref id="bib123"><label>123</label><element-citation publication-type="journal" id="sref123"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>You</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy <italic toggle="yes">in vitro</italic> while favor tumorgenesis <italic toggle="yes">in vivo</italic></article-title><source>J. Exp. Clin. Cancer Res.</source><volume>37</volume><year>2018</year><fpage>190</fpage><pub-id pub-id-type="pmid">30103789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13046-018-0863-7</pub-id><pub-id pub-id-type="pmcid">PMC6090784</pub-id></element-citation></ref><ref id="bib124"><label>124</label><element-citation publication-type="journal" id="sref124"><person-group person-group-type="author"><name name-style="western"><surname>Naseri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bozorgmehr</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zoller</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Tumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy</article-title><source>OncoImmunology</source><volume>9</volume><year>2020</year><object-id pub-id-type="publisher-id">1779991</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/2162402X.2020.1779991</pub-id><pub-id pub-id-type="pmcid">PMC7466856</pub-id><pub-id pub-id-type="pmid">32934883</pub-id></element-citation></ref><ref id="bib125"><label>125</label><element-citation publication-type="journal" id="sref125"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy</article-title><source>Nat. Nanotechnol.</source><volume>17</volume><year>2022</year><fpage>531</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">35410368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41565-022-01098-0</pub-id></element-citation></ref><ref id="bib126"><label>126</label><element-citation publication-type="journal" id="sref126"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Ultrasound responsive nanovaccine armed with engineered cancer cell membrane and RNA to prevent foreseeable metastasis</article-title><source>Adv. Sci.</source><volume>10</volume><year>2023</year><object-id pub-id-type="publisher-id">2301107</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202301107</pub-id><pub-id pub-id-type="pmcid">PMC10323640</pub-id><pub-id pub-id-type="pmid">37097746</pub-id></element-citation></ref><ref id="bib127"><label>127</label><element-citation publication-type="journal" id="sref127"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy</article-title><source>Adv. Drug Deliv. Rev.</source><volume>186</volume><year>2022</year><object-id pub-id-type="publisher-id">114321</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2022.114321</pub-id><pub-id pub-id-type="pmid">35533789</pub-id></element-citation></ref><ref id="bib128"><label>128</label><element-citation publication-type="journal" id="sref128"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Q.L.</given-names></name><etal/></person-group><article-title>Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma</article-title><source>ACS Nano</source><volume>9</volume><year>2015</year><fpage>6918</fpage><lpage>6933</lpage><pub-id pub-id-type="pmid">26153897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.5b01042</pub-id></element-citation></ref><ref id="bib129"><label>129</label><element-citation publication-type="journal" id="sref129"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>T.</given-names></name><name name-style="western"><surname>He</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Cancer cell membrane-encapsulated biomimetic nanoparticles for tumor immuno-photothermal therapy</article-title><source>Chem. Eng. J.</source><volume>463</volume><year>2023</year><object-id pub-id-type="publisher-id">142495</object-id></element-citation></ref><ref id="bib130"><label>130</label><element-citation publication-type="journal" id="sref130"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Personalized nanovaccine coated with calcinetin-expressed cancer cell membrane antigen for cancer immunotherapy</article-title><source>Nano Lett.</source><volume>21</volume><year>2021</year><fpage>8418</fpage><lpage>8425</lpage><pub-id pub-id-type="pmid">34546061</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.1c03004</pub-id></element-citation></ref><ref id="bib131"><label>131</label><element-citation publication-type="journal" id="sref131"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>C.</given-names></name><etal/></person-group><article-title>A protein-based cGAS-STING nanoagonist enhances T cell-mediated anti-tumor immune responses</article-title><source>Nat. Commun.</source><volume>13</volume><year>2022</year><fpage>5685</fpage><pub-id pub-id-type="pmid">36167857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-33301-0</pub-id><pub-id pub-id-type="pmcid">PMC9515186</pub-id></element-citation></ref><ref id="bib132"><label>132</label><element-citation publication-type="journal" id="sref132"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Manganese is critical for antitumor immune responses <italic toggle="yes">via</italic> cGAS-STING and improves the efficacy of clinical immunotherapy</article-title><source>Cell Res.</source><volume>30</volume><year>2020</year><fpage>966</fpage><lpage>979</lpage><pub-id pub-id-type="pmid">32839553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41422-020-00395-4</pub-id><pub-id pub-id-type="pmcid">PMC7785004</pub-id></element-citation></ref><ref id="bib133"><label>133</label><element-citation publication-type="journal" id="sref133"><person-group person-group-type="author"><name name-style="western"><surname>Kuai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Son</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>Elimination of established tumors with nanodisc-based combination chemoimmunotherapy</article-title><source>Sci. Adv.</source><issue>4</issue><year>2018</year><object-id pub-id-type="publisher-id">eaao1736</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.aao1736</pub-id><pub-id pub-id-type="pmcid">PMC5906077</pub-id><pub-id pub-id-type="pmid">29675465</pub-id></element-citation></ref><ref id="bib134"><label>134</label><element-citation publication-type="journal" id="sref134"><person-group person-group-type="author"><name name-style="western"><surname>Noh</surname><given-names>I.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Cellular nanodiscs made from bacterial outer membrane as a platform for antibacterial vaccination</article-title><source>ACS Nano</source><volume>17</volume><year>2022</year><fpage>1120</fpage><lpage>1127</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.2c08360</pub-id><pub-id pub-id-type="pmcid">PMC10225015</pub-id><pub-id pub-id-type="pmid">36441916</pub-id></element-citation></ref><ref id="bib135"><label>135</label><element-citation publication-type="journal" id="sref135"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Noh</surname><given-names>I.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>A.T.</given-names></name><etal/></person-group><article-title>Cancer cell membrane nanodiscs for antitumor vaccination</article-title><source>Nano Lett.</source><volume>23</volume><year>2023</year><fpage>7941</fpage><lpage>7949</lpage><pub-id pub-id-type="pmid">37602707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.3c01775</pub-id><pub-id pub-id-type="pmcid">PMC10542934</pub-id></element-citation></ref><ref id="bib136"><label>136</label><element-citation publication-type="journal" id="sref136"><person-group person-group-type="author"><name name-style="western"><surname>Asadi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gholami</surname><given-names>A.</given-names></name></person-group><article-title>Virosome-based nanovaccines: a promising bioinspiration and biomimetic approach for preventing viral diseases: a review</article-title><source>Int. J. Biol. Macromol.</source><volume>182</volume><year>2021</year><fpage>648</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">33862071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2021.04.005</pub-id><pub-id pub-id-type="pmcid">PMC8049750</pub-id></element-citation></ref><ref id="bib137"><label>137</label><element-citation publication-type="journal" id="sref137"><person-group person-group-type="author"><name name-style="western"><surname>Tsoras</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Champion</surname><given-names>J.A.</given-names></name></person-group><article-title>Protein and peptide biomaterials for engineered subunit vaccines and immunotherapeutic applications</article-title><source>Annu. Rev. Chem. Biomol. Eng.</source><volume>10</volume><year>2019</year><fpage>337</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">31173518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-chembioeng-060718-030347</pub-id></element-citation></ref><ref id="bib138"><label>138</label><element-citation publication-type="journal" id="sref138"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.E.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Intranasal nanovaccine confers homo-and hetero-subtypic influenza protection</article-title><source>Small</source><volume>14</volume><year>2018</year><object-id pub-id-type="publisher-id">1703207</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.201703207</pub-id><pub-id pub-id-type="pmid">29430819</pub-id></element-citation></ref><ref id="bib139"><label>139</label><element-citation publication-type="journal" id="sref139"><person-group person-group-type="author"><name name-style="western"><surname>Molino</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Neek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses</article-title><source>Biomaterials</source><issue>86</issue><year>2016</year><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2016.01.056</pub-id><pub-id pub-id-type="pmcid">PMC4775383</pub-id><pub-id pub-id-type="pmid">26894870</pub-id></element-citation></ref><ref id="bib140"><label>140</label><element-citation publication-type="journal" id="sref140"><person-group person-group-type="author"><name name-style="western"><surname>Encapsulins</surname><given-names>T.W. Giessen</given-names></name></person-group><article-title>Microbial nanocompartments with applications in biomedicine, nanobiotechnology and materials science</article-title><source>Curr. Opin. Chem. Biol.</source><volume>34</volume><year>2016</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">27232770</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cbpa.2016.05.013</pub-id></element-citation></ref><ref id="bib141"><label>141</label><element-citation publication-type="journal" id="sref141"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kickhoefer</surname><given-names>V.A.</given-names></name><etal/></person-group><article-title>A protective vaccine against chlamydia genital infection using vault nanoparticles without an added adjuvant</article-title><source>Vaccines</source><issue>5</issue><year>2017</year><fpage>3</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines5010003</pub-id><pub-id pub-id-type="pmcid">PMC5371739</pub-id><pub-id pub-id-type="pmid">28106821</pub-id></element-citation></ref><ref id="bib142"><label>142</label><element-citation publication-type="journal" id="sref142"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Turning the old adjuvant from gel to nanoparticles to amplify CD8<sup>+</sup> T cell responses</article-title><source>Adv. Sci.</source><issue>5</issue><year>2018</year><object-id pub-id-type="publisher-id">1700426</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.201700426</pub-id><pub-id pub-id-type="pmcid">PMC5770685</pub-id><pub-id pub-id-type="pmid">29375970</pub-id></element-citation></ref><ref id="bib143"><label>143</label><element-citation publication-type="journal" id="sref143"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.F.</given-names></name><etal/></person-group><article-title>Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response</article-title><source>Nat. Commun.</source><volume>11</volume><year>2020</year><fpage>1110</fpage><pub-id pub-id-type="pmid">32111828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-14906-9</pub-id><pub-id pub-id-type="pmcid">PMC7048802</pub-id></element-citation></ref><ref id="bib144"><label>144</label><element-citation publication-type="journal" id="sref144"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Moynihan</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Structure-based programming of lymph-node targeting in molecular vaccines</article-title><source>Nature</source><volume>507</volume><year>2014</year><fpage>519</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">24531764</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12978</pub-id><pub-id pub-id-type="pmcid">PMC4069155</pub-id></element-citation></ref><ref id="bib145"><label>145</label><element-citation publication-type="journal" id="sref145"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><etal/></person-group><article-title><italic toggle="yes">In situ</italic> programming of nanovaccines for lymph node-targeted delivery and cancer immunotherapy</article-title><source>ACS Nano</source><volume>16</volume><year>2022</year><fpage>15226</fpage><lpage>15236</lpage><pub-id pub-id-type="pmid">36018240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.2c06560</pub-id></element-citation></ref><ref id="bib146"><label>146</label><element-citation publication-type="journal" id="sref146"><person-group person-group-type="author"><name name-style="western"><surname>Xi</surname><given-names>X.B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.H.</given-names></name><etal/></person-group><article-title>Lymph node-targeting nanovaccine through antigen-CpG self-assembly potentiates cytotoxic T Cell activation</article-title><source>J. Immunol. Res.</source><year>2018</year><object-id pub-id-type="publisher-id">3714960</object-id><comment>2018</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2018/3714960</pub-id><pub-id pub-id-type="pmcid">PMC6029500</pub-id><pub-id pub-id-type="pmid">30018987</pub-id></element-citation></ref><ref id="bib147"><label>147</label><element-citation publication-type="journal" id="sref147"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Effects of gold nanoparticle-based vaccine size on lymph node delivery and cytotoxic T-lymphocyte responses</article-title><source>J. Contr. Release</source><volume>256</volume><year>2017</year><fpage>56</fpage><lpage>67</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2017.04.024</pub-id><pub-id pub-id-type="pmid">28428066</pub-id></element-citation></ref><ref id="bib148"><label>148</label><element-citation publication-type="journal" id="sref148"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Vokali</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lund</surname><given-names>A.W.</given-names></name><etal/></person-group><article-title>Targeting the tumor-draining lymph node with adjuvanted nanoparticles reshapes the anti-tumor immune response</article-title><source>Biomaterials</source><issue>35</issue><year>2014</year><fpage>814</fpage><lpage>824</lpage><pub-id pub-id-type="pmid">24144906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2013.10.003</pub-id></element-citation></ref><ref id="bib149"><label>149</label><element-citation publication-type="journal" id="sref149"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.H.</given-names></name><etal/></person-group><article-title>&#8220;Minimalist&#8221; nanovaccine constituted from near whole antigen for cancer immunotherapy</article-title><source>ACS Nano</source><volume>12</volume><year>2018</year><fpage>6398</fpage><lpage>6409</lpage><pub-id pub-id-type="pmid">29927574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.8b00558</pub-id></element-citation></ref><ref id="bib150"><label>150</label><element-citation publication-type="journal" id="sref150"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Huebsch</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Infection-mimicking materials to program dendritic cells <italic toggle="yes">in situ</italic></article-title><source>Nat. Mater.</source><issue>8</issue><year>2009</year><fpage>151</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">19136947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nmat2357</pub-id><pub-id pub-id-type="pmcid">PMC2684978</pub-id></element-citation></ref><ref id="bib151"><label>151</label><element-citation publication-type="journal" id="sref151"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>P.M.</given-names></name><etal/></person-group><article-title>Development of an <italic toggle="yes">in situ</italic> cancer vaccine <italic toggle="yes">via</italic> combinational radiation and bacterial-membrane-coated nanoparticles</article-title><source>Adv. Mater.</source><volume>31</volume><year>2019</year><object-id pub-id-type="publisher-id">e1902626</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.201902626</pub-id><pub-id pub-id-type="pmcid">PMC6810793</pub-id><pub-id pub-id-type="pmid">31523868</pub-id></element-citation></ref><ref id="bib152"><label>152</label><element-citation publication-type="journal" id="sref152"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.P.</given-names></name><etal/></person-group><article-title>Dendritic cell targeting peptide-based nanovaccines for enhanced cancer immunotherapy</article-title><source>ACS Appl. Bio Mater.</source><issue>2</issue><year>2019</year><fpage>1241</fpage><lpage>1254</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsabm.8b00811</pub-id><pub-id pub-id-type="pmid">35021373</pub-id></element-citation></ref><ref id="bib153"><label>153</label><element-citation publication-type="journal" id="sref153"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells</article-title><source>Nat. Commun.</source><volume>10</volume><year>2019</year><fpage>3199</fpage><pub-id pub-id-type="pmid">31324770</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-11157-1</pub-id><pub-id pub-id-type="pmcid">PMC6642123</pub-id></element-citation></ref><ref id="bib154"><label>154</label><element-citation publication-type="journal" id="sref154"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y.D.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.Y.</given-names></name><etal/></person-group><article-title>Mannan-decorated pathogen-like polymeric nanoparticles as nanovaccine carriers for eliciting superior anticancer immunity</article-title><source>Biomaterials</source><issue>284</issue><year>2022</year><object-id pub-id-type="publisher-id">121489</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2022.121489</pub-id><pub-id pub-id-type="pmid">35364489</pub-id></element-citation></ref><ref id="bib155"><label>155</label><element-citation publication-type="journal" id="sref155"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vishwasrao</surname><given-names>H.D.</given-names></name><etal/></person-group><article-title>Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy</article-title><source>Nat. Commun.</source><issue>8</issue><year>2017</year><fpage>1482</fpage><pub-id pub-id-type="pmid">29133898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-017-01386-7</pub-id><pub-id pub-id-type="pmcid">PMC5684198</pub-id></element-citation></ref><ref id="bib156"><label>156</label><element-citation publication-type="journal" id="sref156"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><etal/></person-group><article-title>A DNA nanodevice-based vaccine for cancer immunotherapy</article-title><source>Nat. Mater.</source><volume>20</volume><year>2021</year><fpage>421</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">32895504</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41563-020-0793-6</pub-id></element-citation></ref><ref id="bib157"><label>157</label><element-citation publication-type="journal" id="sref157"><person-group person-group-type="author"><name name-style="western"><surname>John</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yuzhakov</surname><given-names>O.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity</article-title><source>Vaccine</source><volume>36</volume><year>2018</year><fpage>1689</fpage><lpage>1699</lpage><pub-id pub-id-type="pmid">29456015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2018.01.029</pub-id></element-citation></ref><ref id="bib158"><label>158</label><element-citation publication-type="journal" id="sref158"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Z.X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Self-adjuvant effect by manipulating the bionano interface of liposome-based nanovaccines</article-title><source>Nano Lett.</source><volume>21</volume><year>2021</year><fpage>4744</fpage><lpage>4752</lpage><pub-id pub-id-type="pmid">34010008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.1c01133</pub-id></element-citation></ref><ref id="bib159"><label>159</label><element-citation publication-type="journal" id="sref159"><person-group person-group-type="author"><name name-style="western"><surname>Atukorale</surname><given-names>P.U.</given-names></name><name name-style="western"><surname>Raghunathan</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Raguveer</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Nanoparticle encapsulation of synergistic immune agonists enables systemic codelivery to tumor sites and IFN&#946;-driven antitumor immunity</article-title><source>Cancer Res.</source><volume>79</volume><year>2019</year><fpage>5394</fpage><lpage>5406</lpage><pub-id pub-id-type="pmid">31431457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-19-0381</pub-id><pub-id pub-id-type="pmcid">PMC6801091</pub-id></element-citation></ref><ref id="bib160"><label>160</label><element-citation publication-type="journal" id="sref160"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>G.</given-names></name><etal/></person-group><article-title>The manipulation of natural killer cells to target tumor sites using magnetic nanoparticles</article-title><source>Biomaterials</source><issue>33</issue><year>2012</year><fpage>5584</fpage><lpage>5592</lpage><pub-id pub-id-type="pmid">22575830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2012.04.041</pub-id><pub-id pub-id-type="pmcid">PMC3571620</pub-id></element-citation></ref><ref id="bib161"><label>161</label><element-citation publication-type="journal" id="sref161"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.Q.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Z.H.</given-names></name><etal/></person-group><article-title>Magnetic delivery of Fe<sub>3</sub>O<sub>4</sub>@polydopamine nanoparticle-loaded natural killer cells suggest a promising anticancer treatment</article-title><source>Biomater. Sci.</source><issue>6</issue><year>2018</year><fpage>2714</fpage><lpage>2725</lpage><pub-id pub-id-type="pmid">30151523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c8bm00588e</pub-id></element-citation></ref><ref id="bib162"><label>162</label><element-citation publication-type="journal" id="sref162"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>X.X.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.X.</given-names></name><etal/></person-group><article-title>Remodeling tumor immunosuppressive microenvironment <italic toggle="yes">via</italic> a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy</article-title><source>Bioact. Mater.</source><issue>16</issue><year>2022</year><fpage>107</fpage><lpage>119</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2022.03.008</pub-id><pub-id pub-id-type="pmcid">PMC8958467</pub-id><pub-id pub-id-type="pmid">35386322</pub-id></element-citation></ref><ref id="bib163"><label>163</label><element-citation publication-type="journal" id="sref163"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>M.D.</given-names></name><etal/></person-group><article-title>Tumors and their microenvironment dual-targeting chemotherapy with local immune adjuvant therapy for effective antitumor immunity against breast cancer</article-title><source>Adv. Sci.</source><volume>6</volume><year>2019</year><object-id pub-id-type="publisher-id">1801868</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.201801868</pub-id><pub-id pub-id-type="pmcid">PMC6425447</pub-id><pub-id pub-id-type="pmid">30937266</pub-id></element-citation></ref><ref id="bib164"><label>164</label><element-citation publication-type="journal" id="sref164"><person-group person-group-type="author"><name name-style="western"><surname>Ramesh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brouillard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy</article-title><source>Biomaterials</source><volume>227</volume><year>2020</year><object-id pub-id-type="publisher-id">119559</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2019.119559</pub-id><pub-id pub-id-type="pmcid">PMC7238715</pub-id><pub-id pub-id-type="pmid">31670078</pub-id></element-citation></ref><ref id="bib165"><label>165</label><element-citation publication-type="journal" id="sref165"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y.F.</given-names></name><etal/></person-group><article-title>Molecular-targeted immunotherapeutic strategy for melanoma <italic toggle="yes">via</italic> dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages</article-title><source>ACS Nano</source><volume>11</volume><year>2017</year><fpage>9536</fpage><lpage>9549</lpage><pub-id pub-id-type="pmid">28858473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.7b05465</pub-id></element-citation></ref><ref id="bib166"><label>166</label><element-citation publication-type="journal" id="sref166"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Polarization of tumor-associated macrophages by TLR7/8 conjugated radiosensitive peptide hydrogel for overcoming tumor radioresistance</article-title><source>Bioact. Mater.</source><issue>16</issue><year>2022</year><fpage>359</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">35386314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2021.12.033</pub-id><pub-id pub-id-type="pmcid">PMC8965723</pub-id></element-citation></ref><ref id="bib167"><label>167</label><element-citation publication-type="journal" id="sref167"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.L.</given-names></name><etal/></person-group><article-title>Engineered iron-based nanoplatform amplifies repolarization of M2-like tumor-associated macrophages for enhanced cancer immunotherapy</article-title><source>Chem. Eng. J.</source><volume>433</volume><year>2022</year><object-id pub-id-type="publisher-id">133847</object-id></element-citation></ref><ref id="bib168"><label>168</label><element-citation publication-type="journal" id="sref168"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B.Y.</given-names></name><etal/></person-group><article-title>Remodeling tumor-associated neutrophils to enhance dendritic cell-based HCC neoantigen nano-vaccine efficiency</article-title><source>Adv. Sci.</source><volume>9</volume><year>2022</year><object-id pub-id-type="publisher-id">2105631</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202105631</pub-id><pub-id pub-id-type="pmcid">PMC9009112</pub-id><pub-id pub-id-type="pmid">35142445</pub-id></element-citation></ref><ref id="bib169"><label>169</label><element-citation publication-type="journal" id="sref169"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.B.</given-names></name><etal/></person-group><article-title>Supramolecular tadalafil nanovaccine for cancer immunotherapy by alleviating myeloid-derived suppressor cells and heightening immunogenicity</article-title><source>Small Methods</source><volume>5</volume><year>2021</year><object-id pub-id-type="publisher-id">2100115</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smtd.202100115</pub-id><pub-id pub-id-type="pmid">34927922</pub-id></element-citation></ref><ref id="bib170"><label>170</label><element-citation publication-type="journal" id="sref170"><person-group person-group-type="author"><name name-style="western"><surname>Sasso</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lollo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pitorre</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy</article-title><source>Biomaterials</source><issue>96</issue><year>2016</year><fpage>47</fpage><lpage>62</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2016.04.010</pub-id><pub-id pub-id-type="pmid">27135716</pub-id></element-citation></ref><ref id="bib171"><label>171</label><element-citation publication-type="journal" id="sref171"><person-group person-group-type="author"><name name-style="western"><surname>Ledo</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Sasso</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Bronte</surname><given-names>V.</given-names></name><etal/></person-group><article-title><italic toggle="yes">Co</italic>-delivery of RNAi and chemokine by polyarginine nanocapsules enables the modulation of myeloid-derived suppressor cells</article-title><source>J. Contr. Release</source><volume>295</volume><year>2019</year><fpage>60</fpage><lpage>73</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2018.12.041</pub-id><pub-id pub-id-type="pmid">30593832</pub-id></element-citation></ref><ref id="bib172"><label>172</label><element-citation publication-type="journal" id="sref172"><person-group person-group-type="author"><name name-style="western"><surname>Sainz</surname><given-names>V.</given-names></name><name name-style="western"><surname>Moura</surname><given-names>L.I.F.</given-names></name><name name-style="western"><surname>Peres</surname><given-names>C.</given-names></name><etal/></person-group><article-title>&#945;-galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma</article-title><source>Acta Biomater.</source><volume>76</volume><year>2018</year><fpage>193</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">29940370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2018.06.029</pub-id><pub-id pub-id-type="pmcid">PMC6124890</pub-id></element-citation></ref><ref id="bib173"><label>173</label><element-citation publication-type="journal" id="sref173"><person-group person-group-type="author"><name name-style="western"><surname>Ou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Thapa</surname><given-names>R.K.</given-names></name><etal/></person-group><article-title>Combination of NIR therapy and regulatory T cell modulation using layer-by-layer hybrid nanoparticles for effective cancer photoimmunotherapy</article-title><source>Theranostics</source><volume>8</volume><year>2018</year><fpage>4574</fpage><lpage>4590</lpage><pub-id pub-id-type="pmid">30279723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/thno.26758</pub-id><pub-id pub-id-type="pmcid">PMC6160765</pub-id></element-citation></ref><ref id="bib174"><label>174</label><element-citation publication-type="journal" id="sref174"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Regulating T-cell metabolic reprogramming and blocking PD-1 <italic toggle="yes">co</italic>-promote personalized postoperative autologous nanovaccines</article-title><source>Biomaterials</source><volume>297</volume><year>2023</year><object-id pub-id-type="publisher-id">122104</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2023.122104</pub-id><pub-id pub-id-type="pmid">37058898</pub-id></element-citation></ref><ref id="bib175"><label>175</label><element-citation publication-type="journal" id="sref175"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Targeting dendritic cells in lymph node with an antigen peptide-based nanovaccine for cancer immunotherapy</article-title><source>Biomaterials</source><volume>98</volume><year>2016</year><fpage>171</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">27192420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2016.05.008</pub-id></element-citation></ref><ref id="bib176"><label>176</label><element-citation publication-type="journal" id="sref176"><person-group person-group-type="author"><name name-style="western"><surname>Bois</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Heim</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Lund</surname><given-names>A.W.</given-names></name></person-group><article-title>Tumor-draining lymph nodes: at the crossroads of metastasis and immunity</article-title><source>Sci. Immunol.</source><issue>6</issue><year>2021</year><comment>eabg3551</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciimmunol.abg3551</pub-id><pub-id pub-id-type="pmcid">PMC8628268</pub-id><pub-id pub-id-type="pmid">34516744</pub-id></element-citation></ref><ref id="bib177"><label>177</label><element-citation publication-type="journal" id="sref177"><person-group person-group-type="author"><name name-style="western"><surname>Wen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Nanovaccines fostering tertiary lymphoid structure to attack mimicry nasopharyngeal carcinoma</article-title><source>ACS Nano</source><volume>17</volume><year>2023</year><fpage>7194</fpage><lpage>7206</lpage><pub-id pub-id-type="pmid">37057967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.2c09619</pub-id></element-citation></ref><ref id="bib178"><label>178</label><element-citation publication-type="journal" id="sref178"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>Lymph node targeting strategies to improve vaccination efficacy</article-title><source>J. Contr. Release</source><volume>267</volume><year>2017</year><fpage>47</fpage><lpage>56</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2017.08.009</pub-id><pub-id pub-id-type="pmid">28818619</pub-id></element-citation></ref><ref id="bib179"><label>179</label><element-citation publication-type="journal" id="sref179"><person-group person-group-type="author"><name name-style="western"><surname>Trevaskis</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Kaminskas</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>C.J.H.</given-names></name></person-group><article-title>From sewer to saviour-targeting the lymphatic system to promote drug exposure and activity</article-title><source>Nat. Rev. Drug Discov.</source><volume>14</volume><year>2015</year><fpage>781</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">26471369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd4608</pub-id></element-citation></ref><ref id="bib180"><label>180</label><element-citation publication-type="journal" id="sref180"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Impact of semiconducting perylene diimide nanoparticle size on lymph node mapping and cancer imaging</article-title><source>ACS Nano</source><volume>11</volume><year>2017</year><fpage>4247</fpage><lpage>4255</lpage><pub-id pub-id-type="pmid">28345873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.7b01261</pub-id></element-citation></ref><ref id="bib181"><label>181</label><element-citation publication-type="journal" id="sref181"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>D.J.</given-names></name></person-group><article-title>Biomaterial-assisted targeted modulation of immune cells in cancer treatment</article-title><source>Nat. Mater.</source><volume>17</volume><year>2018</year><fpage>761</fpage><lpage>772</lpage><pub-id pub-id-type="pmid">30104668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41563-018-0147-9</pub-id></element-citation></ref><ref id="bib182"><label>182</label><element-citation publication-type="journal" id="sref182"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Archer</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.N.</given-names></name></person-group><article-title>Innovations in lymph node targeting nanocarriers</article-title><source>Semin. Immunol.</source><volume>56</volume><year>2021</year><object-id pub-id-type="publisher-id">101534</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.smim.2021.101534</pub-id><pub-id pub-id-type="pmcid">PMC8792237</pub-id><pub-id pub-id-type="pmid">34836772</pub-id></element-citation></ref><ref id="bib183"><label>183</label><element-citation publication-type="journal" id="sref183"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.P.</given-names></name><etal/></person-group><article-title>Magnetic metal micelles for enhanced delivery of self-immolating CD8<sup>+</sup> T Cell epitopes for cancer immunotherapy</article-title><source>Chem. Mater.</source><volume>33</volume><year>2021</year><fpage>9780</fpage><lpage>9794</lpage></element-citation></ref><ref id="bib184"><label>184</label><element-citation publication-type="journal" id="sref184"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><etal/></person-group><article-title>CCR7 mediated mimetic dendritic cell vaccine homing in lymph node for head and neck squamous cell carcinoma therapy</article-title><source>Adv. Sci.</source><volume>10</volume><year>2023</year><object-id pub-id-type="publisher-id">2207017</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/advs.202207017</pub-id><pub-id pub-id-type="pmcid">PMC10265089</pub-id><pub-id pub-id-type="pmid">37092579</pub-id></element-citation></ref><ref id="bib185"><label>185</label><element-citation publication-type="journal" id="sref185"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Direct presentation of tumor-associated antigens to induce adaptive immunity by personalized dendritic cell-mimicking nanovaccines</article-title><source>Adv. Mater.</source><volume>34</volume><year>2022</year><object-id pub-id-type="publisher-id">2205950</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202205950</pub-id><pub-id pub-id-type="pmid">36217832</pub-id></element-citation></ref><ref id="bib186"><label>186</label><element-citation publication-type="journal" id="sref186"><person-group person-group-type="author"><name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Medzhitov</surname><given-names>R.</given-names></name></person-group><article-title>Regulation of adaptive immunity by the innate immune system</article-title><source>Science</source><volume>327</volume><year>2010</year><fpage>291</fpage><lpage>295</lpage><pub-id pub-id-type="pmid">20075244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1183021</pub-id><pub-id pub-id-type="pmcid">PMC3645875</pub-id></element-citation></ref><ref id="bib187"><label>187</label><element-citation publication-type="journal" id="sref187"><person-group person-group-type="author"><name name-style="western"><surname>Tacken</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>I.J.M.</given-names></name><name name-style="western"><surname>Torensma</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Dendritic-cell immunotherapy: from <italic toggle="yes">ex vivo</italic> loading to <italic toggle="yes">in vivo</italic> targeting</article-title><source>Nat. Rev. Immunol.</source><issue>7</issue><year>2007</year><fpage>790</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">17853902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri2173</pub-id></element-citation></ref><ref id="bib188"><label>188</label><element-citation publication-type="journal" id="sref188"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine</article-title><source>Biomaterials</source><volume>113</volume><year>2017</year><fpage>191</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">27816821</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2016.10.047</pub-id></element-citation></ref><ref id="bib189"><label>189</label><element-citation publication-type="journal" id="sref189"><person-group person-group-type="author"><name name-style="western"><surname>Cruz</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Tacken</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Fokkink</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Targeted PLGA nano-but not microparticles specifically deliver antigen to human dendritic cells <italic toggle="yes">via</italic> DC-SIGN <italic toggle="yes">in vitro</italic></article-title><source>J. Contr. Release</source><volume>144</volume><year>2010</year><fpage>118</fpage><lpage>126</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2010.02.013</pub-id><pub-id pub-id-type="pmid">20156497</pub-id></element-citation></ref><ref id="bib190"><label>190</label><element-citation publication-type="journal" id="sref190"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.Y.</given-names></name><etal/></person-group><article-title>Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy</article-title><source>Bioact. Mater.</source><issue>7</issue><year>2022</year><fpage>167</fpage><lpage>180</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bioactmat.2021.05.036</pub-id><pub-id pub-id-type="pmcid">PMC8379363</pub-id><pub-id pub-id-type="pmid">34466725</pub-id></element-citation></ref><ref id="bib191"><label>191</label><element-citation publication-type="journal" id="sref191"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Tayalia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Shvartsman</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Inflammatory cytokines presented from polymer matrices differentially generate and activate DCs <italic toggle="yes">in situ</italic></article-title><source>Adv. Funct. Mater.</source><volume>23</volume><year>2013</year><fpage>4621</fpage><lpage>4628</lpage><pub-id pub-id-type="pmid">24688455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adfm.201203859</pub-id><pub-id pub-id-type="pmcid">PMC3968866</pub-id></element-citation></ref><ref id="bib192"><label>192</label><element-citation publication-type="journal" id="sref192"><person-group person-group-type="author"><name name-style="western"><surname>Bhattacharya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Budnick</surname><given-names>I.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Dual role of GM-CSF as a pro-inflammatory and a regulatory cytokine: implications for immune therapy</article-title><source>J. Interferon Cytokine Res.</source><issue>35</issue><year>2015</year><fpage>585</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">25803788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/jir.2014.0149</pub-id><pub-id pub-id-type="pmcid">PMC4529096</pub-id></element-citation></ref><ref id="bib193"><label>193</label><element-citation publication-type="journal" id="sref193"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.X.</given-names></name><etal/></person-group><article-title>Targeted delivery of nanovaccine to dendritic cells <italic toggle="yes">via</italic> DC-binding peptides induces potent antiviral immunity <italic toggle="yes">in vivo</italic></article-title><source>Int. J. Nanomed.</source><volume>17</volume><year>2022</year><fpage>1593</fpage><lpage>1608</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S357462</pub-id><pub-id pub-id-type="pmcid">PMC8994610</pub-id><pub-id pub-id-type="pmid">35411142</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="expression-of-concern" ext-link-type="pmc" xlink:href="PMC11772996"/></element-citation></ref><ref id="bib194"><label>194</label><element-citation publication-type="journal" id="sref194"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Hobson</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Nanoparticles for immune system targeting</article-title><source>Drug Discov. Today</source><volume>22</volume><year>2017</year><fpage>1295</fpage><lpage>1301</lpage><pub-id pub-id-type="pmid">28390214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2017.03.013</pub-id></element-citation></ref><ref id="bib195"><label>195</label><element-citation publication-type="journal" id="sref195"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Valente</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dolen</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Endolysosomal-escape nanovaccines through adjuvant-induced tumor antigen assembly for enhanced effector CD8<sup>+</sup> T cell activation</article-title><source>Small</source><volume>14</volume><year>2018</year><object-id pub-id-type="publisher-id">1703539</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/smll.201703539</pub-id><pub-id pub-id-type="pmid">29493121</pub-id></element-citation></ref><ref id="bib196"><label>196</label><element-citation publication-type="journal" id="sref196"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.Y.</given-names></name><etal/></person-group><article-title>Current advances in T-cell-based cancer immunotherapy</article-title><source>Immunotherapy</source><issue>6</issue><year>2014</year><fpage>1265</fpage><lpage>1278</lpage><pub-id pub-id-type="pmid">25524383</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2217/imt.14.86</pub-id><pub-id pub-id-type="pmcid">PMC4372895</pub-id></element-citation></ref><ref id="bib197"><label>197</label><element-citation publication-type="journal" id="sref197"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Kye</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>C.H.</given-names></name></person-group><article-title>The role of nanovaccine in cross-presentation of antigen-presenting cells for the activation of CD8<sup>+</sup> T cell responses</article-title><source>Pharmaceutics</source><volume>11</volume><year>2019</year><fpage>612</fpage><pub-id pub-id-type="pmid">31731667</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics11110612</pub-id><pub-id pub-id-type="pmcid">PMC6920862</pub-id></element-citation></ref><ref id="bib198"><label>198</label><element-citation publication-type="journal" id="sref198"><person-group person-group-type="author"><name name-style="western"><surname>Cheung</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.K.Y.</given-names></name><name name-style="western"><surname>Koshy</surname><given-names>S.T.</given-names></name><etal/></person-group><article-title>Scaffolds that mimic antigen-presenting cells enable <italic toggle="yes">ex vivo</italic> expansion of primary T cells</article-title><source>Nat. Biotechnol.</source><volume>36</volume><year>2018</year><fpage>160</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">29334370</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt.4047</pub-id><pub-id pub-id-type="pmcid">PMC5801009</pub-id></element-citation></ref><ref id="bib199"><label>199</label><element-citation publication-type="journal" id="sref199"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H.Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S.J.</given-names></name><etal/></person-group><article-title>Size-transformable antigen-presenting cell-mimicking nanovesicles potentiate effective cancer immunotherapy</article-title><source>Sci. Adv.</source><issue>6</issue><year>2020</year><object-id pub-id-type="publisher-id">eabd1631</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.abd1631</pub-id><pub-id pub-id-type="pmcid">PMC7732193</pub-id><pub-id pub-id-type="pmid">33310853</pub-id></element-citation></ref><ref id="bib200"><label>200</label><element-citation publication-type="journal" id="sref200"><person-group person-group-type="author"><name name-style="western"><surname>Carson</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Garland</surname><given-names>K.M.</given-names></name><etal/></person-group><article-title>A nanovaccine for enhancing cellular immunity <italic toggle="yes">via</italic> cytosolic <italic toggle="yes">co</italic>-delivery of antigen and polyIC RNA</article-title><source>J. Contr. Release</source><volume>345</volume><year>2022</year><fpage>354</fpage><lpage>370</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2022.03.020</pub-id><pub-id pub-id-type="pmcid">PMC9133199</pub-id><pub-id pub-id-type="pmid">35301055</pub-id></element-citation></ref><ref id="bib201"><label>201</label><element-citation publication-type="journal" id="sref201"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Rui</surname><given-names>X.</given-names></name><etal/></person-group><article-title>A universal cyclodextrin-based nanovaccine platform delivers epitope peptides for enhanced antitumor immunity</article-title><source>Adv. Healthcare Mater.</source><volume>12</volume><year>2023</year><object-id pub-id-type="publisher-id">2301099</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202301099</pub-id><pub-id pub-id-type="pmid">37602523</pub-id></element-citation></ref><ref id="bib202"><label>202</label><element-citation publication-type="journal" id="sref202"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Nanotechnology-empowered vaccine delivery for enhancing CD8<sup>+</sup> T cells-mediated cellular immunity</article-title><source>Adv. Drug Deliv. Rev.</source><volume>176</volume><year>2021</year><object-id pub-id-type="publisher-id">113889</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2021.113889</pub-id><pub-id pub-id-type="pmid">34364931</pub-id></element-citation></ref><ref id="bib203"><label>203</label><element-citation publication-type="journal" id="sref203"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M.A.</given-names></name></person-group><article-title>DNA vaccines: an historical perspective and view to the future</article-title><source>Immunol. Rev.</source><volume>239</volume><year>2011</year><fpage>62</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">21198665</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-065X.2010.00980.x</pub-id></element-citation></ref><ref id="bib204"><label>204</label><element-citation publication-type="journal" id="sref204"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>F.W.</given-names></name><etal/></person-group><article-title>mRNA vaccines-A new era in vaccinology</article-title><source>Nat. Rev. Drug Discov.</source><volume>17</volume><year>2018</year><fpage>261</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">29326426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmcid">PMC5906799</pub-id></element-citation></ref><ref id="bib205"><label>205</label><element-citation publication-type="journal" id="sref205"><person-group person-group-type="author"><name name-style="western"><surname>Mandl</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Aberle</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Aberle</surname><given-names>S.W.</given-names></name><etal/></person-group><article-title><italic toggle="yes">In vitro</italic>-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model</article-title><source>Nat. Med.</source><issue>4</issue><year>1998</year><fpage>1438</fpage><lpage>1440</lpage><pub-id pub-id-type="pmid">9846585</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/4031</pub-id></element-citation></ref><ref id="bib206"><label>206</label><element-citation publication-type="journal" id="sref206"><person-group person-group-type="author"><name name-style="western"><surname>Kose</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sapparapu</surname><given-names>G.</given-names></name><etal/></person-group><article-title>A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection</article-title><source>Sci. Immunol.</source><issue>4</issue><year>2019</year><object-id pub-id-type="publisher-id">eaaw6647</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciimmunol.aaw6647</pub-id><pub-id pub-id-type="pmcid">PMC6629435</pub-id><pub-id pub-id-type="pmid">31101672</pub-id></element-citation></ref><ref id="bib207"><label>207</label><element-citation publication-type="journal" id="sref207"><person-group person-group-type="author"><name name-style="western"><surname>Jirikowski</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Sanna</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Maciejewski-Lenoir</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA</article-title><source>Science</source><volume>255</volume><year>1992</year><fpage>996</fpage><lpage>998</lpage><pub-id pub-id-type="pmid">1546298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1546298</pub-id></element-citation></ref><ref id="bib208"><label>208</label><element-citation publication-type="journal" id="sref208"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>El Sahly</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</article-title><source>N. Engl. J. Med.</source><volume>384</volume><year>2021</year><fpage>403</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">33378609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id></element-citation></ref><ref id="bib209"><label>209</label><element-citation publication-type="journal" id="sref209"><person-group person-group-type="author"><name name-style="western"><surname>Selbo</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Weyergang</surname><given-names>A.</given-names></name><name name-style="western"><surname>H&#248;gset</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Photochemical internalization provides time-and space-controlled endolysosomal escape of therapeutic molecules</article-title><source>J. Contr. Release</source><volume>148</volume><year>2010</year><fpage>2</fpage><lpage>12</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2010.06.008</pub-id><pub-id pub-id-type="pmid">20600406</pub-id></element-citation></ref><ref id="bib210"><label>210</label><element-citation publication-type="journal" id="sref210"><person-group person-group-type="author"><name name-style="western"><surname>Pinillos Bayona</surname><given-names>A.M.D.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Loizidou</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Enhancing the efficacy of cytotoxic agents for cancer therapy using photochemical internalisation</article-title><source>Int. J. Cancer</source><volume>138</volume><year>2016</year><fpage>1049</fpage><lpage>1057</lpage><pub-id pub-id-type="pmid">25758607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.29510</pub-id><pub-id pub-id-type="pmcid">PMC4973841</pub-id></element-citation></ref><ref id="bib211"><label>211</label><element-citation publication-type="journal" id="sref211"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Photothermally controlled MHC class I restricted CD8<sup>+</sup> T-cell responses elicited by hyaluronic acid decorated gold nanoparticles as a vaccine for cancer immunotherapy</article-title><source>Adv. Healthcare Mater.</source><issue>7</issue><year>2018</year><object-id pub-id-type="publisher-id">1701439</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.201701439</pub-id><pub-id pub-id-type="pmid">29508543</pub-id></element-citation></ref><ref id="bib212"><label>212</label><element-citation publication-type="journal" id="sref212"><person-group person-group-type="author"><name name-style="western"><surname>Hakerud</surname><given-names>M.</given-names></name><name name-style="western"><surname>Selbo</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Waeckerle</surname><given-names>M.Y.</given-names></name><etal/></person-group><article-title>Photosensitisation facilitates cross-priming of adjuvant-free protein vaccines and stimulation of tumour-suppressing CD8 T cells</article-title><source>J. Contr. Release</source><volume>198</volume><year>2015</year><fpage>10</fpage><lpage>17</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2014.11.032</pub-id><pub-id pub-id-type="pmid">25482339</pub-id></element-citation></ref><ref id="bib213"><label>213</label><element-citation publication-type="journal" id="sref213"><person-group person-group-type="author"><name name-style="western"><surname>Suchanek</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ferdinand</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Tuong</surname><given-names>Z.K.</given-names></name><etal/></person-group><article-title>Tissue-resident B cells orchestrate macrophage polarisation and function</article-title><source>Nat. Commun.</source><volume>14</volume><year>2023</year><fpage>7081</fpage><pub-id pub-id-type="pmid">37925420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-023-42625-4</pub-id><pub-id pub-id-type="pmcid">PMC10625551</pub-id></element-citation></ref><ref id="bib214"><label>214</label><element-citation publication-type="journal" id="sref214"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Su</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.M.</given-names></name></person-group><article-title>Rational design of T-cell- and B-cell-based therapeutic cancer vaccines</article-title><source>Acc. Chem. Res.</source><volume>55</volume><year>2022</year><fpage>2660</fpage><lpage>2671</lpage><pub-id pub-id-type="pmid">36048514</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.accounts.2c00360</pub-id></element-citation></ref><ref id="bib215"><label>215</label><element-citation publication-type="journal" id="sref215"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Pompano</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Santiago</surname><given-names>F.W.</given-names></name><etal/></person-group><article-title>The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation</article-title><source>Biomaterials</source><volume>34</volume><year>2013</year><fpage>8776</fpage><lpage>8785</lpage><pub-id pub-id-type="pmid">23953841</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2013.07.063</pub-id><pub-id pub-id-type="pmcid">PMC3814015</pub-id></element-citation></ref><ref id="bib216"><label>216</label><element-citation publication-type="journal" id="sref216"><person-group person-group-type="author"><name name-style="western"><surname>Argos</surname><given-names>B.V.</given-names></name><name name-style="western"><surname>Chiodin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Forconi</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Lymphoma-specific subversion of B-cell receptor signaling by macrophage lectins</article-title><source>Blood</source><volume>132</volume><year>2018</year><fpage>2865</fpage></element-citation></ref><ref id="bib217"><label>217</label><element-citation publication-type="journal" id="sref217"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>H.X.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>Y.N.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>H.M.</given-names></name><etal/></person-group><article-title>A minimalist supramolecular nanovaccine forcefully propels the Tfh cell and GC B cell responses</article-title><source>Chem. Eng. J.</source><volume>435</volume><year>2022</year><object-id pub-id-type="publisher-id">134782</object-id></element-citation></ref><ref id="bib218"><label>218</label><element-citation publication-type="journal" id="sref218"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.X.</given-names></name><etal/></person-group><article-title>Periodic mesoporous organosilica as a nanoadjuvant for subunit vaccines elicits potent antigen-specific germinal center responses by activating naive B cells</article-title><source>ACS Nano</source><volume>17</volume><year>2023</year><fpage>15424</fpage><lpage>15440</lpage><pub-id pub-id-type="pmid">37552584</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c00991</pub-id></element-citation></ref><ref id="bib219"><label>219</label><element-citation publication-type="journal" id="sref219"><person-group person-group-type="author"><name name-style="western"><surname>Burger</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Wiestner</surname><given-names>A.</given-names></name></person-group><article-title>Targeting B cell receptor signalling in cancer: preclinical and clinical advances</article-title><source>Nat. Rev. Cancer</source><issue>18</issue><year>2018</year><fpage>148</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">29348577</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrc.2017.121</pub-id></element-citation></ref><ref id="bib220"><label>220</label><element-citation publication-type="journal" id="sref220"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Tenzer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Storck</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Protein corona-mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses</article-title><source>J. Allergy Clin. Immunol.</source><volume>142</volume><year>2018</year><fpage>1558</fpage><lpage>1570</lpage><pub-id pub-id-type="pmid">29382591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaci.2017.08.049</pub-id></element-citation></ref><ref id="bib221"><label>221</label><element-citation publication-type="journal" id="sref221"><person-group person-group-type="author"><name name-style="western"><surname>Pal Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dammeijer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hendriks</surname><given-names>R.W.</given-names></name></person-group><article-title>Role of Bruton's tyrosine kinase in B cells and malignancies</article-title><source>Mol. Cancer</source><volume>17</volume><year>2018</year><fpage>57</fpage><pub-id pub-id-type="pmid">29455639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-018-0779-z</pub-id><pub-id pub-id-type="pmcid">PMC5817726</pub-id></element-citation></ref><ref id="bib222"><label>222</label><element-citation publication-type="journal" id="sref222"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Barrientos</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Ferrer</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Duvelisib eliminates CLL B Cells, impairs CLL-supporting cells, and overcomes ibrutinib resistance in a Xenograft model</article-title><source>Clin. Cancer Res.</source><volume>29</volume><year>2023</year><fpage>1984</fpage><lpage>1995</lpage><pub-id pub-id-type="pmid">37071496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-22-2386</pub-id><pub-id pub-id-type="pmcid">PMC10192081</pub-id></element-citation></ref><ref id="bib223"><label>223</label><element-citation publication-type="journal" id="sref223"><person-group person-group-type="author"><name name-style="western"><surname>Raza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Janjua</surname><given-names>T.I.</given-names></name><etal/></person-group><article-title>Nanobiomaterials to modulate natural killer cell responses for effective cancer immunotherapy</article-title><source>Trends Biotechnol.</source><issue>41</issue><year>2023</year><fpage>77</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">35840426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tibtech.2022.06.011</pub-id></element-citation></ref><ref id="bib224"><label>224</label><element-citation publication-type="journal" id="sref224"><person-group person-group-type="author"><name name-style="western"><surname>Phung</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.O.</given-names></name></person-group><article-title>Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: a review</article-title><source>Arch Pharm. Res. (Seoul)</source><volume>43</volume><year>2020</year><fpage>32</fpage><lpage>45</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12272-020-01218-1</pub-id><pub-id pub-id-type="pmid">31993969</pub-id></element-citation></ref><ref id="bib225"><label>225</label><element-citation publication-type="journal" id="sref225"><person-group person-group-type="author"><name name-style="western"><surname>Dunkelberger</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Song</surname><given-names>W.C.</given-names></name></person-group><article-title>Complement and its role in innate and adaptive immune responses</article-title><source>Cell Res.</source><volume>20</volume><year>2010</year><fpage>34</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">20010915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cr.2009.139</pub-id></element-citation></ref><ref id="bib226"><label>226</label><element-citation publication-type="journal" id="sref226"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.Y.</given-names></name><etal/></person-group><article-title>Tumor associated macrophages and TAMs-based anti-tumor nanomedicines</article-title><source>Adv. Healthcare Mater.</source><volume>10</volume><year>2021</year><object-id pub-id-type="publisher-id">2100590</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adhm.202100590</pub-id><pub-id pub-id-type="pmid">34292673</pub-id></element-citation></ref><ref id="bib227"><label>227</label><element-citation publication-type="journal" id="sref227"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Q.Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy</article-title><source>Acta Pharm. Sin. B</source><volume>10</volume><year>2020</year><fpage>2156</fpage><lpage>2170</lpage><pub-id pub-id-type="pmid">33304783</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2020.04.004</pub-id><pub-id pub-id-type="pmcid">PMC7714989</pub-id></element-citation></ref><ref id="bib228"><label>228</label><element-citation publication-type="journal" id="sref228"><person-group person-group-type="author"><name name-style="western"><surname>Ruffell</surname><given-names>B.</given-names></name><name name-style="western"><surname>Coussens</surname><given-names>L.M.</given-names></name></person-group><article-title>Macrophages and therapeutic resistance in cancer</article-title><source>Cancer Cell</source><volume>27</volume><year>2015</year><fpage>462</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">25858805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccell.2015.02.015</pub-id><pub-id pub-id-type="pmcid">PMC4400235</pub-id></element-citation></ref><ref id="bib229"><label>229</label><element-citation publication-type="journal" id="sref229"><person-group person-group-type="author"><name name-style="western"><surname>Gomez-Roca</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Italiano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Le Tourneau</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages</article-title><source>Ann. Oncol.</source><volume>30</volume><year>2019</year><fpage>1381</fpage><lpage>1392</lpage><pub-id pub-id-type="pmid">31114846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdz163</pub-id><pub-id pub-id-type="pmcid">PMC8887589</pub-id></element-citation></ref><ref id="bib230"><label>230</label><element-citation publication-type="journal" id="sref230"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.G.</given-names></name><etal/></person-group><article-title>Spatial targeting of tumor-associated macrophages and tumor cells with a pH-sensitive cluster nanocarrier for cancer chemoimmunotherapy</article-title><source>Nano Lett.</source><volume>17</volume><year>2017</year><fpage>3822</fpage><lpage>3829</lpage><pub-id pub-id-type="pmid">28488871</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.7b01193</pub-id></element-citation></ref><ref id="bib231"><label>231</label><element-citation publication-type="journal" id="sref231"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.Q.</given-names></name><etal/></person-group><article-title>HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors</article-title><source>ACS Nano</source><volume>3</volume><year>2009</year><fpage>3165</fpage><lpage>3174</lpage><pub-id pub-id-type="pmid">19761191</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/nn900649v</pub-id><pub-id pub-id-type="pmcid">PMC3733355</pub-id></element-citation></ref><ref id="bib232"><label>232</label><element-citation publication-type="journal" id="sref232"><person-group person-group-type="author"><name name-style="western"><surname>Rong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.S.</given-names></name><etal/></person-group><article-title>Iron chelated melanin-like nanoparticles for tumor-associated macrophage repolarization and cancer therapy</article-title><source>Biomaterials</source><issue>225</issue><year>2019</year><object-id pub-id-type="publisher-id">119515</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2019.119515</pub-id><pub-id pub-id-type="pmid">31590119</pub-id></element-citation></ref><ref id="bib233"><label>233</label><element-citation publication-type="journal" id="sref233"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q.D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Engineered a dual-targeting biomimetic nanomedicine for pancreatic cancer chemoimmunotherapy</article-title><source>J. Nanobiotechnol.</source><volume>20</volume><year>2022</year><fpage>85</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12951-022-01282-3</pub-id><pub-id pub-id-type="pmcid">PMC8851720</pub-id><pub-id pub-id-type="pmid">35177078</pub-id></element-citation></ref><ref id="bib234"><label>234</label><element-citation publication-type="journal" id="sref234"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>A DNA-polymer hybrid nanocomplex based bi-adjuvant vaccine for tumor immunotherapy</article-title><source>Nano Today</source><volume>54</volume><year>2024</year><object-id pub-id-type="publisher-id">102061</object-id></element-citation></ref><ref id="bib235"><label>235</label><element-citation publication-type="journal" id="sref235"><person-group person-group-type="author"><name name-style="western"><surname>Costa da Silva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Breckwoldt</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Vinchi</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Iron induces anti-tumor activity in tumor-associated macrophages</article-title><source>Front. Immunol.</source><volume>8</volume><year>2017</year><fpage>1479</fpage><pub-id pub-id-type="pmid">29167669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2017.01479</pub-id><pub-id pub-id-type="pmcid">PMC5682327</pub-id></element-citation></ref><ref id="bib236"><label>236</label><element-citation publication-type="journal" id="sref236"><person-group person-group-type="author"><name name-style="western"><surname>Moradi</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Shojaei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mohammad</surname><given-names>Y.S.</given-names></name><etal/></person-group><article-title>Transfer of miRNA in tumor-derived exosomes suppresses breast tumor cell invasion and migration by inducing M1 polarization in macrophages</article-title><source>Life Sci.</source><volume>282</volume><year>2021</year><object-id pub-id-type="publisher-id">119800</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2021.119800</pub-id><pub-id pub-id-type="pmid">34245773</pub-id></element-citation></ref><ref id="bib237"><label>237</label><element-citation publication-type="journal" id="sref237"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>Y.D.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>C.H.</given-names></name></person-group><article-title>Combination antitumor immunotherapy with VEGF and PIGF siRNA <italic toggle="yes">via</italic> systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells</article-title><source>Biomaterials</source><volume>185</volume><year>2018</year><fpage>117</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">30241030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2018.09.017</pub-id></element-citation></ref><ref id="bib238"><label>238</label><element-citation publication-type="journal" id="sref238"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>H.Q.</given-names></name><name name-style="western"><surname>He</surname><given-names>H.M.</given-names></name><etal/></person-group><article-title>Tumor associated macrophage-targeted microRNA delivery with dual-responsive polypeptide nanovectors for anti-cancer therapy</article-title><source>Biomaterials</source><volume>134</volume><year>2017</year><fpage>166</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">28463694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2017.04.043</pub-id></element-citation></ref><ref id="bib239"><label>239</label><element-citation publication-type="journal" id="sref239"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.H.</given-names></name><etal/></person-group><article-title>Recombinant cancer nanovaccine for targeting tumor-associated macrophage and remodeling tumor microenvironment</article-title><source>Nano Today</source><volume>40</volume><year>2021</year><object-id pub-id-type="publisher-id">101244</object-id></element-citation></ref><ref id="bib240"><label>240</label><element-citation publication-type="journal" id="sref240"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Z.Y.</given-names></name><etal/></person-group><article-title>Mannosylated engineered trichosanthin-legumain protein vaccine hydrogel for breast cancer immunotherapy</article-title><source>Int. J. Biol. Macromol.</source><volume>223</volume><year>2022</year><fpage>1485</fpage><lpage>1494</lpage><pub-id pub-id-type="pmid">36395942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2022.11.045</pub-id></element-citation></ref><ref id="bib241"><label>241</label><element-citation publication-type="journal" id="sref241"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Diao</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.K.</given-names></name><etal/></person-group><article-title>Neutrophils deficient in innate suppressor IRAK-M enhances anti-tumor immune responses</article-title><source>Mol. Ther.</source><issue>28</issue><year>2020</year><fpage>89</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">31607540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2019.09.019</pub-id><pub-id pub-id-type="pmcid">PMC6953792</pub-id></element-citation></ref><ref id="bib242"><label>242</label><element-citation publication-type="journal" id="sref242"><person-group person-group-type="author"><name name-style="western"><surname>Sheng</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A twindrive precise delivery system of platelet-neutrophil hybrid membrane regulates macrophage combined with CD47 blocking for postoperative immunotherapy</article-title><source>ACS Nano</source><volume>18</volume><year>2024</year><fpage>4981</fpage><lpage>4992</lpage><pub-id pub-id-type="pmid">38193386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c10862</pub-id></element-citation></ref><ref id="bib243"><label>243</label><element-citation publication-type="journal" id="sref243"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Roles of tumor-associated neutrophils in tumor metastasis and its clinical applications</article-title><source>Front. Cell Dev. Biol.</source><volume>10</volume><year>2022</year><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcell.2022.938289</pub-id><pub-id pub-id-type="pmcid">PMC9428510</pub-id><pub-id pub-id-type="pmid">36060811</pub-id></element-citation></ref><ref id="bib244"><label>244</label><element-citation publication-type="journal" id="sref244"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y.K.</given-names></name><etal/></person-group><article-title>Tumor-associated neutrophil extracellular traps regulating nanocarrier-enhanced inhibition of malignant tumor growth and distant metastasis</article-title><source>ACS Appl. Mater. Interfaces</source><issue>13</issue><year>2021</year><fpage>59683</fpage><lpage>59694</lpage><pub-id pub-id-type="pmid">34902970</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsami.1c18660</pub-id></element-citation></ref><ref id="bib245"><label>245</label><element-citation publication-type="journal" id="sref245"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.Q.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Light-assisted &#8220;nano-neutrophils&#8221; with high drug loading for targeted cancer therapy</article-title><source>Int. J. Nanomed.</source><volume>18</volume><year>2023</year><fpage>6487</fpage><lpage>6502</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IJN.S432854</pub-id><pub-id pub-id-type="pmcid">PMC10642559</pub-id><pub-id pub-id-type="pmid">37965278</pub-id></element-citation></ref><ref id="bib246"><label>246</label><element-citation publication-type="journal" id="sref246"><person-group person-group-type="author"><name name-style="western"><surname>Rogers</surname><given-names>T.</given-names></name><name name-style="western"><surname>DeBerardinis</surname><given-names>R.J.</given-names></name></person-group><article-title>Metabolic plasticity of neutrophils: relevance to pathogen responses and Cancer</article-title><source>Trends Cancer</source><issue>7</issue><year>2021</year><fpage>700</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">34023325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trecan.2021.04.007</pub-id><pub-id pub-id-type="pmcid">PMC9270875</pub-id></element-citation></ref><ref id="bib247"><label>247</label><element-citation publication-type="journal" id="sref247"><person-group person-group-type="author"><name name-style="western"><surname>Hao</surname><given-names>M.X.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>S.Y.</given-names></name><etal/></person-group><article-title>Sensitizing tumors to immune checkpoint blockage <italic toggle="yes">via</italic> STING agonists delivered by tumor-penetrating neutrophil cytopharmaceuticals</article-title><source>ACS Nano</source><volume>17</volume><year>2023</year><fpage>1663</fpage><lpage>1680</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.2c11764</pub-id><pub-id pub-id-type="pmid">36595464</pub-id></element-citation></ref><ref id="bib248"><label>248</label><element-citation publication-type="journal" id="sref248"><person-group person-group-type="author"><name name-style="western"><surname>Pylaeva</surname><given-names>E.</given-names></name><name name-style="western"><surname>Harati</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Spyra</surname><given-names>I.</given-names></name><etal/></person-group><article-title>NAMPT signaling is critical for the proangiogenic activity of tumor-associated neutrophils</article-title><source>Int. J. Cancer</source><volume>144</volume><year>2019</year><fpage>136</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">30121947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.31808</pub-id></element-citation></ref><ref id="bib249"><label>249</label><element-citation publication-type="journal" id="sref249"><person-group person-group-type="author"><name name-style="western"><surname>Fridlender</surname><given-names>Z.G.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Polarization of tumor-associated neutrophil phenotype by TGF-&#946;: &#8220;N1&#8221; versus &#8220;N2&#8221; TAN</article-title><source>Cancer Cell</source><volume>16</volume><year>2009</year><fpage>183</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">19732719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ccr.2009.06.017</pub-id><pub-id pub-id-type="pmcid">PMC2754404</pub-id></element-citation></ref><ref id="bib250"><label>250</label><element-citation publication-type="journal" id="sref250"><person-group person-group-type="author"><name name-style="western"><surname>Moorlag</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rodriguez-Rosales</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Gillard</surname><given-names>J.</given-names></name><etal/></person-group><article-title>BCG vaccination induces long-term functional reprogramming of human neutrophils</article-title><source>Cell Rep.</source><volume>33</volume><year>2020</year><object-id pub-id-type="publisher-id">108387</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2020.108387</pub-id><pub-id pub-id-type="pmcid">PMC7672522</pub-id><pub-id pub-id-type="pmid">33207187</pub-id></element-citation></ref><ref id="bib251"><label>251</label><element-citation publication-type="journal" id="sref251"><person-group person-group-type="author"><name name-style="western"><surname>Wesolowski</surname><given-names>R.</given-names></name><name name-style="western"><surname>Markowitz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Carson</surname><given-names>W.E.</given-names></name></person-group><article-title>Myeloid derived suppressor cells-a new therapeutic target in the treatment of cancer</article-title><source>J. Immunother. Cancer</source><issue>1</issue><year>2013</year><fpage>10</fpage><pub-id pub-id-type="pmid">24829747</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/2051-1426-1-10</pub-id><pub-id pub-id-type="pmcid">PMC4019895</pub-id></element-citation></ref><ref id="bib252"><label>252</label><element-citation publication-type="journal" id="sref252"><person-group person-group-type="author"><name name-style="western"><surname>Hassel</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bender</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Tadalafil has biologic activity in human melanoma, results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe)</article-title><source>OncoImmunology</source><volume>6</volume><year>2017</year><object-id pub-id-type="publisher-id">e1326440</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/2162402X.2017.1326440</pub-id><pub-id pub-id-type="pmcid">PMC5599085</pub-id><pub-id pub-id-type="pmid">28932631</pub-id></element-citation></ref><ref id="bib253"><label>253</label><element-citation publication-type="journal" id="sref253"><person-group person-group-type="author"><name name-style="western"><surname>Gebremeskel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Slauenwhite</surname><given-names>D.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>B.</given-names></name></person-group><article-title>Reconstitution models to evaluate natural killer T cell function in tumor control</article-title><source>Immunol. Cell Biol.</source><volume>94</volume><year>2016</year><fpage>90</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">26095148</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/icb.2015.67</pub-id></element-citation></ref><ref id="bib254"><label>254</label><element-citation publication-type="journal" id="sref254"><person-group person-group-type="author"><name name-style="western"><surname>Arrenberg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Halder</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>V.</given-names></name></person-group><article-title>Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens</article-title><source>J. Cell. Physiol.</source><volume>218</volume><year>2009</year><fpage>246</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">18814145</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcp.21597</pub-id><pub-id pub-id-type="pmcid">PMC2653050</pub-id></element-citation></ref><ref id="bib255"><label>255</label><element-citation publication-type="journal" id="sref255"><person-group person-group-type="author"><name name-style="western"><surname>Jahng</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maricic</surname><given-names>I.</given-names></name><name name-style="western"><surname>Aguilera</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide</article-title><source>J. Exp. Med.</source><volume>199</volume><year>2004</year><fpage>947</fpage><lpage>957</lpage><pub-id pub-id-type="pmid">15051763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20031389</pub-id><pub-id pub-id-type="pmcid">PMC2211873</pub-id></element-citation></ref><ref id="bib256"><label>256</label><element-citation publication-type="journal" id="sref256"><person-group person-group-type="author"><name name-style="western"><surname>Iyoda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yamasaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Natural killer T and natural killer cell-based immunotherapy strategies targeting cancer</article-title><source>Biomolecules</source><volume>13</volume><year>2023</year><fpage>348</fpage><pub-id pub-id-type="pmid">36830717</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biom13020348</pub-id><pub-id pub-id-type="pmcid">PMC9953375</pub-id></element-citation></ref><ref id="bib257"><label>257</label><element-citation publication-type="journal" id="sref257"><person-group person-group-type="author"><name name-style="western"><surname>Ghinnagow</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Macho-Fernandez</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Enhancement of adjuvant functions of natural killer T cells using nanovector delivery systems: application in anticancer immune therapy</article-title><source>Front. Immunol.</source><volume>8</volume><year>2017</year><fpage>879</fpage><pub-id pub-id-type="pmid">28798749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2017.00879</pub-id><pub-id pub-id-type="pmcid">PMC5529346</pub-id></element-citation></ref><ref id="bib258"><label>258</label><element-citation publication-type="journal" id="sref258"><person-group person-group-type="author"><name name-style="western"><surname>Faveeuw</surname><given-names>C.</given-names></name><name name-style="western"><surname>Trottein</surname><given-names>F.</given-names></name></person-group><article-title>Optimization of natural killer T cell-mediated immunotherapy in cancer using cell-based and nanovector vaccines</article-title><source>Cancer Res.</source><volume>74</volume><year>2014</year><fpage>1632</fpage><lpage>1638</lpage><pub-id pub-id-type="pmid">24599135</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-13-3504</pub-id></element-citation></ref><ref id="bib259"><label>259</label><element-citation publication-type="journal" id="sref259"><person-group person-group-type="author"><name name-style="western"><surname>Verbeke</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lentacker</surname><given-names>I.</given-names></name><name name-style="western"><surname>Breckpot</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Broadening the message: a nanovaccine co-loaded with messenger RNA and &#945;-GalCer induces antitumor immunity through conventional and natural killer T cells</article-title><source>ACS Nano</source><volume>13</volume><year>2019</year><fpage>1655</fpage><lpage>1669</lpage><pub-id pub-id-type="pmid">30742405</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.8b07660</pub-id></element-citation></ref><ref id="bib260"><label>260</label><element-citation publication-type="journal" id="sref260"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Functional T cell activation by smart nanosystems for effective cancer immunotherapy</article-title><source>Nano Today</source><volume>27</volume><year>2019</year><fpage>28</fpage><lpage>47</lpage></element-citation></ref><ref id="bib261"><label>261</label><element-citation publication-type="journal" id="sref261"><person-group person-group-type="author"><name name-style="western"><surname>Tanaka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>S.</given-names></name></person-group><article-title>Regulatory T cells in cancer immunotherapy</article-title><source>Cell Res.</source><volume>27</volume><year>2017</year><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">27995907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cr.2016.151</pub-id><pub-id pub-id-type="pmcid">PMC5223231</pub-id></element-citation></ref><ref id="bib262"><label>262</label><element-citation publication-type="journal" id="sref262"><person-group person-group-type="author"><name name-style="western"><surname>Ohue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nishikawa</surname><given-names>H.</given-names></name></person-group><article-title>Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target?</article-title><source>Cancer Sci.</source><volume>110</volume><year>2019</year><fpage>2080</fpage><lpage>2089</lpage><pub-id pub-id-type="pmid">31102428</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cas.14069</pub-id><pub-id pub-id-type="pmcid">PMC6609813</pub-id></element-citation></ref><ref id="bib263"><label>263</label><element-citation publication-type="journal" id="sref263"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Engineering PD-1-presenting platelets for cancer immunotherapy</article-title><source>Nano Lett.</source><volume>18</volume><year>2018</year><fpage>5716</fpage><lpage>5725</lpage><pub-id pub-id-type="pmid">30063143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.8b02321</pub-id></element-citation></ref><ref id="bib264"><label>264</label><element-citation publication-type="journal" id="sref264"><person-group person-group-type="author"><name name-style="western"><surname>Gianchecchi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fierabracci</surname><given-names>A.</given-names></name></person-group><article-title>Inhibitory receptors and pathways of lymphocytes: the role of PD-1 in Treg development and their involvement in autoimmunity onset and cancer progression</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><fpage>2374</fpage><pub-id pub-id-type="pmid">30386337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.02374</pub-id><pub-id pub-id-type="pmcid">PMC6199356</pub-id></element-citation></ref><ref id="bib265"><label>265</label><element-citation publication-type="journal" id="sref265"><person-group person-group-type="author"><name name-style="western"><surname>Bhardwaj</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bhatia</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Advancements in prophylactic and therapeutic nanovaccines</article-title><source>Acta Biomater.</source><volume>108</volume><year>2020</year><fpage>1</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">32268235</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.actbio.2020.03.020</pub-id><pub-id pub-id-type="pmcid">PMC7163188</pub-id></element-citation></ref><ref id="bib266"><label>266</label><element-citation publication-type="journal" id="sref266"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>G.</given-names></name></person-group><article-title>Applications of nanomaterials as vaccine adjuvants</article-title><source>Hum. Vaccines Immunother.</source><issue>10</issue><year>2014</year><fpage>2761</fpage><lpage>2774</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/hv.29589</pub-id><pub-id pub-id-type="pmcid">PMC4977448</pub-id><pub-id pub-id-type="pmid">25483497</pub-id></element-citation></ref><ref id="bib267"><label>267</label><element-citation publication-type="journal" id="sref267"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Marks</surname><given-names>F.</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>J.D.</given-names></name></person-group><article-title>Looking beyond COVID-19 vaccine phase 3 trials</article-title><source>Nat. Med.</source><issue>27</issue><year>2021</year><fpage>205</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">33469205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01230-y</pub-id></element-citation></ref><ref id="bib268"><label>268</label><element-citation publication-type="journal" id="sref268"><person-group person-group-type="author"><name name-style="western"><surname>Janssens</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Joye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Waerlop</surname><given-names>G.</given-names></name><etal/></person-group><article-title>The role of cell-mediated immunity against influenza and its implications for vaccine evaluation</article-title><source>Front. Immunol.</source><volume>13</volume><year>2022</year><object-id pub-id-type="publisher-id">959379</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.959379</pub-id><pub-id pub-id-type="pmcid">PMC9424642</pub-id><pub-id pub-id-type="pmid">36052083</pub-id></element-citation></ref><ref id="bib269"><label>269</label><element-citation publication-type="journal" id="sref269"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Khang</surname><given-names>D.</given-names></name></person-group><article-title>Mucosal delivery of nanovaccine strategy against COVID-19 and its variants</article-title><source>Acta Pharm. Sin. B</source><issue>13</issue><year>2022</year><fpage>2897</fpage><lpage>2925</lpage><pub-id pub-id-type="pmid">36438851</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apsb.2022.11.022</pub-id><pub-id pub-id-type="pmcid">PMC9676163</pub-id></element-citation></ref><ref id="bib270"><label>270</label><element-citation publication-type="journal" id="sref270"><person-group person-group-type="author"><name name-style="western"><surname>Konrath</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Liaw</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection</article-title><source>Cell Rep.</source><volume>38</volume><year>2022</year><object-id pub-id-type="publisher-id">110318</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2022.110318</pub-id><pub-id pub-id-type="pmcid">PMC8747942</pub-id><pub-id pub-id-type="pmid">35090597</pub-id></element-citation></ref><ref id="bib271"><label>271</label><element-citation publication-type="journal" id="sref271"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L.X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.L.</given-names></name><etal/></person-group><article-title>Subunit nanovaccine with potent cellular and mucosal immunity for COVID-19</article-title><source>ACS Appl. Bio Mater.</source><issue>3</issue><year>2020</year><fpage>5633</fpage><lpage>5638</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsabm.0c00668</pub-id><pub-id pub-id-type="pmid">35021794</pub-id></element-citation></ref><ref id="bib272"><label>272</label><element-citation publication-type="journal" id="sref272"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>STING and TLR9 agonists synergistically enhance the immunogenicity of SARS-CoV-2 subunit vaccine</article-title><source>Nano Res.</source><issue>16</issue><year>2023</year><fpage>13322</fpage><lpage>13334</lpage></element-citation></ref><ref id="bib273"><label>273</label><element-citation publication-type="journal" id="sref273"><person-group person-group-type="author"><name name-style="western"><surname>Lai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Universal selenium nanoadjuvant with immunopotentiating and redox-shaping activities inducing high-quality immunity for SARS-CoV-2 vaccine</article-title><source>Signal Transduct. Targeted Ther.</source><issue>8</issue><year>2023</year><fpage>88</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01371-1</pub-id><pub-id pub-id-type="pmcid">PMC9969362</pub-id><pub-id pub-id-type="pmid">36849546</pub-id></element-citation></ref><ref id="bib274"><label>274</label><element-citation publication-type="journal" id="sref274"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Durable and enhanced immunity against SARS-CoV-2 elicited by manganese nanoadjuvant formulated subunit vaccine</article-title><source>Signal Transduct. Targeted Ther.</source><issue>8</issue><year>2023</year><fpage>462</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-023-01718-8</pub-id><pub-id pub-id-type="pmcid">PMC10725496</pub-id><pub-id pub-id-type="pmid">38104162</pub-id></element-citation></ref><ref id="bib275"><label>275</label><element-citation publication-type="journal" id="sref275"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Antigen-caged-adjuvant nanovaccines elicit potent humoral and cellular immune responses</article-title><source>Nano Today</source><volume>53</volume><year>2023</year><object-id pub-id-type="publisher-id">102036</object-id></element-citation></ref><ref id="bib276"><label>276</label><element-citation publication-type="journal" id="sref276"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19</article-title><source>Chem. Eng. J.</source><volume>418</volume><year>2021</year><object-id pub-id-type="publisher-id">129392</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cej.2021.129392</pub-id><pub-id pub-id-type="pmcid">PMC7972832</pub-id><pub-id pub-id-type="pmid">33762883</pub-id></element-citation></ref><ref id="bib277"><label>277</label><element-citation publication-type="journal" id="sref277"><person-group person-group-type="author"><name name-style="western"><surname>Zhuo</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A chitosan-mediated inhalable nanovaccine against SARS-CoV-2</article-title><source>Nano Res.</source><issue>15</issue><year>2022</year><fpage>4191</fpage><lpage>4200</lpage><pub-id pub-id-type="pmid">35126879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12274-021-4012-9</pub-id><pub-id pub-id-type="pmcid">PMC8809230</pub-id></element-citation></ref><ref id="bib278"><label>278</label><element-citation publication-type="journal" id="sref278"><person-group person-group-type="author"><name name-style="western"><surname>Yitbarek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>G.</given-names></name><name name-style="western"><surname>Girma</surname><given-names>T.</given-names></name><etal/></person-group><article-title>The effect of Bacillus Calmette-Guerin (BCG) vaccination in preventing severe infectious respiratory diseases other than TB: implications for the COVID-19 pandemic</article-title><source>Vaccine</source><issue>38</issue><year>2020</year><fpage>6374</fpage><lpage>6380</lpage><pub-id pub-id-type="pmid">32798142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2020.08.018</pub-id><pub-id pub-id-type="pmcid">PMC7416741</pub-id></element-citation></ref><ref id="bib279"><label>279</label><element-citation publication-type="journal" id="sref279"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Floyd</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>BCG vaccination stimulates integrated organ immunity by feedback of the adaptive immune response to imprint prolonged innate antiviral resistance</article-title><source>Nat. Immunol.</source><issue>25</issue><year>2024</year><fpage>41</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">38036767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-023-01700-0</pub-id><pub-id pub-id-type="pmcid">PMC10932731</pub-id></element-citation></ref><ref id="bib280"><label>280</label><element-citation publication-type="journal" id="sref280"><person-group person-group-type="author"><name name-style="western"><surname>Ni</surname><given-names>Q.Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.J.</given-names></name><etal/></person-group><article-title>A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer</article-title><source>Sci. Adv.</source><issue>6</issue><year>2020</year><object-id pub-id-type="publisher-id">eaaw6071</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.aaw6071</pub-id><pub-id pub-id-type="pmcid">PMC7080439</pub-id><pub-id pub-id-type="pmid">32206706</pub-id></element-citation></ref><ref id="bib281"><label>281</label><element-citation publication-type="journal" id="sref281"><person-group person-group-type="author"><name name-style="western"><surname>Shao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Advanced pancreatic cancer patient benefit from personalized neoantigen nanovaccine based immunotherapy: a case report</article-title><source>Front. Immunol.</source><volume>13</volume><year>2022</year><object-id pub-id-type="publisher-id">799026</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.799026</pub-id><pub-id pub-id-type="pmcid">PMC8901600</pub-id><pub-id pub-id-type="pmid">35273594</pub-id></element-citation></ref><ref id="bib282"><label>282</label><element-citation publication-type="journal" id="sref282"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.Y.</given-names></name><etal/></person-group><article-title>Nanovaccines for cancer immunotherapy</article-title><source>Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.</source><volume>11</volume><year>2019</year><fpage>e1559</fpage><pub-id pub-id-type="pmid">31172659</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/wnan.1559</pub-id><pub-id pub-id-type="pmcid">PMC7040494</pub-id></element-citation></ref><ref id="bib283"><label>283</label><element-citation publication-type="journal" id="sref283"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Therapeutic nanovaccines sensitize EBV-associated tumors to checkpoint blockade therapy</article-title><source>Biomaterials</source><issue>255</issue><year>2020</year><object-id pub-id-type="publisher-id">120158</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2020.120158</pub-id><pub-id pub-id-type="pmid">32544717</pub-id></element-citation></ref><ref id="bib284"><label>284</label><element-citation publication-type="journal" id="sref284"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><etal/></person-group><article-title>PolyTLR7/8a-conjugated, antigen-trapping gold nanorods elicit anticancer immunity against abscopal tumors by photothermal therapy-induced <italic toggle="yes">in situ</italic> vaccination</article-title><source>Biomaterials</source><issue>275</issue><year>2021</year><object-id pub-id-type="publisher-id">120921</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2021.120921</pub-id><pub-id pub-id-type="pmid">34139508</pub-id></element-citation></ref><ref id="bib285"><label>285</label><element-citation publication-type="journal" id="sref285"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Photosensitizer-induced HPV16 E7 nanovaccines for cervical cancer immunotherapy</article-title><source>Biomaterials</source><issue>282</issue><year>2022</year><object-id pub-id-type="publisher-id">121411</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2022.121411</pub-id><pub-id pub-id-type="pmid">35189461</pub-id></element-citation></ref><ref id="bib286"><label>286</label><element-citation publication-type="journal" id="sref286"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><etal/></person-group><article-title><italic toggle="yes">Co</italic>-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses</article-title><source>Biomaterials</source><volume>230</volume><year>2020</year><object-id pub-id-type="publisher-id">119649</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2019.119649</pub-id><pub-id pub-id-type="pmid">31791843</pub-id></element-citation></ref><ref id="bib287"><label>287</label><element-citation publication-type="journal" id="sref287"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.M.</given-names></name><etal/></person-group><article-title>Supramolecular assembled programmable nanomedicine as <italic toggle="yes">in situ</italic> cancer vaccine for cancer immunotherapy</article-title><source>Adv. Mater.</source><volume>33</volume><year>2021</year><object-id pub-id-type="publisher-id">2007293</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/adma.202007293</pub-id><pub-id pub-id-type="pmid">33448050</pub-id></element-citation></ref><ref id="bib288"><label>288</label><element-citation publication-type="journal" id="sref288"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Sequential and timely combination of a cancer nanovaccine with immune checkpoint blockade effectively inhibits tumor growth and relapse</article-title><source>Angew. Chem.</source><volume>132</volume><year>2020</year><fpage>14736</fpage><lpage>14746</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.202006117</pub-id><pub-id pub-id-type="pmid">32430981</pub-id></element-citation></ref><ref id="bib289"><label>289</label><element-citation publication-type="journal" id="sref289"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy</article-title><source>Biomaterials</source><volume>207</volume><year>2019</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">30947117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2019.03.037</pub-id></element-citation></ref><ref id="bib290"><label>290</label><element-citation publication-type="journal" id="sref290"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Chemotherapy-induced neoantigen nanovaccines enhance checkpoint blockade cancer immunotherapy</article-title><source>ACS Nano</source><volume>17</volume><year>2023</year><fpage>18818</fpage><lpage>18831</lpage><pub-id pub-id-type="pmid">37750443</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsnano.3c03274</pub-id></element-citation></ref><ref id="bib291"><label>291</label><element-citation publication-type="journal" id="sref291"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>She</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Ultrasound-mediated remotely controlled nanovaccine delivery for tumor vaccination and individualized cancer immunotherapy</article-title><source>Nano Lett.</source><volume>21</volume><year>2021</year><fpage>1228</fpage><lpage>1237</lpage><pub-id pub-id-type="pmid">33522825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.0c03646</pub-id></element-citation></ref><ref id="bib292"><label>292</label><element-citation publication-type="journal" id="sref292"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Z.C.</given-names></name><etal/></person-group><article-title>Surgical tumor-derived photothermal nanovaccine for personalized cancer therapy and prevention</article-title><source>Nano Lett.</source><issue>22</issue><year>2022</year><fpage>3095</fpage><lpage>3103</lpage><pub-id pub-id-type="pmid">35357839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.2c00500</pub-id></element-citation></ref><ref id="bib293"><label>293</label><element-citation publication-type="journal" id="sref293"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>PD-L1 aptamer-functionalized metal-organic framework nanoparticles for robust photo-immunotherapy against cancer with enhanced safety</article-title><source>Angew. Chem., Int. Ed.</source><issue>62</issue><year>2023</year><object-id pub-id-type="publisher-id">e202214750</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.202214750</pub-id><pub-id pub-id-type="pmid">36458940</pub-id></element-citation></ref><ref id="bib294"><label>294</label><element-citation publication-type="journal" id="sref294"><person-group person-group-type="author"><name name-style="western"><surname>Gun</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.W.L.</given-names></name><name name-style="western"><surname>Sieow</surname><given-names>J.L.</given-names></name><etal/></person-group><article-title>Targeting immune cells for cancer therapy</article-title><source>Redox Biol.</source><volume>25</volume><year>2019</year><object-id pub-id-type="publisher-id">101174</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.redox.2019.101174</pub-id><pub-id pub-id-type="pmcid">PMC6859550</pub-id><pub-id pub-id-type="pmid">30917934</pub-id></element-citation></ref><ref id="bib295"><label>295</label><element-citation publication-type="journal" id="sref295"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>A STING-activating nanovaccine for cancer immunotherapy</article-title><source>Nat. Nanotechnol.</source><issue>12</issue><year>2017</year><fpage>648</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">28436963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nnano.2017.52</pub-id><pub-id pub-id-type="pmcid">PMC5500418</pub-id></element-citation></ref><ref id="bib296"><label>296</label><element-citation publication-type="journal" id="sref296"><person-group person-group-type="author"><name name-style="western"><surname>Azharuddin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Sengupta</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Nano toolbox in immune modulation and nanovaccines</article-title><source>Trends Biotechnol.</source><issue>40</issue><year>2022</year><fpage>1195</fpage><lpage>1212</lpage><pub-id pub-id-type="pmid">35450779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tibtech.2022.03.011</pub-id><pub-id pub-id-type="pmcid">PMC10439010</pub-id></element-citation></ref><ref id="bib297"><label>297</label><element-citation publication-type="journal" id="sref297"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Construction of orthogonal modular proteinaceous nanovaccine delivery vectors based on mSA-biotin binding</article-title><source>Nanomaterials</source><volume>12</volume><year>2022</year><fpage>734</fpage><pub-id pub-id-type="pmid">35269221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nano12050734</pub-id><pub-id pub-id-type="pmcid">PMC8911943</pub-id></element-citation></ref><ref id="bib298"><label>298</label><element-citation publication-type="journal" id="sref298"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><etal/></person-group><article-title><italic toggle="yes">In situ</italic> thermal ablation of tumors in combination with nano-adjuvant and immune checkpoint blockade to inhibit cancer metastasis and recurrence</article-title><source>Biomaterials</source><issue>224</issue><year>2019</year><object-id pub-id-type="publisher-id">119490</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biomaterials.2019.119490</pub-id><pub-id pub-id-type="pmid">31542515</pub-id></element-citation></ref><ref id="bib299"><label>299</label><element-citation publication-type="journal" id="sref299"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name></person-group><article-title>Combining nanovaccine and radiotherapy to revert the immunosuppressive environment in tumor</article-title><source>Nano Biomed. Eng.</source><volume>10</volume><year>2018</year><fpage>310</fpage></element-citation></ref><ref id="bib300"><label>300</label><element-citation publication-type="journal" id="sref300"><person-group person-group-type="author"><name name-style="western"><surname>Gou</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Engineered nanovaccine targeting clec9a<sup>+</sup> dendritic cells remarkably enhances the cancer immunotherapy effects of STING agonist</article-title><source>Nano Lett.</source><volume>21</volume><year>2021</year><fpage>9939</fpage><lpage>9950</lpage><pub-id pub-id-type="pmid">34779631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.nanolett.1c03243</pub-id></element-citation></ref><ref id="bib301"><label>301</label><element-citation publication-type="journal" id="sref301"><person-group person-group-type="author"><name name-style="western"><surname>Gebre</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Brito</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Tostanoski</surname><given-names>L.H.</given-names></name><etal/></person-group><article-title>Novel approaches for vaccine development</article-title><source>Cell</source><volume>184</volume><year>2021</year><fpage>1589</fpage><lpage>1603</lpage><pub-id pub-id-type="pmid">33740454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2021.02.030</pub-id><pub-id pub-id-type="pmcid">PMC8049514</pub-id></element-citation></ref><ref id="bib302"><label>302</label><element-citation publication-type="journal" id="sref302"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ayala</surname><given-names>O.C.</given-names></name><name name-style="western"><surname>Rauta</surname><given-names>P.R.</given-names></name><etal/></person-group><article-title>The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective</article-title><source>Nanoscale</source><volume>11</volume><year>2019</year><fpage>17157</fpage><lpage>17178</lpage><pub-id pub-id-type="pmid">31531445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c9nr05371a</pub-id><pub-id pub-id-type="pmcid">PMC6778734</pub-id></element-citation></ref><ref id="bib303"><label>303</label><element-citation publication-type="journal" id="sref303"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Orecchioni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ley</surname><given-names>K.</given-names></name></person-group><article-title>How the immune system shapes atherosclerosis: roles of innate and adaptive immunity</article-title><source>Nat. Rev. Immunol.</source><issue>22</issue><year>2022</year><fpage>251</fpage><lpage>265</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-021-00584-1</pub-id><pub-id pub-id-type="pmcid">PMC10111155</pub-id><pub-id pub-id-type="pmid">34389841</pub-id></element-citation></ref><ref id="bib304"><label>304</label><element-citation publication-type="journal" id="sref304"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Nanovaccine based on a biepitope antigen to potentiate the immunogenicity of a neoantigen</article-title><source>ACS Macro Lett.</source><issue>12</issue><year>2023</year><fpage>281</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">36752382</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsmacrolett.2c00742</pub-id></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgments</title><p id="p0380">This work was financially supported by the <funding-source id="gs1">National Key R&amp;D Program of China</funding-source> (Grant No. 2022YFB3808000/2022YFB3808001; Grant No. 2021YFC2400600/2021&#160;YFC2400604), the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100014125</institution-id><institution>Medical Innovation Project of Science and Technology Program of Fujian Provincial Health Commission</institution></institution-wrap></funding-source> (Grant No. 2021CXA006), the <funding-source id="gs3">Project for High-Level Talent Innovation and Entrepreneurship of Quanzhou</funding-source> (Grant No. 2022C016R), and the <funding-source id="gs6">Key Program of Qingyuan Innovation Laboratory</funding-source> (Grant No. 00221002). The authors also gratefully acknowledged the kind financial support provided by the Top <funding-source id="gs5">Young Talents of Foal Eagle Program of Fujian Province</funding-source> and the <funding-source id="gs7">Youth Promotion Talent Project of Fujian Province to Jin Zhang</funding-source>.</p></ack><fn-group><fn id="d36e1403"><p id="ntpara0010">Peer review under responsibility of KeAi Communications Co., Ltd.</p></fn></fn-group></back></article></pmc-articleset>